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ABSTRACT 
Eukaryotic translation initiation factor 2 (eIF2) is a heterotrimeric G-protein that 
plays a critical role in protein synthesis regulation. eIF2-GTP binds Met-tRNAi to form 
the eIF2-GTP:Met-tRNAi ternary complex (TC), that is recruited to the 40S ribosomal 
subunit. Following GTP hydrolysis, eIF2-GDP is recycled back to TC by its guanine 
nucleotide exchange factor (GEF), eIF2B. Phosphorylation of the eIF2α subunit in 
response to various cellular stresses converts eIF2 into a competitive inhibitor of eIF2B, 
triggering the integrated stress response. Dysregulation of eIF2B activity is associated 
with a number of pathologies, including neurodegenerative diseases, metabolic disorders, 
and cancer. However, despite decades of research, the underlying molecular mechanisms 
remain unknown. This is due in large part to the absence of a structural understanding of 
the eIF2B assembly and of the eIF2B:eIF2 interaction. Common methods, such as yeast 
genetics, have been unable to unambiguously determine these mechanisms. Meanwhile, 
expanded interest in the integrated stress response has uncovered a diverse array of 
pathologies for which therapeutic modulation of the eIF2B:eIF2 interaction may 
ameliorate or overcome disease states. 
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In this dissertation, a combination of structural and biochemical techniques is 
employed to elucidate the mechanisms of eIF2B action and its regulation by eIF2α 
phosphorylation. The aim is to provide a direct, unambiguous, structural understanding of 
eIF2B assembly and of eIF2B’s interactions with phosphorylated and unphosphorylated 
eIF2α. The work described here was among the first to challenge the widely held notion 
of a pentameric eIF2B assembly, as eventually confirmed by the recent publication of 
eIF2B’s crystal structure. The work further aims to overturn another long-standing 
assumption regarding the nature of inhibition of eIF2B activity: that competitive 
inhibition is mediated by a “direct effect” of the negatively charged phosphate group on 
the eIF2α:eIF2B interaction. Instead, we present evidence for an “indirect effect,” 
whereby phosphorylation disrupts a novel intramolecular interface within eIF2α, 
exposing an eIF2α surface that binds eIF2B and is responsible for inhibition of eIF2B. In 
the end, we combine a structural model of the eIF2B:eIF2 complex with our novel 
mechanism of inhibition, placing them within the larger thermodynamic context of eIF2-
GDP recycling by eIF2B. 
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Chapter 1: Introduction 
 
1.1. Overview of Translation Initiation 
All three domains of life (bacteria, archaea, and eukaryotes) have the same 
requirement to synthesize proteins. Given the potential consequences of deviation, it is 
not surprising that many of the mechanisms underlying the process of protein synthesis 
(i.e. translation) are remarkably conserved between all three domains. No matter the 
organism, the basic principle remains the same: DNA containing the base genetic 
material is copied into a more temporary form called messenger RNA (mRNA), and the 
sequence of mRNA must be read and converted to a corresponding chain of amino acids 
(i.e. the protein). The central role this process plays in all life necessitates a high degree 
of regulation and control. Protein translation can broadly be divided into four phases:  
(a) initiation: assembling the machinery necessary to begin linking amino acids 
together according to the code prescribed by the mRNA,  
(b) elongation: the actual process of sequentially linking amino acids to the growing 
polypeptide chain, 
(c) termination: detachment of the completed polypeptide upon completion of 
synthesis, and  
(d) recycling of all the components in preparation for the next round of initiation. 
On the physiological timescale of translation (~seconds to minutes) (Schreier et al. 1977), 
translation initiation is the rate-limiting step, is the most complex and highly regulated, 
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and thus unsurprisingly is also the least conserved between the three domains of life 
(reviewed in (Marintchev & Wagner 2004; Jackson et al. 2010; Hinnebusch 2014)). 
Nevertheless, there are still substantial similarities in how translation initiation 
occurs in bacteria, archaea, and eukaryotes. mRNA consists of a sequence of nucleotides, 
triplets of which code for a single amino acid. The ribosome, a massive complex 
composed of dozens of proteins and molecules of ribosomal RNA, functions to bind 
mRNA, select for amino acids corresponding to the sequence encoded in the mRNA, and 
synthesize the bonds to connect amino acids together. Regulation occurs at many points 
throughout the process. Mechanisms exist to control the availability of mRNA and its 
recruitment to the ribosome. Proper identification of where the protein coding sequence 
on the mRNA molecule actually begins, and thus where the ribosome should start 
synthesis, is clearly critical. Maintaining appropriate levels of the necessary amino acids 
in a form readily incorporated by the ribosome as it reads the mRNA is necessary for 
rapid and efficient synthesis. The protein must be released exactly when it is finished 
being synthesized for maximum efficiency. Finally, as translation is a cyclic process, all 
the machinery must prepare itself for another round of translation (reviewed in 
(Marintchev & Wagner 2004; Laursen et al. 2005; Jackson et al. 2010; Benelli & Londei 
2011; Hinnebusch 2014)). 
In the following sections, several of these processes will be described in greater 
detail. As a thorough overview of translation, let alone translation initiation, is beyond the 
scope of this dissertation, the reader is referred to several more comprehensive reviews in 
order to appreciate the general context (Marintchev & Wagner 2004; Jackson et al. 2010; 
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Hernández & Jagus 2016; Benelli & Londei 2011; Hinnebusch et al. 2007; Hinnebusch 
2014; Laursen et al. 2005). Instead, an attempt will be made to present to the reader only 
as much background and context as is necessary to appreciate the work forming the core 
of this dissertation.  
1.1.1. Universal Elements 
At its core, translation initiation is responsible for three basic tasks: recruitment of 
the mRNA to the ribosome, high fidelity recognition of the start codon on the mRNA, 
and prevention of premature ribosomal assembly until recognition of the start codon 
(Marintchev & Wagner 2004). A basic overview of mRNA, loading of amino acids on 
tRNAs, and the structure and function of the ribosome are given below. Key differences 
between the three domains of life are highlighted.  
1.1.1.1. mRNA 
In all forms of life, mRNA contains the same basic sequence elements. Only a 
limited sequence in the mRNA molecule actually codes for a given protein. These 
sequences, or open reading frames (ORFs), are marked by a triplet of bases called the 
start codon, which is most commonly an adenosine followed by a uracil followed by a 
guanine (AUG). The end of the ORF is marked by another three-base code called the stop 
codon, which is UAA, UAG, or UGA. A single mRNA can carry the code for several 
proteins simultaneously or can be restricted to coding for a single protein. The former is 
called polycistronic mRNA and is representative of the majority of bacterial and archaeal 
mRNAs. The latter is called monocistronic mRNA and is representative of the majority 
of eukaryotic mRNAs (Benelli & Londei 2011). Nevertheless, both polycistronic and 
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monicistronic mRNA possess a sequence of nucleotides “upstream” (i.e in the 5’ 
direction) of the first AUG start codon. This region is necessarily untranslated, and is thus 
referred to as the 5’ untranslated region (5’ UTR). On the opposite end, the stretch of 
mRNA that follows the final stop codon is called the 3’ UTR. mRNA molecules in all 
three domains tend to “fold up” on themselves and create complex secondary structures, 
mediated by base pairing between various bases along the mRNA sequence. In order to 
have the nucleotide sequence be read in order to create a protein, this secondary structure 
must be unraveled (reviewed in (Marintchev & Wagner 2004)).  
Several key differences exist in how mRNA is processed and prepped for protein 
synthesis between the three domains of life. In eukaryotes, mRNA processing in the 
nucleus results in three major modifications to the mRNA molecule: (1) the addition of a 
methylated guanine base at the 5’ end of the mRNA (called the 5’ cap), (2) the addition 
of a long series of adenosine bases at the 3’ end (called the poly-A 3’ tail), and (3) the 
removal of introns and subsequent ligation of exons (i.e. mRNA splicing) (Marintchev & 
Wagner 2004; Jackson et al. 2010; Hinnebusch 2014; De Conti et al. 2013). The first two 
serve an important function to extend the lifetime of mRNA by protecting it from 
degradation, as well as to add new layers of potential regulation of mRNA availability 
and recruitment to the ribosome. Eukaryotic mRNA also typically contains much longer 
5’ UTR sequences than does prokaryotic mRNA (Lynch 2006). Some mRNAs possess no 
5’ UTR sequence and are referred to as leaderless mRNAs. They are much more common 
in archaea than in bacteria/eukaryotes, and in some archaeal species they represent the 
majority of mRNA (Benelli & Londei 2011). While bacterial mRNA can bind directly to 
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the ribosome via a conserved sequence (the Shine-Dalgarno sequence), eukaryotic 
mRNA does not possess such a sequence. Translation initiation in eukaryotes must 
therefore handle the additional responsibility of recruiting and placing the mRNA on the 
ribosome (reviewed in (Marintchev & Wagner 2004; Jackson et al. 2010; Hinnebusch 
2014)).  
1.1.1.2. Aminoacyl-tRNA 
Amino acids are delivered to the ribosome bound to another type of RNA called 
transfer RNA (tRNA). tRNAs possess a common secondary structure consisting of three 
“hairpin loops” in the shape of a three-leaf clover. The middle hairpin loop represents one 
“end” of the tRNA molecule and presents a triplet of unpaired bases, while the other 
“stem” end can be modified with an amino acid to form an aminoacyl-tRNA (aa-tRNA). 
Individual tRNAs are unique for a single type of amino acid, resulting in a set of aa-
tRNAs that couple specific triplets of bases to specific amino acids. Via this mechanism, 
triplets of bases on the mRNA, called codons, thus represent specific amino acids, as 
mediated by base pair matching with corresponding triplets on the aa-tRNA, called anti-
codons. The availability and recruitment of aa-tRNA to the ribosome serves as another 
point of regulation in the cell. Low levels or absence of a given aa-tRNA could result in 
halting of the ribosome on the mRNA, and thus a subsequent slowing or halt in 
translation. High levels of tRNAs without bound amino acids also trigger a regulatory 
response by activation of the kinase GCN2 in eukaryotes (Dever et al. 1992; Dong et al. 
2000). 
 
 
  6 
The “charging” or “loading” of tRNA by the addition of an amino acid is 
performed by amino-acid specific aminoacyl-tRNA synthetases (aaRS) (de Pouplana & 
Schimmel 2001; Eriani et al. 1990). Every aa-tRNA is produced by its own dedicated 
aaRS, which has higher homology to the same type of aaRS in other organisms than to a 
different type of aaRS in the same organism (Hausmann et al. 2007). aa-tRNAs are all 
bound by an elongation factor (EF), tasked with recruiting them to the ribosome and 
properly positioning them for elongation. In bacteria this factor is called EF-Tu, while in 
archaea and eukaryotes it is called aEF1A or eEF1A, respectively (Marintchev & Wagner 
2004; Benelli et al. 2016). Assemblies of aaRSs called multi-synthetase complexes have 
been demonstrated to exist in archaea and eukaryotes, creating a localized “production 
facility” for a variety of aa-tRNAs (Reed et al. 1994; Hausmann et al. 2007). Several 
accessory proteins have been shown to interact with aaRSs and with multi-synthetase 
complexes in a manner that seems to facilitate loading. eEF1A appears to be one such 
protein, and it has been proposed that a potential function of this assembly (and multi-
synthetase complexes more generally) may be to channel newly loaded aa-tRNAs 
directly to the ribosome (Hausmann et al. 2007; Reed et al. 1994). Channeling would 
serve to greatly increase the effective concentration of aa-tRNAs at the ribosome, as well 
as potentially protect them from degradation (Marintchev & Wagner 2004).  
In all three domains, there exist a unique and privileged type of aa-tRNA called 
the initiator methionyl-tRNAi, where the subscript stands for “initiator.” As all start 
codons (even the rarer ones) code for a methionine, the corresponding aa-tRNA that 
initiates translation will always be a methionyl-tRNA. The tRNAi molecule that gets 
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loaded with a methionine to form the initiator methionyl-tRNAi is unique compared to 
other tRNAs, a reflection of the unique location it is required to bind in the ribosome 
compared to other tRNAs. One such feature is the modification of a specific base pair 
interaction between the 1st and 72nd nucleotide, one of several interactions holding 
together the 5’ end and 3’ end that together form the stem region of the tRNA. In bacteria 
this interaction is absent, while in eukaryotes it is always between an A and U. Along 
with several other differentiating features, these changes restrict initiator methionyl-
tRNAi to interacting with its own set of factors as part of translation initiation, rather than 
joining the general pool of methionyl-tRNAs used in elongation. In bacteria, an 
additional step is performed, in which methionyl tRNA transformylase adds a formyl 
group to the initiator methionine (reviewed in (Marintchev & Wagner 2004; Jackson et 
al. 2010; Hinnebusch 2014; Laursen et al. 2005; Benelli & Londei 2011)). 
1.1.1.3. Ribosomes 
The ribosome is tasked with actually performing the work of polypeptide 
formation (Figure 1.1). The core enzymatic process is the formation of a peptide bond 
between the amino acids of two aa-tRNAs, pre-positioned on the ribosome. Three 
adjacent sites on the ribosome are responsible for positioning of tRNAs during this 
process: the A-site, the P-site, and the E-site. The A-site is responsible for 
binding/positioning the incoming aa-tRNA and checking it against the mRNA sequence. 
At the onset of elongation, the neighboring P-site is occupied by the initiator fMet-tRNAi 
or Met-tRNAi, depending on the organism. The ribosome then performs catalytic 
formation of a peptide bond between the aa-tRNA in the A-site and the aa-tRNA in the P-
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site, followed by shifting the occupant of the P-site to the E-site and the occupant of the 
A-site to the P-site. A new aa-tRNA binds the now empty A-site, resulting in 
continuation of the cycle. The sites are named based on their function: the A-site is 
responsible for binding the aa-tRNA, the P-site is responsible for binding the peptidyl-
tRNA (as the tRNA in the P-site is now bound to a polypeptide and not just an amino 
acid), and the E-site is the exit site of the tRNA (reviewed in (Frank & Agrawal 2000; 
Schmeing & Ramakrishnan 2009)). 
The process described above is carried out by a highly conserved structural 
arrangement of ribosomal RNA (rRNA) molecules and ribosomal proteins, divided 
between a large and a small subunit (Figure 1.2AB). Catalytic and functional activity of 
ribosomes are primarily carried out by their rRNA components, while the ribosomal 
proteins primarily provide structural and regulatory accessory functions. For the small 
subunit, this core consists of one large rRNA molecule and 15 ribosomal proteins (Ban et 
al. 2014). For the large subunit, this core consists of two large rRNA molecules and 18 
ribosomal proteins (Ban et al. 2014). Eukaryotes have evolved larger rRNA than 
bacteria/archaea by adding a number of “expansion segments,” as well as the addition of 
a third rRNA molecule in the large subunit (Ben-Shem et al. 2011). In bacteria/archaea, 
the small subunit rRNA is 16S in size, while the two large subunit ribosomal rRNAs are 
23S and 5S (Schmeing & Ramakrishnan 2009). In eukaryotes, the small subunit rRNA is 
18S in size, while the three large ribosomal subunit rRNAs are 25S, 5.8S, and 5S 
(Schmeing & Ramakrishnan 2009). In addition, archaea and eukaryotes share an 
expanded collection of ribosomal proteins, with bacteria and eukaryotes each possessing 
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an additional set of unique ribosomal proteins. Most of the rRNA expansion segments 
and additional ribosomal proteins present in eukaryotes though not in bacteria are 
localized to the solvent-exposed surface of the large and small ribosomal subunits, 
providing almost complete surface area coverage (Figure 1.2C) (Ben-Shem et al. 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  10 
 
 
 
 
 
 
 
 
 
 
Figure 0-1 
Figure 1.1: Function of the ribosome 
The process of translation elongation consists of several steps. First, an incoming aa-tRNA 
binds the A-site on the fully assembled ribosome (Step 1). Ribosomal peptidyl-transferase 
activity links the associated amino acid to the growing polypeptide chain (Step 2), inducing 
a ratcheting that causes transfer of the peptidyl-tRNA from the A-site to the P-site of the 
large subunit and the now uncharged tRNA from the P-site to the E-site (Step 3). The 
ribosome then ratchets back, causing the mRNA, together with the tRNAs, to move with 
respect to the small subunit. The peptidyl-tRNA is now fully in the P site; the A-site is 
empty and the system has returned to a state allowing binding of the next incoming aa-
tRNA (Step 4). The image shown here is taken from (Alberts et al. 2014). 
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Figure 1.2: Structure of the ribosome 
(A) A crystal structure of a bacterial 70S ribosome (2.8 Å) from T. thermophillus. The E-, 
P-, and A-site tRNAs are colored in yellow, green, and purple, respectively. mRNA is 
colored in black. Key structural features are marked. (B) The small 30S and large 50S 
subunits from the structure in (A) are shown separately. (C) Crystal structures (3 Å) of the 
small 40S and large 60S subunits of the eukaryotic ribosome are shown (S. cerevisiae). 
Elements unique to the eukaryotic ribosome are colored red. The view of the small 40S 
subunit (left) and of the large 60S subunit (right) are of the solvent-exposed surface. The 
images in (A) and (B) are taken from (Schmeing & Ramakrishnan 2009). The image in (C) 
is taken from (Ben-Shem et al. 2011). 
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1.1.2. Kingdom-specific Elements in Translation Initiation 
While the basic principle of translation remains conserved between bacteria, 
archaea, and eukaryotes, the specific needs of each differ. Neither bacteria nor archaea 
have a nucleus, meaning that transcription of DNA into mRNA and translation of mRNA 
into protein occur within the same space. Eukaryotes, on the other hand, sequester the 
process of transcription as well as a series of processes devoted to post-transcriptional 
modification of mRNA in the nucleus. Furthermore, in eukaryotes translation can occur 
by free floating ribosomes in the cytoplasm as well as by ribosomes bound to the 
membrane of the endoplasmic reticulum (ER), which allows for the insertion of nascent 
proteins into a dedicated protein folding environment in the ER as they are synthesized. 
This in turn allows tertiary structure that could not otherwise be achieved in the 
cytoplasm. Bacteria are able to do this on the cell surface (reviewed in (Alberts et al. 
2014)). 
While the elongation stage is relatively straightforward and requires only two or 
three factors regardless of the domain of life, the initiation stage is substantially more 
complex. Initiation likely evolved out of elongation as a way to introduce more regulation 
and handle greater complexity in the translation process, as evidenced by the fact that 
numerous initiation factors seem to have evolved from elongation factors. Bacteria make 
use of only three initiation factors, while eukaryotes make use of a dozen or more. While 
archaea do not have a nucleus, they are evolutionarily closer to eukaryotes than to 
bacteria. The complexity and manner in which translation initiation is performed in 
archaea is more similar to that in eukaryotes as compared to that in bacteria. The least 
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understood of all three domains, archaeal translation initiation seems to require only four 
initiation factors. In the following sections, the means whereby bacteria, archaea, and 
eukaryotes manage initiation will be described. While the nomenclature is unfortunately 
obtuse and uninviting, the hope is that the reader can appreciate how different domains of 
life tackle the same underlying problems and do so with effectively the same set of tools, 
albeit with some evolution and repurposing (reviewed in (Marintchev & Wagner 2004; 
Jackson et al. 2010; Benelli et al. 2016; Benelli & Londei 2011; Hinnebusch 2014; 
Laursen et al. 2005)). 
1.1.2.1. Translation Initiation in Bacteria 
In bacteria, three proteins are responsible for performing the necessary steps 
required for translation initiation (Table 1.1). In bacteria the 3’ tail of the 16S rRNA of 
the small 30S ribosomal subunit is capable of directly binding mRNA via a conserved 
sequence in bacterial mRNA called the Shine-Dalgarno sequence (Steitz & Jakes 1975). 
Since the Shine-Dalgarno sequence is typically a fixed distance upstream (towards the 5’ 
end) of the AUG start codon, 16S binding of mRNA also serves to align the start codon 
in the ribosomal P-site (Chen et al. 1994). It is the remaining two functions of initiation, 
high fidelity start codon recognition and assembly of the full ribosome, that are mediated 
by the three bacterial initiation factors (IFs). Initiation factor 1 (IF1) binds in the A-site of 
the small 30S ribosomal unit, thereby only allowing binding of fMet-tRNAi in the P-site 
and blocking the binding of any aa-tRNAs in the A-site. Initiation factor 2 (IF2) is 
responsible for binding and helping to place the initiating fMet-tRNAi properly in the P-
site of the small 30S ribosomal subunit. It does this in part by having a stronger affinity 
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for fMet-tRNAi compared to other aa-tRNAs. To perform this role, IF2 must be bound to 
the nucleotide guanine tri-phosphate (GTP). Initiation factor 3 (IF3) binds the small 30S 
ribosomal subunit, preventing binding of the large 50S ribosomal subunit. All three IFs 
bind the ribosome to form the 30S pre-initiation complex (PIC), and they do so 
cooperatively, meaning that dissociation of one weakens the affinity of the others for the 
complex (reviewed in (Marintchev & Wagner 2004; Laursen et al. 2005)).  
High fidelity recognition of the start codon and subsequent joining of the large 
ribosomal subunit are coordinated by the interactions of the IFs with each other and with 
the 30S PIC. IF3 is responsible for the fidelity of start codon recognition and prevents 
initiation at non-cognate start codons. Within the P-site, binding of the mRNA start 
codon to the anti-codon on the fMet-tRNAi weakens the affinity of IF3 for the rest of the 
components of the 30S PIC, resulting in its dissociation. Dissociation of IF3 allows the 
large 50S ribosomal subunit to bind to the remainder of the 30S PIC. Recognition and 
ideal alignment of all elements allows for large ribosomal subunit GTPase activating 
protein (GAP) activity to hydrolyze IF2-bound GTP into GDP and Pi. A lower affinity of 
the (now assembled) ribosome for IF2-GDP over IF2-GTP results in IF2’s dissociation 
from the ribosome and the transition from initiation into elongation (reviewed in 
(Marintchev & Wagner 2004; Laursen et al. 2005)).  
 
 
  
Table 1.1: Overview of Eukaryotic Initiation Factors and Prokaryotic/Archaeal Homologs 
 
 
Function 
Prokaryotic 
Homologs 
Archaeal 
Homologs 
eIF2 Forms an eIF2-GTP-Met-tRNAi ternary complex that binds to the 40S subunit, thus 
mediating ribosomal recruitment of Met-tRNAi 
 aIF2 
eIF2B A guanosine nucleotide exchange factor that promotes GDP-GTP exchange on eIF2  aIF2B* 
eIF1 Ensures the fidelity of initiation codon selection; promotes ribosomal scanning; stimulates 
binding of eIF2-GTP-Met-tRNAi to 40S subunits; and prevents premature eIF5-induced 
hydrolysis of eIF2-bound GTP and Pi release 
 aIF1 
eIF1A Stimulates binding of eIF2-GTP-Met-tRNAi to 40S subunits and cooperates with eIF1 in 
promoting ribosomal scanning and initiation codon selection 
IF1 aIF1A 
eIF3 Binds 40S subunits, eIF1, eIF4G and eIF5; stimulates binding of eIF2-GTP-Met-tRNAi 
to 40S subunits; promotes attachment of 43S complexes to mRNA and subsequent 
scanning; and possesses ribosome dissociation and anti-association activities, preventing 
joining of 40S and 60S subunits 
  
eIF4E Binds to the m7GpppG 5′ terminal ‘cap’ structure of mRNA   
    
eIF4A DEAD-box ATPase and ATP-dependent RNA helicase   
eIF4G Binds eIF4E, eIF4A, eIF3, PABP, SLIP1 and mRNA and enhances the helicase activity of 
elF4A 
  
eIF4F A cap-binding complex, comprising eIF4E, eIF4A and eIF4G; unwinds the 5′ proximal 
region of mRNA and mediates the attachment of 43S complexes to it; and assists ribosomal 
complexes during scanning 
  
eIF4B An RNA-binding protein that enhances the helicase activity of eIF4A   
eIF4H An RNA-binding protein that enhances the helicase activity of eIF4A and is homologous to 
a fragment of eIF4B 
  
eIF5 A GTPase-activating protein, specific for GTP-bound eIF2, that induces hydrolysis of 
eIF2-bound GTP on recognition of the initiation codon 
  
eIF5B A ribosome-dependent GTPase that mediates ribosomal subunit joining IF2 aIF5B 
*aIF2B is a homolog of three of the five eIF2B subunits (α, β, and δ) 
Table is adapted from (Jackson et al. 2010). 
1
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1.1.2.2. Translation Initiation in Eukaryotes 
Eukaryotic translation initiation is substantially more complex and highly 
regulated than prokaryotic translation initiation (Figure 1.3). This is in part due to the 
inability of mRNA to directly bind ribosomes in the eukaryotic system. This complexity 
is reflected by the fact that over a dozen factors are required for initiation in eukaryotes 
compared to the three required in prokaryotes. Six of these factors are responsible for the 
added function of mRNA recruitment and binding to the ribosome (Table 1.1). In the 
following descriptions of eukaryotic initiation factors, the numbering scheme is in part an 
artifact of the order in which they were named/discovered and the reader should take care 
not to attribute meaning to potentially coincidental “matching” that may occur between 
eukaryotic, bacterial and archaeal factors. It should also be noted that two of these 
initiation factors (eIF2 and eIF2B) form the basis of the work discussed in this 
dissertation and will be only briefly described at this point. An in-depth description of 
eIF2 and eIF2B can be found in a later section. Table 1.1 provides an overview of 
initiation factors from bacteria, archaea, and eukaryotes. Finally, the reader is directed to 
one of several reviews for a more in-depth discussion of eukaryotic translation initiation 
(Jackson et al. 2010; Marintchev & Wagner 2004; Hernández & Jagus 2016; Benelli et al. 
2016).  
A number of eukaryotic initiation factors are responsible for binding, recruiting, 
and presenting mRNA to the ribosome. This is in part due to the long 5’ UTR sequences 
characteristic of eukaryotic mRNA, which lends itself to substantial secondary structure 
that must be unfolded for scanning to occur. eIF4E is responsible for binding the 5’ cap  
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Figure 1.3: An overview of eukaryotic translation initiation 
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Figure 1.3: An overview of eukaryotic translation initiation 
The canonical pathway of eukaryotic translation initiation is divided into eight stages. 
These stages follow the recycling of post-termination complexes to yield separated 40S 
and 60S ribosomal subunits. They result in the formation of an 80S ribosomal initiation 
complex, in which Met-tRNAi is base paired with the initiation codon in the ribosomal P-
site and which is competent to start the translation elongation stage. These stages are: (2) 
TC formation; (3) formation of a 43S preinitiation complex comprising a 40S subunit, eIF1, 
eIF1A, eIF3, TC and probably eIF5; (4) mRNA activation, during which the mRNA cap-
proximal region is unwound in an ATP-dependent manner by eIF4F with eIF4B; (5) 
attachment of the 43S complex to this mRNA region; (6) scanning of the 5′ UTR in a 5′ to 
3′ direction by 43S complexes; (7) recognition of the initiation codon and 48S initiation 
complex formation, which switches the scanning complex to a ‘closed’ conformation and 
leads to displacement of eIF1 to allow eIF5-mediated hydrolysis of eIF2-bound GTP and 
Pi release; (8) joining of 60S subunits to 48S complexes and concomitant displacement of 
eIF2-GDP and other factors (eIF1, eIF3, eIF4B, eIF4F and eIF5) mediated by eIF5B; and 
(9)  GTP hydrolysis by eIF5B and release of eIF1A and GDP-bound eIF5B from assembled 
elongation-competent 80S ribosomes. Translation is a cyclical process, in which 
termination follows elongation and leads to recycling (1), which generates separated 
ribosomal subunits. The model omits potential ‘closed loop’ interactions involving poly-A 
binding protein (PABP), eukaryotic release factor 3 (eRF3) and eIF4F during recycling, 
and the recycling of eIF2-GDP by eIF2B. The figure and above text are adapted from 
(Jackson et al. 2010). 
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of the mRNA, while eIF4A is an RNA helicase responsible for unwinding the mRNA’s 
secondary structure. The protein poly-A tail binding protein (PABP) binds the 3’ poly-A 
tail of the mRNA molecule. PABP seems to have a stimulatory effect on translation by 
inducing circularization of the mRNA, though the exact mechanism remains unclear. 
eIF4G is a scaffold protein that brings together in one complex eIF4E, eIF4A, and PABP, 
as well as increases the affinity of eIF4E for the 5’ cap and inceases eIF4A helicase 
activity. Both eIF4B and eIF4H stimulate eIF4A activity, likely by binding the newly 
unraveled mRNA and preventing “back-tracking” of eIF4A along the mRNA. Altogether 
then, eIF4F (eIF4G:eIF4A:eIF4E), along with PABP and either eIF4B or eIF4H, binds 
and presents unraveled mRNA to the ribosome (Figure 1.3, Steps 4 and 5) (reviewed in 
(Marintchev & Wagner 2004; Jackson et al. 2010)).  
eIF3 and eIF1 are responsible for binding the small 40S ribosomal subunit and 
preventing association of the large 60S ribosomal subunit. The small 40S ribosomal 
subunit along with eIF3, eIF1, eIF1A, eIF5, and the ternary complex (TC: eIF2-GTP-
Met-tRNAi) form what is called the 43S pre-initiation complex (PIC) (Figure 1.3, Steps 
2 and 3). 43S PIC binding of mRNA and associated initiation factors leads to the 
formation of the 48S initiation complex (IC). eIF3 (unrelated to IF3) plays roles 
potentially in stabilizing both eIF4F complex and TC binding to the small 40S ribosomal 
subunit. eIF1A is homologous to bacterial IF1 in both structure and function, binding in 
the A-site of the small 40S ribosomal subunit, while its long, unstructured N- and C-
terminal tails extend into the P-site to regulate binding of Met-tRNAi  (Yu et al. 2009). 
eIF1, along with eIF1A, promotes an open “mRNA scanning-friendly” conformation of 
 
 
  20 
the small 40S ribosomal subunit, allowing for scanning to occur (Figure 1.3, Step 6) 
(reviewed in (Marintchev & Wagner 2004; Jackson et al. 2010; Hinnebusch 2014)). 
Although no homolog of IF3 has been identified in eukaryotes, eIF1 binds to the 
same site and performs a similar function, and proper recognition of the mRNA’s start 
codon by the ribosome-bound Met-tRNAi’s anti-codon results in a conformation of the 
43S PIC that promotes eIF1 dissociation in a manner parallel to IF3 (reviewed in 
(Marintchev & Wagner 2004; Jackson et al. 2010; Hinnebusch 2014)). 
 eIF5B is homologous to bacterial IF2 in structure and binds to the same site on 
the ribosome, though it retains only one of the two functions of IF2: the promotion of 
ribosomal subunit joining. In eukaryotes, the other function of bacterial IF2, recruitment 
of the initiating Met-tRNAi to the ribosome, is performed by the (coincidently named and 
unrelated) protein eIF2. eIF2 is a main focus of the work described in this dissertation, 
and unlike IF2, which is a monomer, eIF2 is a trimeric protein consisting of α-, β-, and γ-
subunits. The γ-subunit contains the nucleotide binding site and is likely evolved from the 
homologous protein elongation factor eEF1A, a eukaryotic elongation factor responsible 
for recruiting aa-tRNAs to the ribosome and dissociating upon subsequent hydrolysis of 
its bound GTP. All three subunits of eIF2 are responsible for binding Met-tRNAi to form 
the ternary complex (TC), which then binds the small 40S ribosomal subunit. The 
initiation factor eIF5 binds eIF2 through the latter’s β-subunit and serves as a GTPase 
activating protein (GAP), promoting GTP hydrolysis either directly or via derepressing 
latent GTPase activity of eIF2γ. Hydrolysis of eIF2-bound GTP is regulated by a set of 
interactions between eIF2β, eIF1, eIF5, and the small 40S ribosomal subunit. GTP 
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hydrolysis is triggered by conformational changes in the 43S PIC, in turn triggered by 
start codon selection, which is opposed by eIF1 (Figure 1.3, Step 7) (reviewed in 
(Marintchev & Wagner 2004; Jackson et al. 2010)).  
 Start codon recognition induces a commitment of the 48S IC to initiation. Base 
pairing of the start codon to the Met-tRNAi’s anti-codon results in a conformational 
change in the P-site leading to ejection of eIF1 and displacement of eIF1A’s C-terminal 
tail (CTT). eIF1 dissociation allows for GTP hydrolysis and phosphate release from eIF2. 
eIF5B promotes dissociation of eIF2-GDP, which together with the roughly ~10-100 fold 
(Kapp & Lorsch 2004; Sokabe et al. 2012) reduced affinity of eIF2-GDP for Met-tRNAi 
as compared to eIF2-GTP results in eIF2-GDP’s release from the 48S initiation complex, 
along with eIF5. Joining of the large 60S ribosomal subunit, along with binding of 
eIF1A’s displaced CTT to eIF5B-CTD, precipitates hydrolysis of eIF5B-bound GTP and 
subsequent dissociation of eIF5B and eIF1A (Figure 1.3, Steps 8 and 9). At this point, 
the ribosome is fully formed, “locked in” on the starting codon, and translation 
elongation can begin (reviewed in (Marintchev & Wagner 2004; Jackson et al. 2010)).  
Upon reaching the stop codon, the system must terminate elongation and recycle 
all its constituent components. Several factors are involved in recognition of the final stop 
codon, subsequent hydrolysis of the final peptidyl-tRNA, and release of the polypeptide. 
The protein ABCE1 promotes dissociation of the large 60S ribosomal subunit, leaving 
the small 40S ribosomal subunit still bound to mRNA and tRNA. Re-binding of the 
initiation factors eIF1, eIF1A, and eIF3 promote dissociation of mRNA and tRNA. 
eIF5B-GDP must be recycled to its GTP-bound form, a spontaneous exchange given a 
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bound lifetime of GDP of ~100 milliseconds and the nearly immediate on-rate of GTP 
(Pisareva et al. 2007). Spontaneous exchange of eIF2-bound GDP for GTP, however, 
does not occur due to the high affinity of GDP for eIF2. Exchange requires the presence 
of the guanine nucleotide exchange factor (GEF) eIF2B to promote dissociation of GDP 
from eIF2, thus allowing GTP binding. This allows for the recycling of eIF2 to a state 
capable of forming a productive ternary complex with Met-tRNAi (Figure 1.4). In order 
for eIF2B to promote dissociation of eIF2-bound GDP, it must first displace eIF5 from 
eIF2-GDP (Singh et al. 2006) (reviewed in (Marintchev & Wagner 2004; Jackson et al. 
2010; Jackson et al. 2012)). 
On some occasions, however, following recognition of the stop codon, mRNA 
fails to dissociate from the small 40S ribosomal subunit. Upon re-binding of eIF1 and 
eIF1A, scanning activity is once again possible. As mentioned above, mRNA scanning is 
bi-directional in the absence of eIF4F (eIF4G:eIF4A:eIF4E). In the case of incomplete 
dissociation of mRNA, eIF3, and eIF4F, the 40S ribosomal subunit is capable of 
continuing to scan mRNA in the 5’ to 3’ direction. Without the ternary complex (TC), 
however, it is incapable of recognizing a start codon. The level of TC in the cell thus 
determines how long scanning can occur before another TC binds the scanning 43S PIC 
and results in a competent initiation complex capable of re-initiating on a downstream 
start codon. This process is known as translation re-initiation, and more than 45% of 
mammalian (13% of yeast) mRNAs possess start codons upstream of the actual coding 
sequence (ORF) (Calvo et al. 2009; Lawless et al. 2009; Ingolia et al. 2009). These  
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Figure 1.4: eIF2 recycling and ternary complex (TC) formation by eIF2B 
Binding of the ternary complex (eIF2-GTP-Met-tRNAi) to the small ribosomal subunit is 
required for proper identification of the start codon during scanning. Following hydrolysis 
of the eIF2-bound GTP and subsequent full assembly of the ribosome, eIF2-GDP must be 
recycled to its active GTP-bound state in order to form another ternary complex and 
subsequently engage in another round of translation. eIF2B is the guanine nucleotide 
exchange factor (GEF) that is responsible for promoting exchange of eIF2-bound GDP for 
GTP. It also serves to recruit the initiator Met-tRNAi and promote formation of a new TC. 
Phosphorylation of eIF2 by one of four kinases converts it into a competitive inhibitor of 
eIF2B, not only reducing the amount of eIF2 capable of forming new TC, but also 
sequestering eIF2B and reducing potential exchange on remaining unphosphorylated eIF2 
(reviewed in (Marintchev & Wagner 2004)). 
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upstream open reading frames (uORFs) are often used for regulation (Skabkin et al. 
2013) (reviewed in (Meijer & Thomas 2002; Lu et al. 2004; Vattem & Wek 2004)). 
1.1.2.3. Translation Initiation in Archaea 
Archaeal translation initiation remains the least understood of all three domains of 
life and for completeness sake is detailed here. It appears to possess elements of both 
bacterial and eukaryotic translation initiation, along with a number of unique elements. 
Many of these elements were identified by homology to structures and functions of 
known eukaryotic factors (Table 1.1). While archaeal mRNA, like bacterial mRNA, is 
polycistronic, one major difference between archaea and both bacteria/eukaryotes lies in 
the fact that a large number (in some species a majority) of archaeal mRNAs are 
leaderless and thus lack a 5’ UTR. They therefore cannot share the same ribosomal 
subunit binding mechanism as bacteria (i.e. the Shine-Dalgarno sequence). Shine-
Dalgarno sequences can still exist upstream of internal start codons, however. Translation 
of leaderless mRNAs remains a mystery, though it appears to require the fully assembled 
ribosome (reviewed in (Benelli & Londei 2011; Benelli et al. 2016)).  
Archaea possess four initiation factors, which perform all the steps of translation 
initiation. Archaeal initiation factor 1A (aIF1A) is homologous to bacterial IF1 and 
eukaryotic eIF1A and plays a similar role in binding in the ribosomal A-site and helping 
to select for Met-tRNAi binding in the P-site. Archaeal initiation factor 5B (aIF5B) is 
homologous to bacterial IF2 and eukaryotic eIF5B, though like the latter it no longer 
serves IF2’s role in binding and directing the initiatior Met-tRNAi. Rather, like eIF5B, 
aIF5B promotes ribosomal subunit joining (Pestova et al. 2000), as supported by its  
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ability to partially recover translation in yeast upon deletion of eIF5B (Maone et al. 2007; 
Lee et al. 1999). As is the case in eukaryotes, no homolog of IF3 appears to exist in 
archaea. Like eukaryotes, archaea have an eIF1 homolog, aIF1, which plays a similar role 
to bacterial IF3 in modulating mRNA binding to the ribosome and ensuring fidelity of 
start codon recognition, though it is not evolutionarily related. Like eIF2, archaeal 
initiation factor aIF2 is a heterotrimer that binds Met-tRNAi and helps place it in the P-
site on the ribosome (reviewed in (Marintchev & Wagner 2004; Benelli & Londei 2011; 
Benelli et al. 2016)). 
1.2. Overview of the Integrated Stress Response 
The integrated stress response (ISR) is the collective name given to a series of 
convergent pathways through which cells adapt to stress by slowing the rate of protein 
synthesis and activating signaling pathways aimed at stress resolution. Induction of ISR 
results in a rapid (~minutes) depletion of ternary complex levels in the cells, necessarily 
leading to a slowing or halt in translation (Figure 1.5). ISR induction also results, 
paradoxically, in a concurrent de-repression of translation of a subset of proteins 
mediating the stress response. ISR is at its core a balancing act: slowing down protein 
synthesis just enough in magnitude and duration to aid in resolution of stress, but not too 
much so as to kill the cell. Simultaneous activation of stress-resolution pathways further 
aids in restoration of homeostasis. It is thus not surprising that ISR is very heavily 
regulated and operates under a default negative feedback loop. Both an overly active 
stress response or an underactive stress response can lead to cell death. Both hyper-active 
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and hypo-active stress responses can be caused by a variety of environmental and genetic 
factors (reviewed in (Harding et al. 2000; Harding, Zhang, H. H. Zeng, et al. 2003)). 
Early studies of the ribosome and protein synthesis were performed primarily in 
rabbit reticulocyte lysates in the context of experiments attempting to understand 
hemoglobin synthesis. A “mashed up” mixture of the innards of red blood cell precursors, 
rabbit reticulocyte lysate contains all the proteins and factors necessary for protein 
synthesis. Addition of radioactively labeled amino acids and measurement of 
radioactivity coming from purified hemoglobin fractions serve as an in vitro translation 
system. It was in this system that it was first noticed that hemin (oxidized heme) was able 
to stimulate complex formation of Met-tRNAi with the small 40S ribosomal subunit and 
subsequently the rate of hemoglobin translation (Grayzel et al. 1966; Waxman & 
Rabinovitz 1966). It was also noted that without hemin, translation would come to a halt 
after several minutes, and that the stimulatory effect of heme addition was occurring in 
the initiation phase of protein synthesis (Zucker & Schulman 1968). Therefore, the effect 
was likely not hemoglobin mRNA specific (Legon et al. 1973). 
It was next noted that a soluble factor was responsible for the loss in capacity of 
rabbit reticulocyte lysate to produce protein, thus acting as a translational repressor 
(Maxwell & Rabinovitz 1969). A similar inhibition of protein synthesis had been noted in 
cells infected by lytic viruses such as poliovirus, mediated by the presence of double 
stranded RNA (dsRNA) (Ehrenfeld & Hunt 1971).This inhibition also required the 
presence of a soluble factor (Hunter et al. 1975). Inhibition did not require the continued 
presence of dsRNA (Ehrenfeld & Hunt 1971) and could be transferred to the rabbit   
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Figure 1.5: The Integrated Stress Response (ISR) 
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Figure 1.5: The Integrated Stress Response (ISR) 
The integrated stress response (ISR) is triggered by a number of stresses, including ER 
stress (e.g. by accumulation of misfolded proteins), amino acid deficiency, heme 
deficiency, and viral infection. These stresses activate, respectively, the kinases PERK, 
GCN2, HRI, and PKR. PERK is activated in response to reduction in levels of chaperone 
proteins in the ER, whose interactions with PERK would otherwise keep it in an inactive 
state. GCN2 is activated by the binding of uncharged tRNAs, the accumulation of which 
marks low levels of free amino acids. Similar to PERK, HRI is kept inactivated by binding 
heme, thus linking HRI activation to low levels of heme in the cell. Finally, PKR is 
activated by binding double-stranded RNA (dsRNA), whose presence marks viral infection 
of the cell. Under normal circumstances, eIF2B mediates nucleotide exchange on eIF2 and 
maintains ternary complex levels in the cell necessary for translation to freely occur. All 
four of the above kinases phosphorylate serine 51 on the N-terminal domain (NTD) of 
eIF2α, converting eIF2 into a competitive inhibitor of eIF2B mediated exchange. This leads 
to reduction in the levels of ternary complex (TC) in the cell, thus limiting the rate of 
translation initiation and subsequently of translation as a whole. Translation of a subset of 
proteins and transcription factors is repressed by the presence of upstream open reading 
frames (uORFs), in a manner relieved by low levels of TC. Low levels of TC increase the 
probability of initiation at downstream start codons, resulting in the paradoxical increase 
in translation of this set of proteins. These transcription factors and proteins mediate a 
series of pro- and anti-apoptotic pathways responsible for relieving or surviving the 
stressed state if possible, or else inducing controlled cell death. One such factor, GADD34, 
is responsible for recruiting the phosphatase PP1 to de-phosphorylate eIF2α, thus providing 
a negative feedback loop that turns off ISR upon resolution of the triggering stresses 
(reviewed in (Harding et al. 2000; Harding, Zhang, H. Zeng, et al. 2003)). 
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reticulocyte lysate system upon addition of cytoplasmic extract from poliovirus-infected 
HeLa cells (Hunt & Ehrenfeld 1971). The factors responsible for translation repression in 
the absence of heme and in the presence of dsRNA were eventually identified as kinases 
that phosphorylated eIF2 (Farrell et al. 1977). The former is now known as heme-
regulated inhibitor (HRI) kinase and the latter as ds-RNA-activated protein kinase (PKR) 
(Levin et al. 1975; Levin et al. 1976; Farrell et al. 1977). Another kinase, general control 
non-derepressible 2 (GCN2), with equivalent function (i.e. phosphorylation of serine 51) 
was found in yeast (Tzamarias et al. 1989; Chen et al. 1991; Dever et al. 1992) and later 
in mammals (Berlanga et al. 1999) to activate ISR in response to amino acid deficiency. 
The fourth and final kinase responsible for activating ISR was found to respond to ER 
stress and is called PKR-like endoplasmic reticulum kinase (PERK) (Harding et al. 
1999). 
Yeast possess only the GCN2 kinase, while mammals possess all four of the 
kinases named above. While each kinase is predominantly responsible for inducing ISR 
in response to a single stress (Figure 1.5), with time additional functionality has been 
recognized and appreciated. GCN2 is activated upon binding of uncharged tRNAs, 
effectively linking induction of ISR to low levels of available amino acids (Dong et al. 
2000; Wek et al. 1989; Dever et al. 1992). PKR is activated upon binding of double-
stranded RNA (dsRNA), thus coupling induction to the presence of viral nucleic acids 
(Hunter et al. 1975). HRI activity is suppressed by binding heme, thus coupling induction 
to low levels of heme (Maxwell et al. 1971; Hunt et al. 1972). Finally, PERK is kept 
inactive by a pool of chaperone proteins, which is rapidly depleted as misfolded proteins 
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accumulate in the ER (Harding et al. 1999). However, these kinases have also been 
implicated in the induction of ISR via mechanisms not yet completely understood. For 
example, GCN2 and PERK appear to activate in response to damage due to UV 
irradiation (Jiang & Wek 2005). HRI can be activated in response to heavy metal toxicity, 
as well as oxidative stress and heat shock (Han et al. 2001; Hinnebusch 1994). The co-
opting of these kinases by the cell to recognize additional stresses is testimony to the 
effectiveness of ISR as a tool to maintain homeostasis. 
Upon activation, all four kinases phosphorylate serine 51 on the N-terminal 
domain of eIF2α, resulting in the subsequent depletion of ternary complex levels via 
sequestration and inhibition of eIF2B. Low levels of TC result in two simultaneous 
effects. The first is an obvious reduction in the rate of translation initiation, and thus of 
protein synthesis. The second is the translation of the otherwise suppressed transcription 
factor ATF4 (among others) via the previously described mechanism of translation re-
initiation. ATF4 is in turn responsible for activation of a complex and interconnected 
series of pathways responsible for mediating stress resolution/adaptation. These factors 
are controlled by uORFs and under normal conditions their expression is repressed. Upon 
induction of ISR and a subsequent decrease in levels of TC, translation re-initiation 
allows for efficient translation of these factors (reviewed in (Harding et al. 2000; 
Harding, Zhang, H. H. Zeng, et al. 2003; Vattem & Wek 2004)).  
ISR operates under the constant pull of a negative feedback loop, which in the 
absence of activated kinases results in a rapid return of the system to normal homeostasis. 
Growth arrest and DNA damage-inducible protein (GADD34) is repressed by uORFs and 
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de-repressed by ISR-induced drops in TC levels. GADD34 is also one of the target genes 
upregulated by ATF4. GADD34 is responsible for binding protein phosphatase 1 (PP1) 
and recruiting it to de-phosphorylate eIF2(α-P), resulting in termination of ISR (Figure 
1.5). Thus, as long as one or more of the kinases remain active, downstream signaling 
pathways activated by ATF4 remain “on.” On the other hand, C/EBP Homologous 
Protein (CHOP) is another protein activated by ATF4, which itself is a transcription 
factor that mediates expression of proteins involved in pro-apoptotic pathways. The 
downstream signaling pathways activated by ATF4 therefore result in a careful balance 
of pro- and anti-apoptotic forces, maximizing the ability of the cell to recover while also 
preparing it for apoptosis in case the stress is too large in magnitude or too long in 
duration (reviewed in (Harding et al. 2000; Harding, Zhang, H. H. Zeng, et al. 2003; 
Vattem & Wek 2004)).  
1.3. Overview of Common Approaches 
The work described in this dissertation seeks to build on and challenge existing 
understandings of the structure and function of eIF2 and its exchange factor, eIF2B. 
Much of what was known about eIF2 and eIF2B at the start of the work described here is 
derived from three types of experiments: biochemical exchange assays, mutational data, 
and structural studies. It is therefore useful to provide some context as to how these 
experiments were performed, prior to moving on to an in-depth review of what was 
known about eIF2 and eIF2B. 
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1.3.1. In-vitro biochemical assays 
In order to understand the mechanisms responsible for nucleotide exchange and 
its regulation, exchange assays were performed in rabbit reticulocyte lysate in which eIF2 
was bound to radioactively or fluorescently labeled GDP. Experiments were generally 
performed by observing the rate of signal decay of pre-incubated labeled GDP in the 
presence of unlabeled GDP. Experiments using unlabeled GTP, however, were 
unsuccessful unless performed in the presence of Met-tRNAi. This is due to the very high 
affinity of eIF2B for eIF2-GTP (the product of exchange), effectively allowing for only 
one exchange to occur per molecule of eIF2B. Exchange for GTP could be observed, 
however, when performed in the presence of Met-tRNAi. This makes sense, given that 
Met-tRNAi binding to eIF2B-bound eIF2 destabilizes the eIF2B:eIF2 interaction and 
allows for product (i.e. ternary complex) release. Ternary complex formation and 
recruitment to the small 40S ribosomal subunit could be followed by using radioactively 
labeled [35S]Met-tRNAi. 
1.3.2. Mutational Data 
A wealth of data about eIF2B assembly and function is derived from experiments 
in yeast genetics. These experiments are typically performed by introducing random 
mutations into yeast cells and observing the resulting phenotype. Here, phenotypes deal 
with induction of ISR, as measured by induction of GCN4. GCN4 can be thought of as 
the yeast equivalent of ATF4, whose expression is upregulated following induction of 
ISR by the activation of GCN2 in response to amino acid deprivation. In this manner, 
mutations in eIF2B can be classified in one of two categories: mutations that prevent 
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induction of ISR in response to amino acid deprivation, and mutations that induce ISR in 
the absence of stress. The former are known as Gcn-, as they result in GCN4 being non-
derepressible (i.e. derepression is prevented). The latter are known as Gcd-, as they result 
in GCN4 being de-repressed, despite the absence of a stress. Sequencing of mutant 
strains with one of these two phenotypes allows for identification of residues potentially 
involved in eIF2B activity (reviewed in (Hinnebusch 2005)). Mapping these mutations on 
a structure or homology model of the proteins in which they occur allows for speculation 
as to the mechanistic basis underlying the mutation’s effect on eIF2B activity. 
A second source of mutational data comes from sequencing the genomes of 
patients with a rare autosomal recessive neurodegenerative disorder called vanishing 
white matter (VWM) disease, or childhood ataxia with central nervous system 
hypomyelination (CACH). Although the mechanism of demyelination and 
neurodegeneration remains unclear, the genetic basis of CACH/VWM has been 
determined to lie in mutations in eIF2B subunits. 
1.3.3. Structures 
To make predictions about assembly and determine mechanisms of action is a 
challenging task, especially in the absence of information about the three dimensional 
structure of the proteins of interest. Solving structures of proteins, however, is no easy 
task either. There are three main techniques used to solve for protein structures: x-ray 
crystallography, nuclear magnetic resonance (NMR), and electron microscopy (EM). X-
ray crystallography is responsible for the vast majority of structures, followed by NMR 
and more recently, cryo-EM. Each has its own advantages and disadvantages, and comes 
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with its own technical challenges. X-ray crystallography requires proteins to arrange 
themselves in regular patterns (crystals), yielding strong signal and allowing high 
resolution structures. Crystal formation, however, is often more of an art than a science. 
Furthermore, crystal packing may introduce non-physiological artifacts into the structure. 
Lastly, only static states can be captured by x-ray crystallography. NMR, on the other 
hand, is capable of examining the behavior of proteins in solution, and thus informing 
about the dynamic motion of secondary/tertiary structure, as well as dynamic interactions 
with other molecules, proteins, ligands, etc. NMR is generally restricted to proteins 
smaller than ~35 kDa, however, due to relaxation-induced signal loss experienced by 
larger proteins. Cryo-EM has recently emerged as an alternative to the above two 
approaches. Cryo-EM allows for substantially simpler and smaller protein preparations, 
and at large sizes can rival x-ray crystallography in resolution. With increasing 
improvement in hardware and software, cryo-EM is becoming increasingly effective at 
determining structures of smaller and smaller proteins. Structures referred to throughout 
this dissertation were solved by one of the three methods just described, and are referred 
to by their protein data bank (PDB) ID, a four-character combination of letters and 
numbers. Further information about these structures, as well as the underlying deposited 
structures can be found at www.rcsb.org.  
1.4. Overview of Key Players 
1.4.1. eIF2 and eIF2(α-P) 
Eukaryotic eIF2 is a heterotrimer, consisting of α-, β-, and γ-subunits, responsible 
for binding and recruitment of the initiatior Met-tRNAi to the ribosome (Figure 1.6A).  
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Figure 1.6: Structure of eIF2 
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Figure 1.6: Structure of eIF2 
(A) A stereo view of the eukaryotic ternary complex (eIF2-GTP-Met-tRNAi) (3JAP.pdb) 
from a 4.9 Å cryo-EM structure of the partial yeast 48S pre-initiation complex  (Llácer et 
al. 2015). eIF2α is colored yellow, eIF2γ is colored green, and eIF2β is colored blue. Met-
tRNAi is shown as a ribbon and colored grey. (B) A stereo view of archaeal aIF2γ 
(1KK3.pdb) from a 1.9 Å crystal structure (Schmitt et al. 2002). The nucleotide binding 
domain (G-domain) is colored green, with the bound GTP colored red. Domain 2 is colored 
orange and domain 3 is colored teal. The two switch regions are colored purple. A loop in 
the switch 2 region does not appear in the structure and is marked by a dashed line. (C) A 
stereo view of human eIF2α (1Q8K.pdb) from an NMR structure (Ito et al. 2004), as 
viewed from the “front” and the “back.” The OB-fold subdomain (orange) and the α-helical 
subdomain (salmon) constitute the N-terminal domain of eIF2α. The C-terminal domain is 
colored teal, with the C-terminal tail (CTT) colored blue. The CTT extends a further 12 
residues beyond that shown in the structure. The phosphorylation loop is marked in purple, 
with the actual site of phosphorylation (serine 51) shown as sticks. 
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When bound to GTP, eIF2 is considered “active” and capable of performing its role, with 
hydrolysis of GTP marking the completion of its task and its subsequent “inactivation.” 
eIF2 was originally purified from rabbit reticulocyte lysate (Balkow et al. 1973; Lloyd et 
al. 1980). Its addition was found to stimulate binding of Met-tRNAi to the small 40S 
ribosomal subunit (Balkow et al. 1973) in a manner dependent on the presence and 
activity of its guanine exchange factor (GEF) eIF2B (de Haro et al. 1978; Siekierka et al. 
1981; Safer 1983).  
eIF2γ is homologous to and likely evolved from the bacterial elongation factor 
EF-Tu and the eukaryotic elongation factor eEF1A, both of which bind GTP in the same 
manner and both of which are responsible for binding and recruiting aa-tRNAs to the 
ribosome during elongation. eIF2γ is a member of the family of small soluble GTPases, 
not to be confused with the “classical” trimeric G-proteins (reviewed in (Marintchev & 
Wagner 2004)).  
eIF2α consists of an N-terminal domain (NTD) and a C-terminal domain (CTD), 
connected by a flexible linker. The C-terminal domain is responsible for binding eIF2γ, 
and interestingly has homology to the C-terminal domain of the elongation factor 
eEF1Bα, which acts as a guanine exchange factor to promote reactivation of eEF1A. 
eIF2α-CTD does not possess this function, however (reviewed in (Marintchev & Wagner 
2004)). 
eIF2β is bound to the opposite side of eIF2γ as is eIF2α, and is itself homologous 
to the N-terminal domain of eIF5 (the domain responsible for eIF5’s GTPase activating 
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(GAP) activity). Like eIF2α, eIF2β does not possess this function (reviewed in 
(Marintchev & Wagner 2004)).  
eIF2 likely evolved from a monomeric elongation factor originally tasked with 
binding and recruitment of aa-tRNAs to the ribosome, later gaining specificity for a 
specific aa-tRNA (i.e. the initiator Met-tRNAi) as well as recruiting its own GEF and 
GAP (though eventually repurposing them for a different function). The above 
description is also true for archaeal aIF2, though with the primary difference that aIF2β is 
missing the N-terminal tail (NTT), which in eukaryotes is responsible for binding eIF5-
CTD and eIF2B. This makes sense, as archaea possess no known homologs of eIF5 or 
eIF2B. In archaea, however, it still remains unclear which proteins serve the GEF 
function, normally carried out in eukaryotes by eIF2B, and the GAP function, normally 
carried out by eIF5 (though only on the pre-initiation complex in response to start-codon 
recognition) (reviewed in (Marintchev & Wagner 2004; Benelli & Londei 2011; Benelli 
et al. 2016)). 
While several partial structures of eIF2 have been solved (Stolboushkina et al. 
2008; Yatime et al. 2006; Yatime et al. 2007), the most complete structures to date are a 
crystal structure (5.34 Å) of an archaeal TC from S. solfataricus (Schmitt et al. 2012) and 
a cryo-EM structure (4.9 Å) of a eukaryotic TC from S. cerevisiae (Llácer et al. 2015). 
The γ-subunit forms the core of the heterotrimer and consists of three domains, one of 
which (domain 1, or the “G” domain) is responsible for nucleotide binding (Figure 
1.6B). The three domains of eIF2γ are somewhat flexible with respect to one another. 
Two switch regions (the first between domain 2 and G, and the second in a pocket 
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between all three) change conformation upon nucleotide binding. eIF2α is bound via its 
C-terminal domain to domain 2 of eIF2γ, while eIF2β is bound to eIF2γ’s G-domain via a 
single α-helix (Schmitt et al. 2002; Llácer et al. 2015). 
As the α-subunit of eIF2 lies at the center of a highly conserved and critically 
important regulatory mechanism in the cell (as well as is the subject of this dissertation), 
a more in-depth description of its structure will be necessary. Unless otherwise stated, 
from this point on references to structural features or residue numbering of eIF2α will 
refer to the 2004 NMR solution structure of human eIF2α (1Q8K.pdb) (Figure 1.6C) (Ito 
et al. 2004). The structure of human eIF2α reveals the presence of two folded domains, 
an NTD (aa 1-183) and a CTD (aa 188-280), connected by a flexible linker. The CTD is 
followed by an extended C-terminal tail (CTT), consisting of residues 280-314. eIF2α-
NTD consists of two subdomains: (1) an oligonucleotide/oligosaccharide-binding (OB) 
fold subdomain formed by residues 18-85, and (2) an α-helical subdomain formed by 
residues 91-183. In between and stabilizing these two domains is an aromatic 
hydrophobic core, consisting of two residues preceding the OB-fold (Phe7 and Tyr8), one 
residue from the β2/β3 loop of the OB-fold (Tyr38), and four residues from the first of 
the five α-helices that forms the α-helical domain (Phe101, Tyr108, Phe130, and Trp135).  
The OB-fold of the S1 subdomain is uncharacteristic in that it has an extended 
β3/β4 loop, whose flexible nature initially resisted crystallization in human eIF2α 
(Nonato et al. 2002), though not in S. cerevisiae eIF2α (Dhaliwal & Hoffman 2003). 
Called the phosphorylation loop (P-loop) since it contains a regulating phosphorylation 
site at serine 51, this stretch of residues (His46 to Arg66) is highly conserved among 
 
 
  40 
eukaryotes and is highly positively charged. Most of eIF2α-CTT is intrinsically 
disordered, except for an α-helical region (residues 281-288). As mentioned earlier, while 
higher order eukaryotes possess the entire CTT, yeast are missing the final dozen or so 
residues and archaea are missing the entire CTT altogether (Marintchev & Wagner 2004). 
tRNA-bound methionine is recognized by eIF2γ, while both eIF2α and eIF2β 
serve to surround the tRNA. In archaea, aIF2α appears to play a larger role than aIF2β. 
The difference in contribution from aIF2α vs eIF2α may come from the presence in 
eukaryotes of the CTT described above, in which a preponderance of highly acidic 
residues likely competes with the negatively charged tRNA for binding to eIF2α (Schmitt 
et al. 2012). The observation that the switch 1 region contacts the tRNA suggests a 
coupling between tRNA binding and the overall conformation of the eIF2 heterotrimer. 
Phosphorylation of serine 51 on eIF2α-NTD is the key element that defines and 
unifies the integrated stress response. Phosphorylation of eIF2 results in a tight, non-
productive binding to eIF2B, which given the small amount of eIF2B compared to eIF2 
in the cell resulted in the sequestration and effective inactivation of eIF2B by 
phosphorylated eIF2 (referred to as eIF2(α-P)). This is the case even when only a fraction 
of eIF2 is phosphorylated. The depletion of functional eIF2B leads to an inability to 
recycle “spent” eIF2-GDP to active eIF2-GTP, a necessary step for the formation of 
ternary complex and thus of translation initiation (see (de Haro et al. 1978; de Haro & 
Ochoa 1978; Panniers & Henshaw 1983; Clemens et al. 1982; Safer 1983; Siekierka et al. 
1984; Goss et al. 1984; Salimans et al. 1984)). 
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1.4.2. eIF2B 
As described earlier, the eukaryotic initiation factor eIF2B is the guanine 
nucleotide exchange factor responsible for exchanging eIF2-bound GDP for GTP. First 
identified in 1978 as a soluble factor capable of restoring stalled initiation in rabbit 
reticulocyte lysate (de Haro et al. 1978), the mechanism underlying eIF2B activity 
remains an active question. Conceptually, however, it has been determined that eIF2B 
acts by inducing dissociation of GDP and passively allowing a GTP to bind, rather than a 
more “active” switching mechanism of GTP for GDP (Safer 1983; Matts et al. 1983; 
Siekierka et al. 1982). 
The primary challenge to fully elucidating how eIF2B performs its role has been a 
lack of structures with which to formulate testable hypotheses. In part, this dissertation 
describes my work in attempting to understand the assembly and structure of eIF2B, a 
question actively and concurrently pursued by many other groups in the field. A choice 
has thus been made to present here the understanding of eIF2B assembly and structure 
held by the field at the onset of the work described in this dissertation. The reader should 
be aware that while descriptions of the individual subunits remain accurate, the 
description of eIF2B assembly is no longer held to be true, and is only presented in an 
attempt to provide the reader with a framework with which to approach the work 
described in Chapters 3-5. A current description of eIF2B assembly and structure is 
provided in Chapter 4.   
eIF2B consists of five subunits, α-ε, named in order of increasing molecular 
weight. All five subunits except for eIF2Bα are essential for catalytic activity in yeast. 
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eIF2Bε is roughly 80 kDa and is capable on its own of catalyzing nucleotide exchange. 
Only partial structures of the catalytic region existed, in both S. cerevisiae (Boesen et al. 
2004) and in humans (Wei et al. 2010) (Figure 1.7D). The C-terminal domain (~20 kDa) 
contains both the catalytic element responsible for promoting nucleotide exchange on 
eIF2γ as well as a binding site for eIF2β. 
eIF2Bγ is homologous to eIF2Bε, though it is missing an equivalent to eIF2Bε-
CTD. This is consistent with evidence that unlike eIF2Bε, eIF2Bγ is unable to perform 
nucleotide exchange on its own (Marintchev & Wagner 2004).  
The α-, β-, and δ-subunits of eIF2B are homologous to each other as well (Figure 
1.7A-C). As the crystal structure (2.65 Å) of human eIF2Bα was solved in 2009 
(3ECS.pdb) (Hiyama et al. 2009), generalizations could be made about eIF2Bβ and 
eIF2Bδ based on their homology over the entire length of eIF2Bα. eIF2Bα consists of an 
N-terminal α-helical domain and a C-terminal Rossman-fold domain totaling ~35 kDa, 
with a positively-charged pocket about 15 Å in diameter in between the two. eIF2Bβ 
(~40 kDa) contains an additional extended loop in the N-terminal domain. eIF2Bδ (~60 
kDa) contains a long, ~170 residue N-terminal tail, absent in both eIF2Bα and eIF2Bβ. 
Both eIF2Bβ and eIF2Bδ possess the positively charged pocket between their N- and C-
terminal domains. 
1.4.2.1. Assembly of eIF2B subunits 
Speculation as to the assembly and mechanism underlying eIF2B activity was 
based on phenotypes arising from mutations of subunits in yeast, and 
structures/assemblies of proteins with sequence homology. Mapping these mutations to  
 
 
  43 
 
Figure 1.7: Structure of eIF2B subunits 
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Figure 1.7: Structure of eIF2B subunits 
(A) A stereo view of human eIF2Bα (3ECS.pdb) from a 2.65 Å crystal structure (Hiyama 
et al. 2009). The N-terminal domain is colored orange, while the C-terminal domain is 
colored teal. An unstructured loop that does not appear entirely in the crystal structure is 
marked by a dashed line. Homology models of human eIF2Bβ (B) and eIF2Bδ (C) are 
shown in stereo view as well. eIF2Bδ possesses a long N-terminal tail that is not found in 
either eIF2Bα or eIF2Bβ, and is not shown here. (D) The eIF2Bγ and eIF2Bε homolog, 
ADP-Glc PPase (1YP2.pdb) from a 2.11 Å crystal structure (Jin et al. 2005). The sugar-
nucleotidyl transferase-like (SNT) domain is colored grey, while the acyl-transferase (AT) 
domain is colored teal. eIF2Bε possesses a mobile C-terminal domain responsible for its 
catalytic activity, that is missing in eIF2Bγ. The human eIF2Bε-CTD (3JUI.pdb) from a 2 
Å crystal structure (Wei et al. 2010) is shown in salmon. A dashed line represents the 
flexible linker between the body of eIF2Bε and its C-terminal domain 
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the structure of eIF2Bα, as well as to homology-based structures of eIF2Bβ and eIF2Bδ, 
allowed for some initial predictions about potential interactions responsible for eIF2B 
assembly as well as about interactions with eIF2 and discrimination between eIF2 and 
eIF2(α-P). eIF2B is divided into two subcomplexes: a regulatory subcomplex consisting 
of eIF2Bα/β/δ and a catalytic subcomplex consisting of eIF2Bγ/ε. This classification was 
based on an accumulation of GCN- mutations on the α-, β-, and δ-subunits of eIF2B, data 
showing that overexpression recovers translation in the presence of eIF2(α-P), and 
demonstration that they lacked any catalytic activity (Yang & Hinnebusch 1996). 
eIF2B had been identified early on as roughly ~200-300 kDa in size by analytical 
ultracentrifugation (de Haro & Ochoa 1978; de Haro et al. 1978; Ranu & London 1979; 
Siekierka et al. 1981). Given that the sum molecular weight of all five subunits adds up to 
~260 kDa, it was believed that eIF2B consisted of one copy each of its five subunits. This 
would therefore indicate an assembly consisting of a trimeric regulatory sub-complex 
(eIF2Bα/β/δ) and a dimeric catalytic sub-complex (eIF2Bγ/ε). This assembly, along with 
the mutational data described above, could now be combined with an investigation of 
structures/assemblies of proteins with sequence homology. 
The regulatory subcomplex subunits (i.e. eIF2Bα, β, and δ) have some homology 
from which structural conclusions might be drawn. All three are most closely related to 
the dimeric archaeal initiation factor aIF2B (Kakuta et al. 2004), and less so to the 
metabolic enzymes methylthioribose-1-phosphate isomerase (MTNA) and ribose-1,5-
bisphosphate isomerases (RBPI). A crystal structure (2.2 Å) of aIF2B was determined in 
2004 (1VB5.pdb) (Kakuta et al. 2004), of yeast MTNA and bacterial MTNA in 2004 
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(Bumann et al. 2004) and 2008 (Tamura et al. 2008), respectively, and finally of archaeal 
RBPI in 2012 (Nakamura et al. 2012). In all cases, the smallest asymmetric unit is a 
homodimer, and while the exact angle of orientation differed, all were defined by the 
same contact surface between the respective molecules’ C-terminal domains. Although 
not deposited, a hexameric assembly of aIF2B was described by the authors of the 2004 
aIF2B structure (Figure 1.8A) (Kakuta et al. 2004). Three aIF2B dimers appeared to 
interact in a three-fold symmetrical manner via surfaces at the extreme N-terminal 
domain of one subunit from each dimer. Given the homology of aIF2B to each of the 
three regulatory subunits of eIF2B, this arrangement was viewed as the potential basis for 
assembly of the trimeric eIF2B regulatory subcomplex (Kakuta et al. 2004; Dev et al. 
2009).  
eIF2Bε and eIF2Bγ both contain an N-terminal sugar-nucleotidyl transferase-like 
(SNT) and a C-terminal (truncated) acyl transferase-like (AT) domain, similar to the 
enzyme adenylyltransferase ADP-glucose pyrophosphorylase (ADP-Glc PPase), whose 
crystal structure (2.11 Å) was solved in 2005 (1YP2.pdb) (Jin et al. 2005). In the crystals 
giving rise to that structure, ADP-Glc PPase was found to form homo-tetrameric 
complexes, with major interacting surfaces comprising a back-to-back assembly of the β-
helices forming the AT domain as well as an interaction between the N-terminal SNT 
domains (Figure 1.8B). In the case of the uridyltransferase UDP-n-acetylglucosamine 
pyrophosphorylase (GlmU), which possesses the entire AT domain and whose crystal 
structure (2.54 Å) was solved in 2007 (2OI7.pdb) (Olsen et al. 2007), a homo-trimeric 
complex is formed by a 3-fold symmetrical alignment of the AT domains, with the SNT 
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domains all arranged on one side of the homo-trimer (Figure 1.8C). Therefore, when 
predicting the interface responsible for the eIF2Bγ:eIF2Bε interaction, several very 
different assemblies presented themselves. How the catalytic dimer bound to this 
arrangement remained unclear (Figure 1.8D). 
1.5. Significance 
Dysfunction in the way in which eIF2B interacts with both phosphorylated and 
unphosphorylated eIF2 is associated with a number of pathological conditions. Given 
how important and central a role ISR plays in cell survival, it is unsurprising that over-
activation, under-activation, or general dysregulation can have this effect. Childhood 
ataxia with central nervous system hypomyelination (CACH), also known as vanishing 
white matter disease (VWM), is a neurodegenerative disease caused by mutations in the 
subunits comprising eIF2B. Chronic over-activation of ISR may play a role in the 
progression of neurodegenerative disease such as Alzheimer’s, Huntington’s, Parkinsons, 
ALS, MS, and prion disease (Chang et al. 2002; Freeman & Mallucci 2016; Radford et 
al. 2015; Halliday & Mallucci 2015; Hoozemans et al. 2007; Kim et al. 2014; Moreno et 
al. 2012). Under-activation may play a role in susceptibility to and severity of viral 
infections (Mohr & Sonenberg 2012). Various cancers have managed to hijack ISR in 
order to access both its pro- and anti-apoptotic aspects (Bobrovnikova-marjon et al. 2010; 
Dey et al. 2015; Wang et al. 2014; Pytel et al. 2015). ISR has been shown to be protective 
in cases as diverse as blood disorders (Han et al. 2005) and UV radiation (Collier et al. 
2015), and its dysregulation, as evidenced by PERK deficiency, leads to pancreatic  
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Figure 1.8: Assembly of eIF2B 
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Figure 1.8: Assembly of eIF2B 
(A) Crystal packing of archaeal aIF2B reveals a three-fold symmetrical axis of aIF2B 
dimers (1VB5.pdb) (Kakuta et al. 2004) formed by interactions between the N-terminal 
domains of the individual aIF2B monomers. Individual aIF2B monomers are marked in 
green, blue, and red dashed lines. The C-terminal domain interface conserved in all 
structurally homologous homodimers is identified by the label “1,” while those responsible 
for the three-fold crystal packing contacts are identified by the label “2.” As aIF2B is 
homologous to eIF2Bα, eIF2Bβ, and eIF2Bδ, the three-fold symmetrical arrangement, as 
mediated by the interfaces labeled “2,” is a hypothesized assembly of the eIF2B regulatory 
subcomplex. (B) A structure of the homotetrameric enzyme ADP-Glc PPase (1YP2.pdb) 
(Jin et al. 2005), whose monomer is homologous to both eIF2Bγ and eIF2Bε. Assembly 
occurs along two interfaces, marked “1” and “2.” (C) A structure of the homotrimeric 
enzyme GlmU (2OI7.pdb) (Olsen et al. 2007), whose monomer is also homologous to both 
eIF2Bγ and eIF2Bε. Assembly occurs along the long axis. (D) A hypothesized model for 
assembly of a trimeric eIF2B regulatory subcomplex and a dimeric eIF2B catalytic 
subcomplex. Residues whose mutation affects eIF2B activity are colored. The putative 
binding site of eIF2α is highlighted. The images in panel (A) and panel (D)  are taken from 
(Dev et al. 2009). 
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dysfunction and metabolic disorders (Harding et al. 2001; Laybutt et al. 2007; Gao et al. 
2012; Zhang et al. 2002). In all these cases, therapeutic modulation of ISR can serve to 
reverse dysfunction, suppress symptoms, halt progression, or even induce apoptosis. 
Given the widespread impact of ISR on cellular function, as well as the specific 
relationship to the conditions described above, the modulation of ISR for therapeutic 
benefit is increasingly being studied. Three broad approaches currently exist, two of 
which serve to turn down ISR while the third seeks to turn it up. The first approach 
involves inhibition of the ISR-activating kinases, with initial attempts specifically 
targeting inhibition of PERK. The second approach involves stimulating eIF2B activity, 
thus counteracting the effects of ISR induction by increasing exchange performed by 
non-sequestered eIF2B. The third approach involves inhibiting phosphatase activity 
responsible for the negative feedback loop, thus maintaining or artificially inducing ISR. 
These approaches serve as validation of the concept of targeting ISR as a therapeutic 
strategy.  
Given the potential possibility of PERK modulation in the treatment of cancer, the 
pharmaceutical company GlaxoSmithKline (GSK) initiated a screening and lead 
optimization program seeking to identify a potential PERK inhibitor. In 2012, the 
compound 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3- dihydro-1H-indol-5-
yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, or GSK2606414, was found to inhibit PERK 
activity in cell lines and inhibit tumor growth in mice xenografts (Axten et al. 2012). A 
version of GSK2606414 modified for improved pharmacokinetics, GSK2656157, was 
developed a year later (Axten et al. 2013). Both of these compounds are becoming 
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increasingly adopted in research laboratories for both clinical translation as well as basic 
scientific work. Despite near complete inhibition of PERK activity and successful 
prevention of neurodegeneration in a mouse model of prion disease (Moreno et al. 2013), 
PERK inhibition demonstrates substantial pancreatic toxicity (Halliday et al. 2015). This 
is consistent with data showing PERK knockout in mice and loss of function mutations in 
humans results in neonatal diabetes (i.e. Wolcott-Rallison Syndrome), pancreatic 
degeneration, skeletal defects, and growth retardation (Gupta et al. 2010; Gao et al. 
2012). PERK inhibition causes acute islet and β-cell apoptosis and pancreatic 
degeneration (Zhang et al. 2002; Harding et al. 2012; Halliday et al. 2015; Atkins et al. 
2013). While some approaches exist to modulate the pancreatic toxicity attendant with 
use of GSK2606414 (Yu et al. 2015), it is likely such a strategy will be limited to cases 
such as cancer, where risk-benefit may warrant its use.  
A second approach relies on modulation of eIF2B activity. The small molecule 
ISRIB, which stands for ISR Inhibitor, was identified in a high throughput screen also 
aiming to identify compounds that would prevent ER stress induction of ISR (Sidrauski 
et al. 2013). ISRIB made cells resistant to eIF2α phosphorylation and ISR, reduced stress 
granule formation, and was demonstrated to improve synaptic plasticity and long-term 
memory formation in mice (Sidrauski et al. 2013; Sidrauski, McGeachy, et al. 2015). 
Follow up work improved its affinity, as well as isolated the mechanism to improving 
eIF2B activity, possibly through binding of eIF2Bδ (Sidrauski, Tsai, et al. 2015). eIF2Bδ 
binding was later confirmed on the N-terminal domain of eIF2Bδ (Sekine et al. 2015), 
with a potential binding site proposed (Kashiwagi et al. 2016). While treatment with 
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ISRIB proved free of the pancreatic toxicity secondary to PERK inhibition, its efficacy to 
date remains disappointing (Halliday et al. 2015). 
Yet another approach is to target the phosphatase activity responsible for shifting 
the equilibrium back in favor of eIF2 over eIF2(α-P). Although PP1 is the responsible 
phosphatase, it must be recruited to eIF2(α-P) by an effector protein. One such protein is 
the Constitutive Repressor of eIF2α phosphorylation (CReP), which remains 
constitutively active and thus provides a steady state control over eIF2 phosphorylation 
independent of ISR (Jousse et al. 2003). The other is GADD34, discussed previously, 
whose expression is rapidly increased during ISR in response to activation of the 
transcription factor ATF4 (Novoa et al. 2001). In a high-throughput screen looking for 
compounds that would protect cells from ER stress-induced apoptosis, the small molecule 
salubrinal was identified as an agent that prevented dephosphorylation of eIF2(α-P) 
(Boyce et al. 2005). It was determined that salubrinal’s effect acted through inhibition of 
CReP and GADD34, rather than of PP1 activity. It was also found that salubrinal 
prevented herpes simplex virus (HSV) replication in treated mammalian cells. Another 
small molecule, guanabenz, was also discovered by a high-throughput screen, looking for 
compounds with protective action in prion-infected yeast (Tribouillard-Tanvier et al. 
2008). The protective activity of guanabenz was found to extend to a mouse model of 
prion disease. Unlike salubrinal, guanabenz specifically targets GADD34, without 
affecting activity of CReP (Tsaytler et al. 2011). These inhibitors are currently making 
their way into the clinic. 
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1.6. Experimental Approach 
Several critical limitations exist for the approaches typically employed for 
investigation of eIF2B assembly and activity. Yeast genetics provides a wealth of 
mutations, but it is difficult to unambiguously identify the mechanism whereby they have 
their effect. For example, the Gcd- phenotype theoretically represents constitutive 
induction of ISR, when in reality it is a read-out of low levels of ternary complex. While 
it may be safe to assume that ternary complex levels are a proxy for eIF2B activity, 
ambiguity still remains. Mutations resulting in reduction of eIF2B activity, and thus a 
Gcd- phenotype, may be due to disruption of eIF2B assembly, a decrease in affinity of the 
eIF2B:eIF2 interaction, an increase in the affinity of the eIF2B:eIF2(α-P) interaction, a 
conformational change in eIF2B that mimics that induced by binding eIF2(α-P), or a 
decrease in eIF2B catalytic activity. Furthermore, mutations affecting the most critical 
residues are likely to result in a lethal phenotype, restricting one’s ability to draw any 
conclusion other than that the residue is somehow important.  
Furthermore, one cannot reliably identify the impacts of mutations on structure or 
assembly without a structure of the protein or a good homology model. Thus, while the 
use of mutational data from yeast genetics experiments has informed much of what we 
know about eIF2, eIF2B, and their interaction, one’s analysis can never be more than 
indirect. As a result, multiple (and potentially incorrect) interpretations may 
simultaneously exist. As an example, most people in the field, including us, believed that 
a cluster of Gcn- mutations on eIF2B’s regulatory subcomplex disrupts eIF2(α-P) binding 
(Bogorad et al. 2014), when in fact it disrupts eIF2B assembly. There was also a model 
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that a cluster of Gcd- mutations in the positively charged pocket found between domains 
of eIF2Bα might represent a potential binding pocket for the phosphate in eIF2(α-P), 
which also turned out to be incorrect (Hiyama et al. 2009). 
The only in vitro assay for eIF2B catalytic activity currently used is too simplistic 
and inadequate for a number of applications. It measures exchange of labeled GDP bound 
to eIF2 for unlabeled GDP. Since under normal conditions eIF2-GDP (substrate) release 
from eIF2B is slower than GDP release from eIF2B:eIF2, and thus rate-limiting, the 
assay effectively measures substrate release. Only when GDP dissociation from 
eIF2B:eIF2 is inhibited and becomes rate-limiting, as is the case when eIF2 is 
phosphorylated, does the assay have any practical value. In most other cases, this assay 
measuring labeled for unlabeled GDP exchange is at best useless, if not misleading. For 
example, a change in the substrate (eIF2-GDP) dissociation rate would be measured as a 
change in eIF2B “activity,” as long as eIF2-GDP release remains the rate-limiting step. It 
is for reasons like this that this assay has been unable to recapitulate the effects of known 
CACH/VWM mutations. While introducing the corresponding mutations in yeast eIF2B 
cause Gcd- phenotypes, consistent with low eIF2B activity and ISR inductions 
(Richardson et al. 2004), the in vitro eIF2B assay with mutant eIF2B measures decreased, 
unchanged, and for some mutations, even increased eIF2B “activity.” The assay cannot 
be performed with unlabeled GTP, because eIF2-GTP is a reaction intermediate that is 
bound too tightly to eIF2B and does not get released, which causes eIF2B to perform a 
single round of catalysis and get stuck in an eIF2B:eIF2-GTP complex. The assay could 
work with GTP if Met-tRNAi is also added, because the eIF2-GTP:Met-tRNAi ternary 
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complex (the actual product of the catalysis) has faster rate of dissociation from eIF2B. 
However, surprisingly, no one in the field uses this more complete and adequate assay.  
In order to circumvent the issues described above, we sought to take a direct, 
structure-based approach in our investigation of eIF2B assembly and activity. With this 
in mind, a few key decisions were made from the outset and applied whenever possible. 
First, we would use human versions of proteins to maintain regulatory complexity and 
therapeutic relevance. Second, wild-type proteins were used in order to be sure that no 
important interactions or functions have been modified or abrogated. Third, all 
experiments would be performed under physiological conditions to make sure that 
observed effects are physiologically relevant and not an artifact of experimental 
conditions. Finally, by working in vitro with individually expressed and purified proteins, 
we can eliminate as many confounding variables as possible, thus greatly simplifying 
interpretation of our results. At times we were forced to violate one or more of the desires 
listed. 
1.7.  The Central Question 
The questions, experiments, and data described throughout this dissertation all 
center on how phosphorylation of eIF2’s α-subunit leads to inhibition of eIF2B activity 
and reduction in ternary complex levels in the cell. Although seemingly straightforward, 
to answer this question three things needed to be understood:  
(1) how eIF2B is assembled,  
(2) how eIF2B interacts with eIF2, and 
(3) how eIF2B interacts with eIF2(α-P). 
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eIF2B was believed to be a pentamer, consisting of one copy each of its five subunits. It 
was believed to contain a trimeric regulatory subcomplex, formed by the α-, β-, and δ-
subunits, and a dimeric catalytic subcomplex, formed by the γ- and ε-subunits. 
Phosphorylation of eIF2 was presumed to increase its affinity for eIF2B due to a more 
favorable electrostatic pairing of eIF2B with the highly negatively charged phosphate 
group. The fact that eIF2Bα appears to be non-essential in yeast for eIF2B activity under 
normal conditions, but in its absence phosphorylation of eIF2α fails to inhibit eIF2B and 
induce ISR, suggested that this direct effect of phosphorylation may be mediated by 
eIF2Bα. 
 The work presented in this dissertation details our attempts to demonstrate that 
none of these assertions are correct. Chapter 3 details my work demonstrating that eIF2B 
could not, in fact, be a pentamer, but rather was likely a decamer. The issue was finally 
put to rest when a crystal structure was published in 2016 of a nearly complete yeast 
eIF2B complex, demonstrating unequivocally its decameric nature and the organization 
of its subunits (Kashiwagi et al. 2016). Chapter 4 details my work demonstrating the 
existence of an “indirect” effect of phosphorylation, whereby phosphorylation 
destabilized an intramolecular interaction in eIF2. Chapter 4 also describes our proposed 
model for eIF2B activity and inhibition by eIF2(α-P), supported by our own data, the 
eIF2B crystal structure, and existing biochemical and thermodynamic data. It further 
incorporates an additional role for eIF2B in formation and subsequent channeling of the 
ternary complex, a function that has yet to be widely considered or accepted. Chapter 5 
details ongoing experiments that have not yet made their way into a publication, and for 
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which further analysis and experimentation is necessary. Ultimately, the hope is that by 
better understanding the mechanism and surfaces involved in both productive and un-
productive interactions between eIF2 and eIF2B, new and improved strategies can be 
designed to modulate ISR for therapeutic benefit. 
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Chapter 2: Methodology and Experimental Techniques 
 
2.1. Experimental Techniques 
2.1.1. Light Scattering Experiments 
Light scattering is a phenomenon in which interactions between an 
electromagnetic wave of a given frequency/wavelength and the atomic elements of 
particles in solution imparts a deviation in angle of the electromagnetic wave following 
the interaction. At large wavelengths (e.g. visible light) the incident wave sees an atom as 
an electron:proton dipole, while at short wavelengths (e.g. x-rays) it interacts with the 
individual electron or protons individually. In both cases, an effective “cross-section” 
exists, within which incident light is scattered and outside of which no interaction occurs. 
The mathematical model that describes scattering in the short wavelength (high 
frequency) regime is called Thomson scattering and serves as the basis for small-angle x-
ray scattering (SAXS) (reviewed in (Blanchet & Svergun 2013)). In this case, the 
wavelength of light is much larger than the size of the scatterer. The mathematical model 
that describes scattering in the long wavelength (lower frequency) regime is called Mie 
scattering and serves as the basis for multi-angle laser light scattering (MALLS) 
(reviewed in (Wen et al. 1996; Takagi 1990; Wyatt 1993)). In this case, the wavelength 
of light is on the order of the size of the scatterer. Mie scattering is heavily dependent on 
the wavelength of incident light (inversely related to λ4), while Thomson scattering is 
wavelength independent. 
The underlying premise of SAXS and MALLS is similar, as is the ultimate goal: 
determination of the absolute size (molecular weight) of the particle as well as 
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information about its shape (Rg, radius of gyration). A beam is passed through a sample 
containing the purified protein, and detectors placed at several angles from the central 
axis collect any scattered light and provide a read-out of intensity as a function of angle. 
Measurements are usually taken at a series of known concentrations, with intensities 
collected at several angles for each sample concentration. Data is compared or 
normalized to a reference, and the underlying mathematical models allow extraction of 
the parameters of interest. These parameters can be identified by plotting the 
experimental data in the form of either a Guinier plot or a Zimm plot. 
2.1.2. Nuclear Magnetic Resonance (NMR) Experiments 
Nuclear magnetic resonance spectroscopy infers information about a system of 
atoms based on its behavior in response to being placed in a combination of static and 
dynamic magnetic fields. Many types of NMR experiments are possible, each providing 
different information about the target system. One dimensional (1D) experiments are 
often performed for small molecules, in which pulse sequences manipulate magnetization 
of protons in the sample. A limited number of protons allows for their unique 
identification. 1D experiments are of limited use in the investigation of proteins due to 
their large size and number of protons. Instead, 2D and 3D experiments are typically used 
with 15N-labeled or 15N/13C-labeled proteins, respectively.  
A 2D or a 3D experiment correlates two or three nuclei, respectively, that are 
linked through covalent bonds or are close in space. A common 2D experiment is the 
heteronuclear single-quantum coherence (HSQC) experiment, which correlates protons 
and nitrogens covalently attached to each other. The result is a 2D plot with 1H chemical 
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shifts on the x-axis and 15N chemical shifts in the y-axis. Each backbone amide NH pair 
in a protein yields a peak in this 2D plot, providing a “fingerprint” that uniquely identifies 
the amino acids in the protein. Changes in the chemical environment surrounding an 
amino acid, such as buffer conditions (e.g. salt concentration, pH), temperature, or 
interaction with ligands or other binding partners, will cause a change in the chemical 
shifts and thus a change in the location of the peak.  
3D experiments correlate three nuclei to each other. Common 3D experiments 
correlate amide NH pairs with a Cα carbon, a carbonyl carbon, or a Cβ carbon. 3D plots 
are thus created, consisting of a series of 2D 1H-15N “slices” stacked along a third, 13C 
dimension. In the same way that a 2D experiment allows resolution of degenerate peaks 
in a 1D proton spectrum, a 3D experiment spreads peaks further in three dimensions. In a 
process known as a backbone assignment, 3D experiments are typically run in pairs. An 
HNCA and HN(CO)CA pair correlates the amide pair of an amino acid with its own Cα 
carbon, as well as that of the preceding amino acid. An HNCACB and HN(CO)CACB pair 
correlates the amide pair of an amino acid with its own Cα and Cβ carbons and those of 
the preceding residue. An HN(CA)CO and HNCO pair correlates the amide pair of an 
amino acid with its own carbonyl carbon and that of the preceding residue. With the 
primary sequence of the protein in hand, a combination of these experiments can yield 
backbone assignments for the protein.  
Two critical factors limit the efficacy of an NMR experiment: the resolution in a 
given dimension (i.e. how many frequencies can be sampled) as well as the signal-to-
noise ratio (SNR). The signal increases linearly with the concentration of spins (i.e. of 
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small molecule or protein) in the sample. The signal to noise increases as the square root 
of the number of times the experiment is repeated. For a combination of experimental, 
logistical, and cost considerations, an NMR experiment is limited in the total time that it 
can be performed. A 2D experiment can be thought of effectively as a series of 1D 
experiments on 15N embedded in a single 1D 1H experiment. Therefore, given a fixed 
total experimental time, the desired resolution in the 15N dimension must be weighed 
against the desire to accumulate more overall experiments, or scans, to improve SNR. 
This tradeoff is felt even more acutely for 3D experiments. Optimizing SNR is thus a 
high priority, especially when signal is low due to a low concentration of protein being 
used.  
Multiple factors increase the relaxation rate, thus limiting the duration of time 
signal can be acquired for and forcing a greater number of scans. The main mechanism of 
relaxation for 1H, 15N, and 13C is dipole-dipole (DD) coupling, though at higher magnetic 
fields a second mechanism (chemical shift anisotropy, or CSA) can be problematic as 
well (Marintchev et al. 2007). DD coupling allows magnetization of the amide proton, 
amide nitrogen, or 13C carbon to disperse itself to un-desirable hydrogen atoms, both 
those incorporated in the protein and those in solution (i.e. in water). The magnitude of 
this effect depends on the orientation of the interacting nuclei relative to the static 
external magnetic field. For a small molecule or small protein in solution, random 
rotational diffusion is able to suppress this effect. For a large protein or complex, 
however, rotational diffusion is too slow and DD coupling causes significant loss in 
signal. Replacing the water in the sample with deuterium oxide (D2O) can reduce 
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relaxation to DD coupling by replacing the hydrogens in solution with deuterium (2H), 
which couples much more weakly with 1H, 15N, and 13C (Marintchev et al. 2007). 
Expressing the protein in D2O-media instead of H2O (isotope labeling) replaces almost all 
sidechain and Cα hydrogens with deuterium, effectively leaving only the desired amide 
hydrogens and further reducing potential avenues for loss of magnetization via DD 
coupling (Marintchev et al. 2007). A third method to reduce the relaxation rate in large 
proteins is to use a modified HSQC pulse sequence called transverse relaxation-
optimized spectroscopy (TROSY-HSQC), which causes the two primary sources of 
relaxation, DD coupling and CSA, to cancel each other out (Pervushin et al. 1997). 
Comparison of NMR spectra of isotope labeled proteins in the presence or 
absence of a binding partner can reveal the presence of an interaction as well as those 
amino acids responsible for mediating that interaction. In a simple binding experiment, 
peaks corresponding to amino acids at the interface of an interaction will move, allowing 
for their identification. Such an analysis is known as a chemical shift perturbation (CSP) 
assay (Marintchev et al. 2007). Another method is to label a protein with a compound 
that increases the relaxation rate of surrounding spins, in a distance dependent manner. 
Typically, this compound is reversibly bound to a surface exposed cysteine, and can be 
removed by reduction of the cysteine or by addition of ascorbic acid. Disappearance of 
peaks relative to a reference indicate amino acids close to the label in physical space, 
indicating not only potential interaction but also allowing for determination of 
orientation. This type of experiment is known as paramagnetic relaxation (PRE) 
(Marintchev et al. 2007). 
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2.1.3. Fluorescence Anisotropy Experiments 
Fluorescence anisotropy assays take advantage of the manner in which polarized 
light is both absorbed and emitted by fluorescent molecules, or fluorophores (Figure 2.1) 
reviewed in (Lakowicz 2013)). Fluorescence describes the process by which an atom 
absorbs incoming light (i.e. a photon), is excited to a higher electronic energy level, and 
after some time relaxes back to its ground state by emission of second photon. As some 
energy is lost to heat and/or other non-radiative mechanisms, the emitted photon is 
always lower energy than the absorbed photon, and thus of a longer wavelength. 
Fluorophores are molecules that possess fluorescent activity, and are characterized by 
several factors: the wavelength of light that is maximally absorbed, the wavelength of 
light that is emitted, the lifetime of the excited state, and the efficiency with which 
absorbed photon actually initiates fluorescent emission. Fluorophores also have different 
degrees of stability, as defined by their resistance to photobleaching, a process whereby 
fluorescent ability is lost after absorption of some maximal amount of photons.  
 Polarization refers to the orientation of the electric field component of an 
electromagnetic wave. Relative to a given frame of reference, incoming light can be 
vertically polarized, horizontally polarized, or a mixture of both. Anisotropy refers to the 
degree to which a given beam is a mixture of these two states, given by 
𝑟 =
I∥ − I⊥
I∥ + 2I⊥
 
where parallel and perpendicular intensities are given in reference to the laboratory 
reference frame. A polarization filter can be used to select for only horizontally or only 
vertically polarized light, resulting in an anisotropy of 1 or -0.5, respectively. The angle  
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Figure 2.1: Overview of the fluorescence anisotropy assay 
Fluorescence anisotropy describes a phenomenon in which a light wave is unevenly 
polarized in the vertical and horizontal dimensions. Light is typically emitted from excited 
fluorophores within a small solid angle of an intrinsic axis determined by the physical 
orientation of the fluorophore with respect to the polarization axis of the incoming light. 
For a small particle, Brownian rotational diffusion randomly re-orients the particle in the 
time between the absorption of the excitatory photon and emission of the fluorescent 
photon. This results in de-polarization of light emitted by the sample as a whole. On the 
other hand, a large particle rotates more slowly, resulting in an anisotropy more closely 
matched to that of the incoming light. Measurements of emission of polarized light in the 
horizontal and vertical planes are made by use of polarizers and appropriate emission filters 
or monochromators placed in between the sample and the detector. A binding event leads 
to the formation of a larger complex with a correspondingly larger anisotropy. This image 
was taken from http://www.hi-techsci.com/. 
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between the electric field component of the electromagnetic wave and the orientation of 
the fluorophore dictates the likelihood of absorption, and thus of an eventual fluorescence 
emission. The probability of absorption scales as the square of the cosine of the angle 
between them, effectively limiting absorption only to the case where the polarization of 
incoming light is parallel or near parallel to the orientation of the fluorophore. As 
fluorophores or the proteins to which they are attached rotate randomly in solution 
according to Brownian motion, only a small subset of potential fluorophores are capable 
of being excited by an incoming wave.  
Polarization of fluorescently emitted light also follows a probability distribution 
heavily centered on an intrinsic angle relative to the orientation of the fluorophore. For an 
angle of 0 degrees (i.e. emission is aligned with the orientation of the particle), the 
maximum anisotropy possible for the fluorescently emitted light is 0.4. However, in 
reality a fluorophore or the protein to which it is attached rotates in three-dimensional 
space according to Brownian rotational diffusion. Depending on the lifetime of the 
excited state, rotation of the fluorophore results in rotation of the preferred angle of 
emission relative to the polarization of the absorbed light. As a result, the anisotropy of 
fluorescently emitted light will have some value smaller than 0.4. Brownian rotation 
depends, among other factors, on the size of the particle: the larger the particle, the 
slower it rotates/tumbles. As a result, for a given fluorescence lifetime, fluorophores 
attached to larger proteins will emit light with larger anisotropies than fluorophores 
attached to smaller proteins. This phenomenon can be used to identify the presence of 
protein-protein interactions due to the corresponding increase in anisotropy caused by the 
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larger size of the complex compared to the individual fluorescently labeled protein. By 
titrating increasing concentrations of unlabeled protein into a solution of fluorescently 
labeled protein, a binding curve can be obtained by calculating the anisotropy of the 
sample as a function of unlabeled protein concentration. Anisotropy will asymptotically 
approach some maximum value as binding sites are saturated, allowing calculation of the 
KD of the interaction.  
2.2. Bacterial Expression 
2.2.1. Vectors 
Subcloning and site-directed mutagenesis reactions were performed by one of two 
companies, DNAExpress (Montreal, Canada) or Norclone (Montreal, Canada). 
Requirements were similar for both and consisted of a minimum of 0.5 μg of template for 
site-directed mutagenesis or 0.5 μg of template and 5 μg of target for subcloning. All 
sequencing was performed by GeneWiz (Boston, MA), requiring 0.5 μg of plasmid and 
using forward (5'-d(TAA TAC GAC TCA CTA TAG GG)-3') and reverse (5'-d(GCT 
AGT TAT TGC TCA GCG G)-3') primers associated with the T7 promoter and T7 
terminator, respectively. The only exception was sequencing of the NLS1 peptides, in 
which the M13F(-47) forward primer (5'-d(CGC CAG GGT TTT CCC AGT CAC 
GAC)-3') and the M13R reverse primer (5'-d(CAG GAA ACA GCT ATG AC)-3') were 
used. A number of protein constructs were used throughout the work described in this 
dissertation. Key features of several of the most critical are displayed in Figure 2.2. 
Two expression vectors were created by modifying a pET21a-derivative vector 
using TOPO cloning/Gateway cloning or classical cloning. The former resulted in an  
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Figure 2.2: Key constructs 
A schematic of the most commonly used constructs discussed in this dissertation.  
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expression vector with an N-terminal non-cleavable 56 residue GB1 (QYK…TEG) tag 
[designated pET21a-GB1]. The second resulted in an N-terminal 56 residue GB1 tag 
followed by a 21 residue linker (GSELSTSLYKKAGSAAAPFTM) followed by a His6-
tag and a Tobacco Etch Virus nuclear-inclusion-a endopeptidase (TEV protease) cleavage  
site [designated pET21a-GH]. In the latter case, the modified sequence was inserted 
between the Nde1 (CATATG) and BamH1 (GGATCC) restriction sites in the pET21a 
vector (Novagen). The TEV protease cleavage site was defined by the sequence 
ENLYFQ\G where the “\” marks the peptide bond cleaved by the TEV protease. Human 
eIF2Bα, eIF2Bβ, and eIF2Bδ isoform 2 were cloned into pET21a-GH immediately 
following the GB1-His6-TEV protease cleavage site using the BamH1 and XhoI 
restriction sites, creating the GH-eIF2Bα, GH-eIF2Bβ, and GH-eIF2Bδ vectors, 
respectively. Human full length eIF2α was cloned into the pET21a-derivative vector in 
the same manner, creating GH-eIF2α. In all cases, cleavage by TEV protease results in a 
residual glycine at the N-terminal end of the protein of interest. 
The GH-eIF2Bα vector served as a template from which several derivative 
vectors were constructed. GH-eIF2Bα-TM and GH-eIF2Bα-DM were created via site-
directed mutagenesis, for which the first corresponds to the triple mutation 
I209E/V216E/A220D, while the latter corresponds to just the double mutation 
V216E/A220D. eIF2Bα was subcloned into pET21a-GB1 using the NdeI and NotI 
(GCGGCCGC) restriction sites to create eIF2Bα-H, thus eliminating the N-terminal GB1 
tag and incorporating the C-terminal His6-tag that follows the multiple cloning site in 
pET21a with an Ala-Ala-Ala-Leu-Glu (AAALE) linker corresponding to the Not1 and 
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remaining sequence. Double and triple mutants, eIF2Bα-TM-H and eIF2Bα-DM-H, 
respectively, were created in the same manner as detailed above, but with eIF2Bα-H as 
the template for site-directed mutagenesis rather than GH-eIF2Bα. Again using eIF2Bα-
H as a template for site-directed mutagenesis, the deletion mutant eIF2Bα-Δloop-H was 
created in which an 11 residue sequence corresponding to residues 255-265 were 
removed. eIF2Bα-Δloop-H in turn served as a template for creation of eIF2Bα-Δloop-TM-
H. Finally, using eIF2Bα-H as a template, a new C-terminal mutant, eIF2Bα-CM-H was 
created, in which a double mutation I300E/L304D was combined with modification of 
the linker preceding the C-terminal His6-tag from Ala-Ala-Ala-Leu-Glu (AAALE) to Ser-
Gly-Ser-Leu-Glu (SGSLE). 
The GH-eIF2Bβ vector also served as a template from which several derivative 
constructs were created. GH-eIF2Bβ-NTD and GH-eIF2Bβ-CTD were constructed via 
insertion of a stop codon following residue 143 (site-directed mutagenesis) and by 
subcloning eIF2Bβ142-350 into pET21a-GB1, respectively. An additional sequence was 
added to the beginning of the eIF2B143-350 insert, resulting in the addition of a Gly-Ser 
(GS) from the BamHI site, a His7-tag, the TEV cleavage site, and finally a Ser-Gly-Ser 
(SGS) linker in between the 56 residue GB1-tag provided by pET-GB1 and the eIF2Bβ-
CTD gene sequence. This created an alternate to the N-terminal tag sequence contained 
in pET21a-GH described above. GH-eIF2Bβ-TM and GH-eIF2Bβ-DM were created via 
site-directed mutagenesis, for which the first corresponds to the triple mutation 
T248E/L255E/H259D, while the latter corresponds to just the double mutation 
L255E/H259D.  
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The GH-eIF2Bδ vector also served as a template from which several derivative 
constructs were created. GH-eIF2Bδ-NTD and GH-eIF2Bδ-CTD were constructed via 
insertion of a stop codon following residue 311 and by subcloning eIF2Bδ312-523 into 
pET21a-GB1, respectively. GH-eIF2Bδ-TM and GH-eIF2Bδ-DM were created via site-
directed mutagenesis, for which the first corresponds to the triple mutation 
V417E/L424E/A428D, while the latter corresponds to just the double mutation 
L424E/A428D. A mutant, GH-eIF2Bδ-ΔNTT, consisting of deletion of the first 189 
residues of eIF2Bδ corresponding to its N-terminal tail (NTT), was created by subcloning 
eIF2Bδ190-523 into pET21a-GB1, with the same N-terminal addition as for GH-eIF2Bβ-
CTD described above. A mutant, GH-eIF2Bδ-Δloop, was created via removal of a 
flexible 23 residue loop (462-484) and replacement by a Gly-Ser (GS) to reduce tension. 
An alternative H-eIF2Bδ-blg construct was created by subcloning the sequence of a 
codon-optimized N-terminal deletion eIF2Bδ-opt168-522 (Biologics Corp, Indianapolis, IN) 
out of a pUC cloning vector into pET21a-GB1 immediately following the NdeI restriction 
site, with the addition of a HIS6 sequence to the N-terminal end of the gene. This resulted 
in replacement of the N-terminal GB1 tag with a non-cleavable N-terminal His6-tag. 
The GH-eIF2α vector also served as a template from which several derivative 
constructs were created. A pair of truncations, GH-eIF2α302 and GH-eIF2α280, were 
created by inserting a stop-codon after residue 302 and 280, respectively. The 
phosphomimetic mutation S51D was inserted into GH-eIF2α and GH-eIF2α280, yielding 
GH-eIF2α-S51D and GH-eIF2α280-S51D, respectively. A C-terminal domain construct, 
GH-eIF2α-CTD was created by subcloning eIF2α185-314 into pET21a-GB1, with the same 
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N-terminal addition made as described above for GH-eIF2Bβ-CTD. Two C-terminal 
domain truncations, GH-eIF2α-CTD280 and GH-eIF2α-CTD302, were created by 
subcloning eIF2α185-280 and eIF2α185-302, respectively, into pET21a-GB1, again making 
the same N-terminal additions as described above for GH-eIF2Bβ-CTD. 
A number of constructs were derived from a pET30a vector as well. The pET30a 
vector (Novagen) carries a selection marker for kanamycin resistance, a standard T7/LacI 
system for expression, a low copy ColE1-derived Ori, and a His6-tag following the 
multiple cloning site. We initially started with a solubility enhanced variant of human 
eIF2α (Ito et al. 2004; Ito & Wagner 2004), consisting of an N-terminal deletion of the 
first three residues, the triple mutation A27Q/L46H/V71K, and the deletion of the 
extreme C-terminal tail (residues 303-314). eIF2α modified in this manner was cloned 
into pET30a between the NdeI and XhoI (CTCGAG) restriction sites, yielding eIF2α-
mut-H. It should be noted that this leaves a Leu-Glu (LE), corresponding to the XhoI 
sequence, as a linker in between the eIF2α gene and the C-terminal His6-tag. eIF2α-NTD-
mut-H was created by looping out residues 185-314 from eIF2α-mut-H, but retaining the 
C-terminal Leu-Gleu linker and His6-tag. 
A plasmid encoding full-length WT eIF2α (eIF2α-H) was obtained from Dr. 
Takuhiro Ito (Wagner Lab, Harvard Medical School). It is this eIF2α-H vector that 
served as the template for the subcloning of various eIF2α constructs into the pET21a-
GB1 vector described earlier. 
The eIF2α-H vector served as a template from which several derivative constructs 
were created. Two truncations, eIF2α-ΔN3-H and eIF2α280-H, were created by deletion of 
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the first three N-terminal residues of eIF2α (Pro-Gly-Leu, PGL) and insertion of a stop 
codon following residue 280, respectively. eIF2α-NTD and eIF2α-CTD were constructed 
via insertion of a stop-codon after residue 184 and by subcloning eIF2α185-314 into 
pET30a, respectively. eIF2α-CTD in turn was used as a template for creation of a pair of 
truncations, eIF2α-CTD302 and eIF2α-CTD280, by inserting stop-codons following residue 
302 and 280, respectively. Due to the manner in which the four constructs just described 
were created, all four lacked a tag of any kind. While some experiments were performed 
with these constructs, purification proved more complex and thus we sought to add tags 
back in to the constructs. In the case of eIF2α-NTD, this was corrected by inserting a 
sequence coding for a Ser-Gly-Ser (SGS) linker followed by a C-terminal His6-tag, 
resulting in eIF2α-NTD-H. We did not correct eIF2α-CTD, as we simply used the N-
terminally tagged versions described earlier. The phosphomimetic mutation S51D was 
inserted into eIF2α-H and eIF2α-NTD, yielding eIF2α-S51D-H and eIF2α-NTD-S51D. 
Again, as eIF2α-NTD-S51D lacked a tag, one was inserted in the same manner as for 
eIF2α-NTD, yielding eIF2α-NTD-S51D-H.   
The pRSFDuet-1 vector (Novagen) was used for simultaneous co-expression of 
H-eIF2Bβ and GH-eIF2Bδ. pRSFDuet-1 contains an RSF1030-derived Ori (compatible 
with pET21a’s and pET30a’s ColE1-derived Ori), a selection marker for kanamycin 
resistance, and two multiple cloning sites allowing for two genes each with their own 
T7/lacI system of control. The beginning of the first multiple cloning site codes for a 
His6-tag. Human eIF2Bβ was cloned into the first multiple cloning site between the 
EcoRI (GAATTC) and HindIII (AAGCTT) restriction sites. Addition of a guanine (G) 
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immediately following the EcoRI site was required to remain in-frame with the His6-tag, 
resulting in the incorporation of the His6 tag through addition of the sequence Gly-Ser-
Ser-His6-Ser-Gln-Asp-Asn to the N-terminal end of eIF2Bβ. Next, human eIF2Bδ was 
cloned into the second multiple cloning site between NdeI and FseI (GGCCGGCC), with 
the addition of the longer GB1-tag sequence to its N-terminal end, detailed above in the 
description of pET21a. The order of cloning is critical, as cut sites for EcoRI/HindIII 
exist within the eIF2Bδ sequence. The resulting construct, pRSFDUET-eIF2Bβ/d, thus 
yields a non-cleavable N-terminal His6-tagged eIF2Bβ and a cleavable N-terminal GB1-
His7-tagged eIF2Bδ. 
Finally, the pG-Tf2 vector (Clontech) was used to express chaperones to aid in 
improving solubility. pG-Tf2 contains a selection marker for chloramphenicol resistance, 
a pACYC-derived Ori (compatible with ColE1-derived Ori’s), and genes coding for the 
chaperones GroEL (~60 kDa), GroES (~10 kDa), and Trigger factor (~56 kDa). 
Plasmid propagation was performed by transforming Top10 competent cells 
(Invitrogen) with the desired plasmid following standard protocols (Ausubel et al. 2003). 
Plasmids were subsequently purified using a QIAprep Spin Miniprep Kit (Qiagen) and 
stored at -20C. 
2.2.2. Protein Expression 
For many of the vectors described above, a number of conditions were tested in 
an attempt to express soluble protein. For those proteins for which adequate expression of 
soluble protein was achieved, the final expression conditions will be noted here. For 
those proteins for which adequate expression of soluble protein has not yet been 
 
 
  74 
achieved, ongoing optimization efforts are discussed in Chapter 5. For all proteins carried 
in pET21a, pET30a, or pRSFDuet-1 vectors, induction consisted of addition of isopropyl 
β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 1 mM. For chaperone 
proteins contained on the pG-Tf2 plasmid, induction consisted of addition of 
anhydrotetracycline at least two doubling times prior to addition of induction of the gene 
of interest with IPTG. 
All successful expressions occurred in one of three strains: BL21(DE3), 
Rosetta2(DE3), and Rosetta2(DE3)-pLysS. For these three strains and the Top10 strain 
(in which plasmid propagation was performed), homemade competent cells were created 
and kept at -80C following a standard CaCl2 competent cell preparation protocol 
(Ausubel et al. 2003). Commercial versions of the four strains, as well as of BL21 
Star(DE3), BL21 Star(DE3)-pLysS, BL21(DE3)-pLysS, Rosetta(DE3), and 
Rosetta(DE3)-pLysS, were obtained from either Novagen or Invitrogen. Full length 
eIF2α and eIF2α-S51D were expressed in BL21(DE3) cells, while eIF2Bβ was expressed 
in Rosetta2(DE3)-pLysS cells. All remaining proteins were expressed in Rosetta2(DE3) 
cells. For expressions performed at 20C, cells were transferred to 20C between 15 
minutes and 45 minutes prior to induction of expression. All proteins except eIF2Bβ were 
induced at 20C, and were generally expressed overnight (O/N). eIF2Bβ was induced at 
37C for 3 hours. Full length eIF2α and eIF2α-S51D were the only proteins co-expressed 
with chaperones. In these cases, anhydrotetracycline was typically added to a final 
concentration of 0.5 ng/mL for induction of chaperone proteins. Induction with 
anhydrotetracycline was typically performed at an OD600 of ~0.125. 
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A typical transformation consisted of adding 0.5-2 μL of the desired vector to 
between 33 μL and 50 μL of the desired competent cell strain. Cells were allowed to rest 
for 30 minutes on ice, following which cells were heat shocked at 42C for 45 seconds and 
then again allowed to rest on ice for 2 minutes. LB media (Fisher Scientific) was then 
added to bring the total volume to ~200 μL. Cells were then incubated for one hour at 
37C while shaking, before being gently re-suspended, if necessary, and spread on an agar 
plate containing appropriate antibiotics. Carbenicillin was used at 50 μg/mL, kanamycin 
at 50 μg/mL, and chloramphenicol at 32 μg/mL. Following the addition and spreading of 
transformed cells, plates were placed in an incubator at 37C and allowed to rest for 15 
minutes before being flipped and left to grow overnight (~15 hours). 
Individual colonies were picked and added to either a 10 mL or 20 mL starter 
volume of LB containing appropriate antibiotics. Cells were then incubated overnight at 
37C while shaking. The following day, starter volumes were collected and spun down at 
4,500xg for 15 minutes. The supernatant was discarded and cells were re-suspended in 
~10 mL fresh LB and typically allowed to rest for 15-30 minutes at room temperature. 
Cells were then added to a 1L volume of autoclaved or filtered LB containing appropriate 
antibiotic(s) (i.e. inoculation), and incubated at 37C while shaking. In some cases, instead 
of allowing a starter to grow overnight, it was instead allowed to grow for ~3 hours and 
then was used to inoculate the 1L growth. Cells were allowed to grow in the 1L volume 
until an OD600 of 0.6-0.8 was achieved (~3.5-4.5 hrs), at which point expression was 
induced with 1 mM IPTG. If chaperones (GroEL, GroES, Trigger Factor) were used, 
induction with anhydrotetracycline was performed at an OD600 of ~0.125. 
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Following expression, a ~50 mL aliquot was collected from the liter growth, 
while the remainder was spun down at 4,500xg and the resulting pellet stored at -20C. 
From the ~50 mL volume, 1 mL was removed and diluted to 5 mL with ddH2O (5x 
dilution) and its OD600 was measured and recorded as a reference. The remainder of the 
~50 mL was used to test expression and solubility prior to purification of the full liter 
growth. After being spun down at 4,500xg for 15 minutes, the supernatant was discarded 
and the pellet was re-suspended in 5 mL of 10 mM Na-phosphate (pH 7), 150 mM NaCl, 
0.01% NaN3, and 1 mg/mL lysozyme. The volume was then subjected to sonication (50% 
duty cycle, 5.5W, 2 min). 1 mL of lysate was then collected and spun down in a tabletop 
microcentrifuge at 14,000xg for 2 minutes. Samples of the lysate and supernatant 
following centrifugation were run on SDS-PAGE to quantify expression and solubility. 
Several proteins were expressed in a different manner than described above. As 
15N and 13C exist at ~0.3% and ~1% natural abundance, respectively, protein intended for 
2D or 3D NMR experiments had to be labeled with one or both of those isotopes. This 
was achieved by using the starter volume to inoculate a liter of minimal media rather than 
LB media. Minimal media consists of a ddH2O or D2O base, supplemented with critical 
minerals and vitamins, as well as with 15NH4Cl and 
13C6-D-glucose as the sole nitrogen 
and carbon source, respectively (Marintchev et al. 2007), depending on the desired 
labeling. Deuteration, or 2H labeling, serves to improve NMR analysis by decreasing 
large contributors to spin relaxation. In these cases, the H2O component of the minimal 
media was replaced with D2O, allowing for triple labeling of the protein of interest (i.e. 
2H/15N/13C). Growth in minimal media resulted in an increase in doubling time to over an 
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hour, while growth in minimal media containing D2O was even slower. In these cases, 
starter volumes of 20 or 30 mL were used to double or triple the cell count at inoculation, 
though they were re-suspended in only 10 mL of LB prior to inoculation in order not to 
reduce labeling efficiency (i.e. 10 mL LB in 1000 mL minimal media results in 1% loss 
in labeling efficiency).  
eIF2α-NTD-H, eIF2α-NTD-S51D-H, and eIF2α-CTD used for NMR assignments 
were all triple labeled (2H/15N/13C) in the manner described above. For some 
experiments, triple labeled stock continued to be used, though for the majority of 
experiments protein was double labeled (2H/15N). As successful expression in minimal 
media is not necessarily guaranteed, even under conditions identical to those used in 
successful expression in LB media, in all cases a single labeled (15N) expression was 
performed as a test before moving on to additional 2H labeling (due to the high cost of 
D2O). These single-labeled proteins were used for certain NMR experiments and also for 
fluorescence anisotropy experiments. 
2.2.3. Protein Purification 
Cell pellets of a given liter growth were thawed from -20C and re-suspended in 40 
mL of buffer containing 10 mM Na-phosphate (pH 7), 150 mM NaCl, 0.01% NaN3, 0.1 
mM 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF), 7 mM β-
mercaptoethanol (BME), 1 cOmpleteTM ethylenediaminetetraacetic acid (EDTA)-free 
tablet (Roche Diagnostics), and 1 mg/mL lysozyme (Lysis Buffer). The volume was then 
sonicated. The lysate was spun down at 19,500xg for 15 minutes, following which the 
supernatant was collected and the pellet was discarded. 
 
 
  78 
Supernatants containing the soluble fractions from GH-eIF2Bα and GH-eIF2Bβ 
expressions were added to a column packed with GB1-binding IgG resin (GE 
Healthcare), pre-equilibrated in 10 mM Na-phosphate (pH 7), 150 mM NaCl, and 0.01% 
NaN3 (Column Wash Buffer). IgG resin volume was determined based on an assumed 2 
mg/mL binding capacity. The supernatant was allowed to mix with the resin while 
nutating at 4C for one hour, at which point gravity-flow was utilized to collect the flow 
through. The resin was then washed with at least 5 column volumes of Column Wash 
Buffer supplemented with 0.1 mM AEBSF and 7 mM BME (Running Buffer). Protein 
could only be recovered from the IgG resin by cleaving the bound GB1-tag, thus 
releasing the protein of interest. TEV protease was added to a solution of Column Wash 
Buffer supplemented with 0.1 mM AEBSF, 2 mM dithiothreitol (DTT) and 1 mM EDTA 
(Protein Storage Buffer). TEV protease was then added to the protein of interest at 
between a 1:20 and 1:40 w/w ratio of TEV:construct and was typically allowed to cut 
overnight while the column was nutating at 4C. Cleavage efficiencies were determined 
by comparison of samples of pre- and post-incubation with TEV protease run on SDS-
PAGE. 
Both GH-eIF2Bα and GH-eIF2Bα-TM were cleaved inefficiently while bound to 
the IgG resin and also when free, resulting in poor yields and marking GB1-affinity 
chromatography as a poor method for purification of eIF2Bα. As a result, the tag was 
switched from the N-terminal to the C-terminal end of eIF2Bα, resulting in use of 
eIF2Bα-H and its derivative vectors, and thus a corresponding switch to polyhistidine-
affinity chromatography. Although GH-eIF2Bβ cleavage was also inefficient when bound 
 
 
  79 
to IgG resin, cleavage was fully effective when free. Thus, while GB1-affinity 
chromatography was abandoned for eIF2Bβ as well, there was no need to change tags. 
Polyhistidine-affinity chromatography was performed on all constructs using 
gravity-flow columns packed typically with 10 mL of cobalt resin (TALON CellThru, 
Clontech), though on some occasions a nickel resin (Ni-NTA SuperFlow, Clontech) was 
used due to its ability to tolerate small amounts of DTT or EDTA. Following resin 
equilibration in Column Wash Buffer, supernatant containing the soluble fraction of 
protein was incubated with the resin and allowed to nutate for an hour at 4C, in a manner 
identical to described above for GB1-affinity chromatography. The flow-through was 
then collected and the resin was washed in four steps: five column volumes of just 
Running Buffer, five column volumes of Running Buffer supplemented with 1M NaCl, 
five column volumes of just Running Buffer again, and finally five column volumes of 
Running Buffer supplemented with 4 mM imidazole. Bound protein was then eluted 
using Running Buffer supplemented with 200 mM imidazole and collected in a series of 
one column volume fractions. 
SDS-PAGE was run to assess expression (lysate), solubility (supernatant), 
binding efficiency (flow-through), and the amount and purity of protein in each elution 
fraction. Occasionally washes were also loaded. Fractions with sufficient quantity and 
purity of protein were combined and exchanged 1,000-fold out of the 200 mM imidazole 
Running Buffer into Protein Storage Buffer. Exchange was performed by an initial 
concentration of sample volume in Vivaspin 20 concentrators (GE Healthcare) to a final 
volume of ~1 mL per concentrator (or higher, depending on concentration and solubility 
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limit of the protein). Samples were then diluted 10-fold with Protein Storage Buffer to a 
final volume of 10 mL per concentrator, following which another round of concentration 
to a final volume of 1 mL was performed. This process was repeated until ~1,000-fold 
exchange was achieved. The nickel or cobalt resin was then refreshed with 6 M 
guanidinium-HCl, washed with ddH2O, and stored at 4C in 20% ethanol containing 
0.05% NaN3. 
In most cases, size-exclusion chromatography (SEC) followed affinity-
chromatography either in an attempt to increase purity, serve as an alternative to buffer 
exchange, and/or to separate protein from tag following cleavage by TEV protease. SEC 
was performed on one of three columns as part of an automated fast protein liquid 
chromatography (FPLC) system: a Superdex 75 10/300GL (GE Healthcare), a Superose 6 
19/300GL (GE Healthcare), and an Enrich SEC650 10/300 (BioRad). All columns 
contained a void volume of roughly 8-10 mL, and a total volume of 24 mL. SEC was 
typically performed on the S75, equilibrated in Protein Storage Buffer, and with 
collection fractions set at 0.5 mL each. SDS-PAGE was run to assess purity of each 
fraction, with selected fractions ultimately combined and stored at 4C until use (or -80C 
for long term storage).  
Resolution on the S75 and SEC650 was sufficient to resolve the difference 
between eIF2Bβ (39kDa) and the GB1 tag (~8kDa), but not of eIF2α-CTD (~15kDa) or 
eIF2Bβ-NTD (~16kDa) and the GB1 tag, which were separated via cobalt resin 
(following 1,000-fold exchange out of DTT and EDTA), through nickel resin (following 
10-100x exchange out of DTT and EDTA), or through IgG resin. In which case the flow 
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through was collected and itself subjected to a final round of SEC and subsequent storage 
in Protein Storage Buffer. Protein concentration was determined by measuring absorption 
at 280 using  a UV-vis spectrophotometer. Concentrations of proteins in imidazole-
containing buffers were determined by the Bradford method or by SDS-PAGE. 
 eIF2α-NTD and eIF2α-NTD-S51D in both their tag-less and C-terminal His6-
tagged forms were poorly soluble (<50 μM) and quickly precipitated. By raising the salt 
concentration to 300 mM in the Lysis, Column Wash, Running, and Protein Storage 
Buffers, solubility was raised to at least 200 μM. eIF2α-NTD and eIF2α-NTD-S51D were 
stored at 300 mM salt and were exchanged 1,000-fold into 150 mM NaCl Protein Storage 
Buffer when experiments called for physiological conditions. Exchange was performed in 
the manner previously described, using Vivaspin 20 concentrators (GE Healthcare). 
Expression of insoluble eIF2Bδ was performed in Rosetta2(DE3) cells and 
purification required a denaturation/refolding protocol. Attempts at purification of three 
eIF2Bδ constructs were made using a modified protocol obtained from BiologicsCorp: 
GH-eIF2Bδ, GH-eIF2Bδ-ΔNTT, and H-eIF2Bδ-blg. Cell pellets were lysed as described 
above, but with a modified lysis buffer consisting of 50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 1% Triton X-100, 2 mM DTT, 1 mM EDTA, and 0.1 mM AEBSF (Delta Lysis 
Buffer). The sample was spun down at 19,500xg for 15 minutes at 4C, after which the 
lysis step was once again repeated. The resulting pellet was then re-suspended in 50 mM 
Tris-Hcl (pH 7.5), 150 mM NaCl, 8M urea, 0.5% sodium lauroyl sarcosine (SLS or 
sarkosyl), 10% glycerol, 20 mM imidazole, 1 mM tris(2-carboxyethyl)phosphine 
(TCEP), 1 mM EDTA, and 0.1 mM AEBSF (Dissolving Buffer 20 with TCEP, or 
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DB20+T), with additional sonication to break up pellets. Supernatants was effectively 
completely pure, rendering purification by polyhistidine affinity unnecessary. 
The resulting protein was then subjected to a series of rounds of dialysis. Of the 
~40 mL worth of protein in DB20+T, 2 mL aliquots were added to a 2 mL capacity 3.5 
kDa molecular weight cut-off dialysis cassette (Thermo Scientific), placed in a 50 mL 
Falcon tube filled with 20 mM Na-phosphate (pH 7.2), 150 mM NaCl, 2 mM reduced 
glutathione (GSH), 2 mM oxidized glutathione (GSSG), 0.5 M arginine, 20% glycerol, 1 
mM EDTA, and 0.1 mM AEBSF (Refolding Buffer) with a magnetic stir bar and 
incubated overnight at 4C. Buffer was changed four times with intervening overnight 
incubations at 4C. Oxidized and reduced glutathione (GSSG and GSH, respectively) were 
added fresh each time. For the first series, 1 mL of sample was removed each round, 
spun-down at max speed on a tabletop centrifuge, and the supernatant returned to the 
dialysis volume. A sample was taken prior to centrifugation as well as after, in an attempt 
to visualize potential losses as the 8 M urea was dialyzed away (by 25-fold each round). 
No protein loss was observed at any step. Care was also taken to ensure proper pH of 
Refolding Buffer due to the large concentration of highly basic arginine. Following the 
four rounds of exchange into Refolding Buffer, two rounds of exchange (via dialysis) was 
performed into Protein Storage Buffer, supplemented with 20% glycerol. 
2.2.4. Fluorescent Labeling 
Fluorescent labeling was attempted for eIF2α-NTD-H, eIF2α-NTD-S51D-H, 
eIF2Bα-CM-H, and GH-eIF2Bβ using fluorescein 5-maleimide (F5M). Labeling was 
performed according to a protocol provided by the manufacturer. Both eIF2Bα-CM-H 
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and GH-eIF2Bβ were exchanged out of Protein Storage Buffer into 10 mM Na-phosphate 
buffer (pH 7), 150 mM NaCl, 1 mM EDTA, 0.1 mM AEBSF, and 0.1 mM TCEP (pH 7) 
(Fluorescence Labeling Buffer) that had been degassed by vacuum for 30 minutes at 25C 
and further deoxygenated by N2 bubbling for 30-60 seconds. Both eIF2α-NTD-H and 
eIF2α-NTD-S51D-H were exchanged into Fluorescence Labeling Buffer with 300 mM 
NaCl instead. F5M (from a 10 mM stock in DMSO) was then slowly added drop-wise to 
diluted protein in an excess 4:1 ratio of F5M over protein with gentle mixing. Labeling 
was performed at eIF2Bα-CM-H and eIF2Bβ concentrations of 25 μM, and at eIF2α-
NTD-H and eIF2α-NTD-S51D-H concentrations of 10 μM. Labeling was allowed to 
occur either for 4 hours at 25C or overnight at 4C. The sample was then subjected to SEC 
on an S75 column to both exchange the protein back into Protein Storage Buffer and 
separate out free F5M. Labeling efficiency was determined visually (yellow-green color), 
by absorption on FPLC (at 494 nm), and/or by measuring emission at 518 nm following 
excitation on a QuantaMaster QM4 fluorescent spectrometer (PTI), equipped with 
polarizers and dual monochromators. Samples were covered in aluminum foil to reduce 
the rate of photobleaching due to ambient light. 
2.3. Characterization of the eIF2B Regulatory Sub-complex 
2.3.1. Analytical Size-Exclusion Chromatography (SEC) 
Typical loading volumes ranged from 50-250 μL. An S75 column was used as the 
proteins investigated fell solidly within its dynamic range. All proteins were filtered 
through a 0.22 μM filter prior to loading on the column. Flow rates of 0.25-0.35 mL/min 
were used.  A BioLogic QuadTec detector (Bio-Rad) was used to measure absorbance at 
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280 nm, 260 nm, 214 nm, and 230 nm. Apparent molecular weights (MWapp) were 
estimated using a set of protein standards (BioRad) containing bovine serum albumin 
(BSA, 67 kDa), ovalbumin (44 kDa), myoglobin (17 kDa), and vitamin B12 (1.14 kDa). 
Proteins showing concentration dependent increases in MWapp were run at a series of 
concentrations, and their MWapp was plotted as a function of concentration. Apparent KD 
values for dimerization were calculated as previously described (Pan et al. 2001). In cases 
in which the protein was mostly or entirely dimeric at the lowest concentration tested, 
only an upper limit of the KD could be obtained. 
2.3.2. Size Exclusion Chromatography Multi-Angle Laser Light 
Scattering (SEC-MALLS) 
eIF2Bα-H, eIF2Bα-TM-H, and GH-eIF2Bβ-WT were expressed in the manner 
described above. All three proteins were purified by polyhistidine affinity 
chromatography, followed by SEC into Protein Storage Buffer at 150 mM NaCl and 
subsequent collection of the central peak fractions. GH-eIF2Bβ-WT was additionally 
incubated with TEV protease at a 1:30 w/w ratio of TEV:GH-eIF2Bβ-WT for 8 hours 
while nutating at 4C, upon which it was re-run through SEC in Protein Storage Buffer at 
150 mM NaCl concentration. Cleavage of the tag was determined to be complete and 
central peak fractions of cleaved eIF2Bβ-WT were collected. Final samples of 900 μL 
each of 120 μM eIF2Bα-H, 12 μM eIF2Bα-H, and 15 μM eIF2Bβ-WT were prepared and 
sent to the W. M. Keck Biotechnology Resource Facility at Yale University (New Haven, 
CT). There they were run by Dr. Ewa Folta-Stogniew on a Superdex 200 HR10/300 GL 
SEC column (GE Healthcare), connected inline to a DAWN-EOS LS detector and an RI 
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detector (Wyatt Technology). The SEC-MALLS instrumentation was supported by NIH 
Award Number 1S10RR023748-01. 
Several experiments were performed with the provided materials. 10x dilutions of 
both the high (120 μM) and low (12 μM) concentration eIF2Bα-H were made and run as 
well, for a total of five experiments. Proteins showing concentration-dependent self-
association were run at a series of concentrations, and their MW was plotted as a function 
of concentration. The starting sample concentration was used for plotting, instead of the 
estimated concentration at the apex, because it was impossible to determine the degree to 
which the complexes were able to re-equilibrate at the gradually decreasing 
concentrations during the SEC run. All proteins were run in 20 mM HEPES (pH 7.4), 150 
mM NaCl, 1 mM EDTA, and 1 mM DTT. Absolute molecular weights of eIF2Bα and 
eIF2Bβ were obtained in this manner. 
2.3.3. Small Angle X-Ray Scattering (SAXS) 
 eIF2Bα-H was purified by polyhistidine affinity chromatography, followed by 
SEC into Protein Storage Buffer at 150 mM NaCl concentration, collection of the central 
peak fractions, and subsequent concentration using Vivaspin 20 concentrators, as 
previously described. Serial dilution provided 5x120 μL samples at a series of 
concentrations: 1.25 mg/mL (36 μM), 2.5 mg/mL (71 μM), 5 mg/ml (143 μM), and 10 
mg/mL (287 μM). eIF2Bα-TM-H was purified by polyhistidine affinity chromatography, 
though yielded only 5x120 μL of ~1 mg/mL with poor purity. All protein was prepared in 
and diluted with Protein Storage Buffer at 150 mM NaCl concentration, with a blank 
volume supplied as well. Data was collected at the X9 beamline at Brookhaven National 
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Laboratory National Synchrotron Lightsource by Dr. Stefan Jehle (Vajda Lab, 
Department of Biomedical Engineering, Boston University). No reference protein was 
used; therefore, no absolute MW was determined. The low-angle region of the SAXS 
profile at low concentration was merged with the high-angle region of the high-
concentration profile to compensate for inter-particle repulsion. The SAXS data were 
processed using the ATSAS software suite (Petoukhov & Svergun 2007). The radius of 
gyration (Rg) was measured using the program PRIMUS and the maximum dimension 
(Dmax) was determined from the pair-distance distribution function P(r) calculated using 
GNOM. The SAXS profile of eIF2Bα was used for fitting dimer and tetramer assemblies 
from the eIF2Bα crystal structure (3ECS.pdb) using FoXS (Schneidman-Duhovny et al. 
2010).  
2.4. Investigation of the eIF2α Intramolecular Interaction 
2.4.1. NMR experiments for Determination of Backbone Assignments 
A necessary prerequisite to interpreting any of the NMR experiments described 
below is the performance of backbone assignments for eIF2α and eIF2α-S51D. Backbone 
assignments for a mutant protein eIF2α-mut-H at high salt (350 mM Na2SO4) have been 
reported (Ito et al. 2004; Ito & Wagner 2004). Only an HNcaCB and an HNCO were run 
on 2H/15N/13C-labeled eIF2α-NTD-H, and only an HNcaCB, an HNCO, and a 
confirmatory HNCACB were run on 2H/15N/13C-labeled eIF2α-NTD-S51D-H. An 
HNCACB and HNCA were run on 2H/15N/13C-labeled eIF2α-CTD. As 13C peak positions 
are relatively insensitive to salt conditions, the primary difficulty was accounting for the 
effects of the mutations and deletions. Assignments were initially made for the individual 
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domains, following which they were transferred to the full length protein. More than 90% 
of peaks were in this manner assigned for eIF2α-NTD-H, eIF2α-NTD-S51D-H, and 
eIF2α-CTD. Roughly 80% of peaks were in this manner assigned for eIF2α-H and eIF2α-
S51D-H.  
NMR buffer was prepared from Column Wash Buffer, with 2 mM DTT and 0.1 
mM AEBSF added directly to the sample rather than already being contained in the stock 
buffer. Two common stock NMR buffers were maintained, one at 150 mM NaCl and one 
at 300 mM NaCl. Purified protein was exchanged 1,000-fold into the appropriate NMR 
buffer via a series of three 1:10 dilutions (with corresponding concentration steps in 
between). A volume of D2O containing the appropriate 150 mM or 300 mM NaCl was 
added to samples to bring the final D2O concentration of the sample to either 5% or 10%. 
Sample volumes typically ranged between 250 and 300 μL and were loaded into Shigemi 
tubes (Shigemi Inc.). Following loading, tubes were centrifuged at 100xg for 2 minutes to 
maximize sample volume and minimize sample loss due to coating of tube walls. Care 
was taken upon insertion of the associated plunger that no bubbles were introduced into 
the sample volume. All samples were kept at 4C when not in use.  
NMR spectra were recorded at 298K on either a Bruker 500 MHz instrument 
(Boston University School of Medicine) or a Bruker 800 MHz instrument (Brandeis 
NMR Facility, Brandeis University), both equipped with a cryoprobe. NMRPipe was 
used to process raw NMR data into 1D, 2D, or 3D spectra, as well as perform any post-
processing (e.g. window functions, linear extrapolation, solvent flattening, etc.) (Delaglio 
et al. 1995). CARA was also used as a repository for processed NMR spectra, as well as 
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to visualize spectra, pick peaks, generate statistics, and generate spectra overlays (Keller 
2004). Assignments were performed by Cora Lin in CARA, which can be downloaded 
from http://cara.nmr.ch/. 
2.4.2. NMR experiments for Investigation of Protein-Protein 
Interactions 
The majority of experiments made use of 2H/15N labeled proteins, though on 
occasion 2H/15N/13C labeled proteins were used with de-coupling of the carbon channel 
(i.e. suppression of hydrogen carbon coupling) or 15N labeled protein were used. All 
experiments used standard Bruker pulse sequences. Two-dimensional heteronuclear 
single-quantum coherence (HSQC) or transverse relaxation-optimized spectroscopy 
(TROSY-HSQC) experiments were the primary NMR experiments performed. TROSY-
HSQC experiments were performed exclusively on 2H/15N or 2H/15N/13C-labeled 
proteins.  
When assessing the presence of an interaction or when seeking to identify a 
surface responsible for an interaction, an unlabeled protein was added to a sample of 
labeled protein. This was performed in one of two ways: direct addition to the final NMR 
sample, or combination and subsequent preparation of an NMR sample. Direct addition 
entailed adding unlabeled protein (with 5% or 10% D2O) directly to an NMR sample 
prior to loading in a Shigemi tube. This necessarily entailed a dilution of labeled protein 
(as well as of unlabeled protein). In cases where the solubility of unlabeled protein was 
insufficient to create the high concentration stock necessary to achieve the desired final 
concentration in the NMR sample, unlabeled protein was simply added to labeled protein, 
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brought to 5% or 10% D2O, and concentrated using Amicon Ultra 0.5mL concentrators 
(Millipore) to produce the final NMR sample. The final sample was analyzed by SDS-
PAGE as a control. 
NMR chemical shift perturbation (CSP) assays were performed to identify the 
surface responsible for the intramolecular interaction, as well as to determine the effects 
of introducing the S51D phosphomimetic mutation. To minimize potential artifacts, 
spectra were collected of proteins prepared side-by-side or by addition of an unlabeled 
binding partner to an identical amount of labeled protein from the same prep from which 
the reference spectrum was collected. Changes in pH were monitored by observing 
perturbations in chemical shifts of surface-exposed histidines. Peaks positions were 
marked manually for all spectra, with both 1H and 15N chemical shifts exported to 
Microsoft Excel for statistical analysis along with peak intensities. Perturbations resulting 
in disappearance of a peak were assessed on a case by case basis, and in the absence of a 
clear final destination were assigned to the nearest unidentified peak. Adjacent peaks 
with substantial variation in peak intensity were assessed on a case by case basis as a 
means of quality control of the peak picking process.  
Statistical analysis was performed on an assembled set of chemical shift 
perturbations obtained from comparison of a pair of spectra. First, the mean and standard 
deviation was calculated from the entire set. Residues with chemical shift perturbations 
greater than a threshold of 1.5 or 2 standard deviations (1.5σ or 2σ) were then removed 
from the set, and the mean and standard deviation of remaining residues were re-
calculated. This process was continued until the mean chemical shift perturbation reached 
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digital resolution or until no new residues crossed the 1.5σ or 2σ threshold. The set of 
residues thus identified were recorded and represented the interaction surface. Residues 
were mapped to the 2004 NMR solution structure of human eIF2α (1Q8K.pdb) (Ito et al. 
2004). Visualization and figures were produced in PyMOL (Schrödinger 2015) or 
MOLMOL (Koradi et al. 1996). 
 NMR experiments used to investigate the intermolecular interaction between 
eIF2α constructs and eIF2Bα or eIF2Bβ were analyzed in a different manner. Rather than 
chemical shift perturbations, a pattern emerged in which certain peaks experienced more 
intense signal loss compared to others. The selective signal loss is due to cross-relaxation 
between the free and bound state, a phenomenon observed in cases with a weak 
interaction in which the labeled protein is in fast equilibrium between a free state and a 
complex that is too large to observe by NMR (Anthis & Clore 2015). The same statistical 
analysis as described above was performed in these cases, with ratios of peak intensity to 
reference peak intensity assessed instead of peak displacements. The two-step process 
was continued until no new peaks reached threshold or until random peaks started to 
cross the threshold (as determined visually on a case-by-case basis). 
2.4.3. Fluorescence Experiments for the Investigation of eIF2B:eIF2α 
Interactions  
Fluorescence anisotropy measurements were performed on a QuantaMaster QM4 
fluorescent spectrometer (PTI), equipped with polarizers and dual monochromators. 
Baseline anisotropy measurements were taken at sub-μM concentrations of either F5M-
labeled eIF2α-NTD-H or F5M-labeled eIF2α-NTD-S51D-H. Experiments were 
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performed in two ways. The first method involved titrating increasing amounts of 
unlabeled protein (eIF2Bα-CM-H or eIF2Bβ), which had been pre-mixed with the 
appropriate F5M-labeled protein such that the titration stock contained the same 
concentration of F5M-labeled protein as the starting sample. This avoided dilution of 
F5M-labeled protein. Volumes were removed from the cuvette as required. A second 
approach involved measuring the anisotropy of a sample at maximum unlabeled protein 
concentration, followed by a sequential process of removing a portion of the sample 
volume and replacing it with free F5M-labeled protein. In this manner, the concentration 
of unlabeled protein was sequentially diluted in 10% increments (relative to baseline max 
concentration). In both approaches, the sample temperature was maintained at 20C. 
Excitation was performed at 494 nm and emission was measured at 518 nm. The 
fluorescent life-time of F5M is on the order of 5 nanoseconds. G-factors were 
automatically calculated and applied by the software. 
2.5. Building a Thermodynamic Model of eIF2B-catalyzed 
Recycling of eIF2-GDP 
 Known KDs that were consistent among different reports were rounded to 
multiples of ten (Figure 4.14, 4.15, 4.16, and Table 4.1), while ensuring that after 
rounding up, they are internally consistent with thermodynamic coupling (Fersht, 1999). 
Thermodynamically coupled interactions exert reciprocal effects on each other, which 
stems from the Conservation of Energy Principle. For instance, if GDP’s affinity for eIF2 
is ~100-fold greater than its affinity for eIF2B:eIF2, eIF2B lowers the affinity of GDP for 
eIF2 ~100-fold. Therefore, GDP must lower the affinity of eIF2B for eIF2 ~100-fold and 
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the ratio of the KDs of eIF2B for eIF2-GDP and eIF2B for apo-eIF2 must be set at 100 to 
1. 
Where reported KDs varied by more than 2-3 fold between different sources, the 
KD value was selected based on buffer conditions in the reports (e.g. physiological Mg+ 
concentration, salt, and temperature were preferred) and thermodynamic coupling with 
other KDs. 
Where no KD values have been reported, thermodynamic coupling was used to 
calculate the KD from known KDs, or at least to set upper and lower limits for the KD. 
Since the relevant rates in translation and in eIF2 recycling are on the order of 
seconds or faster, steps whose rates were on the order of once per minute or slower were 
considered not physiologically relevant, unless special circumstances make them 
relevant.  
The following relationships among KDs (R1 through R6) were used: 
(R1) eIF2B binding to eIF2 weakens GDP binding 100x, and vice versa (Panniers et al. 
1988): 
KD[GDP]●[2]
KD[GDP]●[2B: 2]
=
1
100
,     𝑡ℎ𝑒𝑟𝑒𝑓𝑜𝑟𝑒     
KD[2B]●[2]
KD[2B]●[2-GDP]
=
1
100
 
(R2) eIF2B binding to eIF2 weakens GTP binding 10x, and vice versa(Panniers et al. 
1988): 
KD[GTP]●[2]
KD[GTP]●[2B: 2]
=
1
10
,   𝑡ℎ𝑒𝑟𝑒𝑓𝑜𝑟𝑒   
KD[2B]●[2]
KD[2B]●[2-GTP]
=
1
10
 
From this relation, we can calculate that KD[2B]●[2-GTP] is 10x greater than 
KD[2B]●[2], or 100 pM. 
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(R3) The affinity of Met-tRNAi for eIF2B:eIF2-GTP and the affinity of eIF2B for TC 
are not known. However, Met-tRNAi and eIF2B binding to eIF2-GTP are 
thermodynamically coupled, allowing the following determination to be made:  
KD[tRNA]●[2-GTP]
KD[tRNA]●[2B: 2-GTP]
=
KD[2B]●[2-GTP]
KD[2B]●[TC]
 
Rearranging this equation yields: 
KD[tRNA]●[2B: 2-GTP]
KD[2B]●[2-TC]
=
KD[tRNA]●[2-GTP]
KD[2B]●[2-GTP]
=
10 𝑛𝑀
0.1 𝑛𝑀
=
100
1
 
Using 10 nM for the KD[tRNA]●[2-GTP] and 100 pM for the KD[2B]●[2-GTP], 
we can calculate that their ratio is 100:1. From the equation above, the ratio of 
KD[tRNA]●[2B: 2-GTP] to KD[2B]●[TC] is also 100:1. Therefore, we are able to 
determine that Met-tRNAi binds to eIF2B:eIF2-GTP roughly 100x weaker than 
eIF2B binds to the TC. 
(R4) Since the affinity of eIF2B for eIF2(α-P) is the same as the affinity of eIF2B for 
eIF2(α-P)-GDP (Goss et al. 1984), 
KD[2B]●[2(α-P)]
KD[2B]●[2(α-P)-GDP]
=  
1
1
 
 using thermodynamic coupling we can obtain the following relation, 
KD[GDP]●[2(α-P)]
KD[GDP]●[2B: 2(α-P)]
=
KD[2B]●[2(α-P)]
KD[2B]●[2(α-P)-GDP]
=
1
1
 
(R5) No effect (Sokabe et al. 2012) or 2x effect (Jennings & Pavitt 2010) of eIF5 on 
GDP dissociation from eIF2 was observed. Therefore, GDP’s affinity for 
eIF5:apo-eIF2 should be similar to its affinity for eIF2 (KD ~ 10 nM). Then, based 
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on thermodynamic coupling, eIF5’s affinity for apo-eIF2 is similar to its affinity 
for eIF2-GDP. 
KD[5]●[2-GDP]
KD[5]●[2]
=
KD[GDP]●[5: 2]
KD[GDP]●[2]
≈
1
1
 
(R6) Since the affinities of eIF5 for apo-eIF2, eIF2-GDP, and TC are all similar (KD 
~10 nM), it is unlikely that eIF5 binding of eIF2 is dependent on whether and 
which nucleotide is bound to eIF2. In this case, we can surmise that eIF5’s 
affinity for eIF2-GTP is likely similar to its affinity for apo-eIF2, eIF2-GDP, and 
TC (KD ~10 nM). Therefore, by thermodynamic coupling, we can expect the 
affinity of GTP for eIF5:apo-eIF2:Met-tRNAi to be similar to the affinity of GTP 
for apo-eIF2:Met-tRNAi (KD ~100 nM). 
Estimation of 𝑲𝑫[𝒕𝑹𝑵𝑨]●[𝟐𝑩: 𝟐-𝑮𝑻𝑷] and 𝑲𝑫[𝟐𝑩]●[𝑻𝑪] 
Given the affinities of Met-tRNAi for eIF2-GTP (KD ~ 10 nM), of eIF2B for 
eIF2-GTP (KD ~100 pM), of eIF5 for TC (KD ~10 nM) and also (R3) above, we can 
estimate a likely limit on the affinity of Met-tRNAi for eIF2B:eIF2-GTP and a 
corresponding limit on the affinity of eIF2B for TC. We estimate the KD of Met-tRNAi 
for eIF2B:eIF2-GTP to be ~100 nM and certainly between 10 nM and 1 μM. 
Correspondingly, the KD of eIF2B for TC should be ~1 nM and certainly between 100 
pM and 10 nM. The logic follows: 
If Met-tRNAi’s affinity were the same as or higher for eIF2B:eIF2-GTP than for 
eIF2-GTP, then by (R3) this would mean that eIF2B’s affinity for TC would be the same 
as or higher than its affinity for eIF2-GTP alone, which is already very high (KD = 100 
pM). This would mean that the affinity of eIF2B for TC would be at least 100-fold higher 
 
 
  95 
than the affinity of eIF5 for TC (i.e. KD ~100 pM or lower vs ~10 nM). Such a disparity 
would make it hard for eIF5 to displace eIF2B from TC, a necessary next step in 
catalysis. Spontaneous TC dissociation from eIF2B would also be negligible, as is the 
case for eIF2-GTP dissociation from eIF2B. Thus, we can conclude that Met-tRNAi’s 
affinity must be lower for eIF2B:eIF2-GTP than for eIF2-GTP. 
If Met-tRNAi’s affinity were much more than 10-fold lower for eIF2B:eIF2-GTP 
than for eIF2-GTP, that would make the KD much greater than 100 nM. As the cellular 
concentration of Met-tRNAi is ~300 nM (Smith, 1975), this would shift the equilibrium 
away from the formation of the product, TC, on eIF2B. Thus, we can conclude that Met-
tRNAi’s affinity is unlikely to be much more than 10-fold lower for eIF2B:eIF2-GTP 
than for eIF2-GTP. Then, again by (R3) this would mean that the KD of eIF2B for TC 
would be unlikely to be much more than 1 nM.  
A KD of Met-tRNAi for eIF2B:eIF2-GTP of ~100 nM is consistent with the report 
that half-maximum stimulation of nucleotide exchange was achieved with 60 nM Met-
tRNAi (Gross et al. 1991). It has also been shown that the dissociation rates of eIF2-GDP 
and TC from eIF2B are similar (Gross et al. 1991), which is consistent with the KD of 
eIF2B for TC being similar to that of eIF2B for eIF2-GDP (~1 nM). Finally, the 10-fold 
lower affinity of TC for eIF5 compared to for eIF2B (10 nM vs 1 nM) is balanced by the 
fact that the cellular concentration of eIF5 is roughly 10-fold higher than that of eIF2B, 
leading to an equilibrium optimally primed for regulation. 
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Chapter 3: Insights into the Architecture of the eIF2Bα/β/δ 
Regulatory Subcomplex 
 
3.1. Introduction 
Eukaryotic translation initiation factor 2 (eIF2) is a G-protein that in its GTP-
bound form binds to the initiator methionyl-tRNA (Met-tRNAi) yielding a ternary 
complex (TC), which is then recruited to the translation initiation complex. Upon start 
codon recognition, eIF2 hydrolyses GTP and is released from the initiation complex 
(reviewed in (Jackson et al. 2010; Marintchev & Wagner 2004; Pestova et al. 2007; 
Sonenberg & Hinnebusch 2009)).  
The TC is regenerated after every cycle of translation initiation through a process 
catalyzed by the guanine nucleotide exchange factor (GEF) eIF2B, which is one of the 
main targets for regulation of translation. Phosphorylation of Serine 51 in the α-subunit 
of eIF2 converts eIF2 from a substrate into a competitive inhibitor of the GEF eIF2B. 
eIF2α phosphorylation is mediated by a group of related kinases: the dsRNA-activated 
Protein Kinase (PKR), PKR-like ER Kinase (PERK), Heme-Regulated Inhibitor (HRI), 
and General Control Nonderepressible 2 (GCN2). eIF2α is phosphorylated in response to 
a number of different stress factors, such as viral infection, unfolded protein response, 
hypoxic stress, heme deficiency, amino acid starvation, etc., collectively known as the 
integrated stress response (ISR). The result is inhibition of translation in the cell, which 
can range from modestly slowing down to nearly completely shutting off protein 
synthesis and induction of apoptosis. At the same time, translation of the mRNA coding 
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for the transcription factor ATF4, which mediates the stress response, is turned on 
through a mechanism called translation reinitiation. Phosphorylation of eIF2α by PKR in 
response to viral infection causes translation shut-off and apoptosis and serves as a 
powerful defense mechanism in the cell. ISR triggered by amino acid starvation or heme 
deficiency typically causes more modest translation inhibition (mediated by GCN2 and 
HRI activation, respectively), and serves to balance supply and demand of metabolites. 
PERK is involved in controlling the accumulation of misfolded proteins as part of the 
unfolded protein response (UPR). Persistent PERK activation leads to cell death in prion 
diseases and other neurodegenerative disorders, and PERK inhibition was recently shown 
to have neuroprotective effects in mice (Moreno et al. 2013). ISR induction via PERK in 
the hypoxic environment inside solid tumors is important for cancer cell survival 
(reviewed in (Dever et al. 2007; Ron & Harding 2007; Wek et al. 2006)).  
The yeast Saccharomyces cerevisiae (S. cerevisiae) has only one of the eIF2α 
kinases, GCN2, whose main role is in balancing amino acid supply and demand. eIF2α 
phosphorylation by GCN2, in response to amino acid starvation, not only slows down 
translation rates, but also turns on translation of a number of proteins, including the 
transcription factor GCN4, which in turn stimulates expression of amino acid 
biosynthetic enzymes (reviewed in (Hinnebusch 2005; Hinnebusch et al. 2007)). 
eIF2B is composed of five different subunits: α through ε. eIF2Bγ and eIF2Bε 
form the catalytic subcomplex. eIF2Bα, β, and δ form the regulatory subcomplex (Pavitt 
et al. 1997; Yang & Hinnebusch 1996). The eIF2Bα, β, and δ subunits are homologous to 
each other over the entire eIF2Bα sequence; eIF2Bδ has an N-terminal tail (NTT) not 
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found in the other two subunits. All the eIF2B subunits except for eIF2Bα are essential in 
S. cerevisiae (reviewed in (Marintchev & Wagner 2004; Hinnebusch et al. 2007)). The 
essential functions of eIF2Bβ, γ, and ε are in nucleotide exchange, whereas eIF2Bδ is 
important for the recruitment of Met-tRNAi to eIF2-GTP (Dev et al. 2010). While 
eIF2Bα plays an accessory role in the GEF function, it is required for the regulation of 
eIF2B activity by phosphorylation of its substrate eIF2. The eIF2Bα subunit is not tightly 
associated with the rest of eIF2B, especially when eIF2B is not bound to its substrate 
eIF2, and is sometimes partially or completely lost during purification (see for example 
(Konieczny & Safer 1983; Oldfield & Proud 1992; Williams et al. 2001)). α-less eIF2B 
has been reported to have either lower (Williams et al. 2001) or similar (Kimball et al. 
1998) activity compared to intact eIF2B and is not inhibited by phosphorylated eIF2 
(eIF2(α-P)) (Pavitt et al. 1997; Kimball et al. 1998).  
Mutations that decrease the activity of eIF2B in S. cerevisiae lead to lower TC 
concentrations, mimicking the effect of eIF2α phosphorylation and derepressing the 
translation of GCN4 in the absence of amino acid starvation. Such a phenotype is called 
general amino acid control derepressed (Gcd-), and Gcd- mutations have been found in all 
five eIF2B subunits. Mutations that prevent derepression of GCN4 translation by amino 
acid starvation, called general amino acid control non-derepressible (Gcn-), have been 
found in all three subunits of the eIF2Bα/β/δ regulatory subcomplex. The Gcn- mutations 
in eIF2Bα, β and δ prevent inhibition of eIF2B activity by eIF2(α-P) (reviewed in 
(Hinnebusch 2005; Hinnebusch et al. 2007)). 
Mutations in human eIF2B have been associated with a genetic neurodegenerative 
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disorder known as childhood ataxia with CNS hypomyelination (CACH) or 
leukoencephalopathy with vanishing white matter (VWM). The CACH/VWM mutations 
seem to lead to decreased eIF2B levels or activity in the cell; however, the underlying 
molecular mechanisms are not understood (reviewed in (Ron & Harding 2007; Bugiani et 
al. 2010; Fogli & Boespflug-Tanguy 2006)). 
Despite decades of research, the architecture of eIF2B remains unknown. It has 
typically been reported to have an apparent molecular weight between 250 and 350 kDa, 
based on size exclusion chromatography (SEC) and analytical ultracentrifugation (AUC) 
experiments (see for example (Cesar de Haro & Ochoa 1979; Ranu & London 1979; 
Siekierka et al. 1981)). Since the combined mass of its five subunits is ~260 kDa, it has 
always been thought to be a heteropentamer composed of one each of the five subunits. 
More recently, mass spectrometry data has confirmed that the five subunits are present in 
equimolar amounts (Kito et al. 2007). Models for the architecture of the catalytic eIF2Bγε 
subcomplex have been proposed, based on distantly related enzymes (Reid et al. 2012; 
Wang et al. 2012). However, no viable model exists for the regulatory eIF2Bα/β/δ 
subcomplex and it is not known how the individual subunits interact with each other (see 
also Discussion, below).  
Since eIF2B is believed to be a heteropentamer, the regulatory eIF2Bα/β/δ 
subcomplex is presumed to be a 1:1:1 trimer, and all three subunits (α, β, and δ) are 
presumed to be monomers. However, it is difficult to reconcile this notion with recent 
data about the structures of homologous proteins, all of which are dimers. More recently, 
when the crystal structure of human eIF2Bα was solved (Hiyama et al. 2009), the authors 
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did not discuss the possibility of eIF2Bα being a dimer, likely because that would conflict 
with the notion that it is a monomer (since eIF2Bα/β/δ is believed to be a trimer). 
However, close inspection of the deposited structure reveals that the eIF2Bα molecules 
found in the asymmetric unit appear to form dimers (See Figure 3.4E). 
Here we show that eIF2Bα is indeed a homodimer, like all its homologs with 
known structures, using the same dimerization interface. We also present evidence 
indicating that the interaction between eIF2Bβ and δ is likely along the same interface, 
forming a heterodimer similar to the eIF2Bα2 homodimer. These results allow us to 
propose a model for the possible architecture of the regulatory eIF2Bα/β/δ subcomplex. 
They also provide insights into the molecular basis of a number of mutations in human 
eIF2B that cause leukoencephalopathy with vanishing white matter. While the 
publication reproduced in this chapter was in preparation, Proud and co-authors reported 
that eIF2Bα is a dimer and eIF2B as a whole is a decamer (Wortham et al. 2014), at odds 
with a number of previous reports (Cesar de Haro & Ochoa 1979; Ranu & London 1979; 
Siekierka et al. 1981), but in line with the results presented here. While the interactions 
between eIF2Bβ and δ were not addressed in this recent report (Wortham et al. 2014), the 
data presented there are consistent with our conclusions.  
3.2. Results 
3.2.1. The human eIF2Bα crystal structure indicates that it is a dimer 
Most archaeons with an eIF2Bα/β/δ homolog have a single protein, archaeal 
translation initiation factor 2B (aIF2B), which is a homodimer. aIF2B dimerization is 
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mediated by the C-terminal domains (CTDs) of the two subunits (Figures 3.1A, 3.4B). A 
long loop (“arm” region) protrudes from each subunit and packs against the other subunit 
in the dimer, effectively extending its β-sheet (Kakuta et al. 2004). More distant relatives, 
such as ribose-1,5-bisphosphate isomerases (RBPI) (Nakamura et al. 2012) and 
methylthioribose-1-phosphate isomerases (MTNAs) (Bumann et al. 2004; Tamura et al. 
2008), are also dimeric and utilize the same dimer interface as aIF2B, including the arm 
region (Figure 3.4CD). All these dimeric structures cast doubt on the widely held view 
that the regulatory eIF2Bαβδ sub-complex is a trimer, which requires the eIF2Bα, β, and 
δ subunits to be monomers.  
The crystal structure of human eIF2Bα was published recently (Hiyama et al. 
2009). The authors reported that eight molecules were found in the asymmetric unit, but 
did not discuss the subject further. Close inspection of the eIF2Bα structure shows that 
the eight molecules in the asymmetric unit form four identical dimers (shown in different 
colors in Figure 3.4E). Dimerization is along the same interface as in all homologs with 
known structures (Figures 3.1BC, 3.4). The arm region (marked with arrows in Figure 
3.1B) is also part of the dimerization interface, again as in all homologous structures. The 
dimer interface is extensive, with over 1,500 Ǻ2 of buried surface. The dimerization 
surface observed in the crystal structure is among the best-conserved surfaces in the 
protein, with significant hydrophobicity, as expected for a protein-protein interaction 
surface (Figures 3.2 and 3.3). Hydrophobic amino acid side-chains are typically found in 
the protein core and at protein interaction surfaces, since exposing them is unfavorable 
and burying them contributes to the binding energy. Hydrophobic side-chains also 
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contribute to the specificity of interaction, because the binding energy is proportional to 
the 6th power of the distance and helps “lock” the complex into place, compared to 
coulombic interactions, which are proportional to the 1st power of the distance. Compared 
to the highly conserved putative eIF2α-P binding surface (Dev et al. 2009), the eIF2Bα 
dimerization surface shows a comparable degree of sequence conservation and even 
greater hydrophobicity, consistent with both surfaces being important for protein-protein 
interactions and the dimerization surface being constitutively buried. These observations 
led us to hypothesize that eIF2Bα is a homodimer, utilizing the same dimerization surface 
as all its homologs with known structure. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: eIF2Bα dimerizes along the same interface as all its homologs with known structures 
(A) The crystal structure (2.2 Å) of the archaeal eIF2Bα/β/δ homolog, aIF2B (1VB5.pdb), which is a homodimer (Kakuta et al. 
2004). The two aIF2B subunits are colored in red and yellow, respectively. The “arm” regions, which interact with the other 
subunit in the dimer, are labeled with arrows. (B) The crystal structure (2.65 Å) of eIF2Bα (3ECS.pdb) (Hiyama et al. 2009) 
shows a dimer with a large buried surface. One subunit is cyan and the other blue. The “arm” regions, which interact with the 
other subunit in the dimer, are labeled with arrows. (C) eIF2Bα dimerizes using the same interface as aIF2B. Structure alignment 
of aIF2B and eIF2Bα, with the same orientation and coloring as in (A) and (B), respectively. The CTDs of the eIF2Bα and aIF2B 
subunits were aligned, Cα RMSD = 1.38 Ǻ (excluding the “arm” region). The interdomain orientations differ somewhat between 
eIF2Bα and aIF2B, as noted previously (Hiyama et al. 2009) and the NTDs of the proteins were not used in the alignment. 
Structure alignments were done in MOLMOL (Koradi et al. 1996). 
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Figure 3.2: The eIF2Bα dimerization interface is highly conserved among eIF2Bα homologs 
eIF2Bα is shown in surface representation. Amino acids are colored by sequence conservation from white (<30% conservation) 
to yellow (65% conservation), to green (100% conservation). The dimerization interface is marked with a light blue line. One 
subunit is omitted in the middle panel, in order to show the dimerization surface. 
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Figure 3.3: The eIF2Bα dimerization interface is highly hydrophobic 
The display is as in Figure 3.2, except that the surface is colored by hydrophobicity/charge. Backbones are colored in dark grey; 
hydrophobic side chains are yellow; positively charged side chains are blue; negatively charged side chains are red; and the 
remaining side chains are light grey. The three residues at the dimerization surface, whose mutation (designated eIF2Bα-TM) 
abolishes dimerization (see Figure 3.5, below) are labeled. 
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Figure 3.4: All eIF2Bα/β/δ homologs are dimers along the same interface 
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Figure 3.4: All eIF2Bα/β/δ homologs are dimers along the same interface 
(A) The eIF2Bα dimer from 3ECS.pdb (Hiyama et al. 2009). One subunit is blue, the other 
is cyan. The eIF2Bα dimer is rotated 180 degrees compared to Figure 3.1, in order to 
facilitate comparison with the octameric assembly observed in the eIF2Bα crystal (panel 
(E) below). (B) The archaeal aIF2B from a crystal structure (2.2 Å) from Pyrococcus 
horikoshii (1VB5.pdb) (Kakuta et al. 2004), in the same orientation as eIF2Bα in (A). (C) 
The enzyme MTNA (methylthioribose-1-phosphate isomerase) from a crystal structure 
(2.4 Å) from Bacillus subtilis (2YVK.pdb) (Tamura et al. 2008), in the same orientation as 
eIF2Bα in (A). (D) The enzyme RBPI (ribose-1,5-bisphosphate isomerase) from a crystal 
structure (2.5 Å) from Thermococcus kodakarensis (3A11.pdb (Nakamura et al. 2012), in 
the same orientation as eIF2Bα in (A). (E) The eight molecules in the eIF2Bα asymmetric 
unit (3ECS.pdb) form four identical dimers. The subunits of one of the dimers on the front 
are blue and cyan, respectively. The subunits of the second dimer on the front are red and 
yellow. The subunits of each of the two dimers on the back are dark grey and light grey, 
respectively. 
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3.2.2. eIF2Bα is a dimer at physiological concentrations 
To test our hypothesis that eIF2Bα is a dimer, we used size exclusion 
chromatography (SEC). We found that eIF2Bα-H (~35 kDa) migrates with an apparent 
molecular weight (MWapp) of ~60 kDa, roughly as expected for a dimer (Figure 3.5A). 
The MWapp of eIF2Bα did not change as its concentration was varied between 0.6 µM 
and 3 µM (Figure 3.5B), indicating that there is no significant fraction of monomer 
within this concentration range. While these results do not allow us to estimate the KD of 
dimerization, the absence of detectable amounts of monomer (below a few %) provides 
an upper limit of ~1 nM for the KD: if there is no detectable monomer at 0.6 µM, the 
protein concentration must be more than two orders of magnitude higher than the KD of 
dimerization. Therefore, eIF2Bα is a dimer at physiological concentrations, estimated to 
be in the low-µM range (von der Haar & McCarthy 2002). The MWapp of eIF2Bα 
gradually increased as its concentration was varied between 3 µM and 230 µM (Figure 
3.5B), indicating that the dimer was in equilibrium with higher order species at 
concentrations above 3 µM. To corroborate the SEC results, we used small angle X-ray 
scattering (SAXS) at concentrations of 57, 143, and 287 µM to characterize the 
oligomeric state of eIF2Bα (Figure 3.6). The radius of gyration (Rg) and the maximum 
dimension (Dmax) of the eIF2Bα particle at 57 µM could be determined from SAXS data 
to be ~44 Å (Rg) and ~150 Å (Dmax), respectively (Figure 3.6). Comparison of these 
results with the values calculated from the crystal structure for a monomer (Rg = 21 Å; 
Dmax = 78 Å) and dimer (Rg = 31 Å; Dmax = 132 Å), showed that the average complex 
size in the eIF2Bα sample at 57 µM was greater than a dimer. Since there are eight  
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Figure 3.5: Size exclusion chromatography (SEC) of eIF2Bα and β 
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Figure 3.5: Size exclusion chromatography (SEC) of eIF2Bα and β 
(A) SEC traces of WT eIF2Bα-H (blue) and eIF2Bα-TM (green) at 15 µM concentration. 
The theoretical MWs for WT eIF2Bα-H and eIF2Bα-TM monomers are both ~35 kDa. The 
apparent molecular weights (MWapp) from SEC are: WT eIF2Bα – 60 kDa (dimer) and 
eIF2Bα-TM – 33 kDa (monomer). The positions of the markers used to calculate MWapp 
are shown with vertical dashed lines. (B) Calculated MWapp as a function of protein 
concentration. WT eIF2Bα (two independent sets of experiments are shown in blue and 
light blue) is dimeric up to 3 µM, but its MWapp starts to gradually increase at higher 
concentrations, indicative of formation of larger complexes. eIF2Bα-Δarm (red) is in 
equilibrium between monomer and dimer, and possibly higher-order complexes, in the 
concentration range tested; eIF2Bα-TM (green) is clearly monomeric. (C) SEC trace of 
untagged eIF2Bβ at 15 µM concentration. The theoretical MW for an eIF2Bβ monomer is 
39 kDa. The apparent molecular weight (MWapp) from SEC is 41 kDa (monomer). The 
positions of the markers used to calculate MWapp are shown with vertical dashed lines. 
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Figure 3.6: SAXS characterization of eIF2Bα 
(A) SAXS curve of eIF2Bα, extrapolated from a series of concentrations, as described in 
Chapter 2. (B) Guinier plot of the eIF2Bα data showing good sample quality and no signs 
of aggregation. (C) Pair-distance distribution function P(r). The values of Rg = 44 Ǻ and 
Dmax = 150 Ǻ, calculated from the SAXS data at 57 µM eIF2Bα concentration are shown. 
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molecules in the asymmetric unit in the eIF2Bα crystal, forming four identical dimers, 
there are more than one possible tetrameric arrangements (and it is also possible that the 
interdimer orientations could be different from those observed in the crystal). The 
calculated values for two of the possible tetrameric arrangements found in the crystal are: 
Rg = 37 Å and Dmax = 133 Å (both values smaller than experimentally determined); and 
Rg = 41 Å and Dmax = 163 Å (Dmax larger than experimentally determined). For reference, 
the values calculated for the octameric arrangement in the crystal were: Rg = 45 Å and 
Dmax = 167 Å. We were unable to fit the SAXS data to a dimer, a tetramer, or a mixture 
thereof with a χ2 of better than 6 by using the program FoXS (Schneidman-Duhovny et 
al. 2010). Nevertheless, the calculated Rg and Dmax show that at the high protein 
concentrations used for SAXS, eIF2Bα is clearly not a monomer, and is larger than a 
dimer, in agreement with the SEC results. 
To determine unambiguously the oligomeric state of eIF2Bα in solution, we used 
size exclusion chromatography - multi-angle laser light scattering (SEC-MALLS), which 
allows the determination of absolute molecular weights, and can also be performed at 
physiological protein concentrations. The SEC-MALLS experiment was performed at 
three different eIF2Bα concentrations: at a physiological concentration (von der Haar & 
McCarthy 2002) of 1 µM (within the concentration range where eIF2Bα mobility in SEC 
is independent of concentration (see Figure 3.5B)), as well as at 10 µM and 100 µM 
(within the concentration range where there is a concentration-dependent increase in 
MWapp in SEC (see Figure 3.5B)). When eIF2Bα was loaded at 1 µM, the MW 
determined by SEC-MALLS was 67 kDa, as expected for a dimer (Table 3.1). At starting 
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concentrations of 10 µM and 100 µM, the MW determined at the apex of the peak by 
SEC-MALLS were 83 kDa and 195 kDa, respectively (at these concentrations, the MW 
decreased toward the tail side of the peak, likely due to the lower eIF2Bα concentrations 
leading to partial complex dissociation, see Figure 3.7). Therefore, the average complex 
size in the eIF2Bα samples was larger than a dimer at 10 µM and corresponded to a 
hexamer at 100 µM. Comparison of the SEC-MALLS results with those from the SEC 
and SAXS experiments shows that SEC and SAXS results qualitatively agree with SEC-
MALLS, with SEC results (both stand-alone and the SEC portion of the SEC-MALLS) 
tending to underestimate the size of the eIF2Bα oligomers. These results also explain our 
inability to fit the SAXS data to a structure model, since at the concentrations used in 
SAXS (57 to 287 µM), eIF2Bα likely exists as a mixture of dimers, tetramers, hexamers, 
and possibly also octamers. In conclusion, these results show that eIF2Bα is a dimer at 
physiological concentrations and oligomerizes at higher concentrations. 
3.2.3. eIF2Bα dimerizes through the same interface as its homologs 
As described above, the dimer interface observed in the crystal structure of 
eIF2Bα, as well as all of its homologs with known structures, is comprised of a large 
interface between the CTD’s of two subunits and a long loop (or “arm”), which protrudes 
across the dimer interface and packs against the other subunit in the dimer (Figure 3.1). 
To confirm that eIF2Bα dimerizes through the interface observed in the crystal structure, 
we used site-directed mutagenesis. We replaced three hydrophobic residues at the 
predicted dimerization surface of the CTD with negatively charged ones (I210E, V217E,  
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Figure 3.7: Representative SEC chromatograms and MWs determined along the 
peak by MALLS 
Chromatograms of three protein samples run on a Superdex 200 HR10/300 GL SEC 
column (GE Healthcare), connected inline to a DAWN-EOS LS detector and an RI detector 
(Wyatt Technology). The dotted lines with the same color are the MW determined by 
MALLS at the corresponding position of the chromatogram. Red, eIF2Bα at 10 µM initial 
concentration; green, eIF2Bα at 1 µM initial concentration; blue, eIF2Bβ at 1 µM initial 
concentration. The theoretical MW of an eIF2Bα-H monomer (34.9 kDa) and dimer (69.8 
kDa), and that of an H-eIF2Bβ monomer (40.8 kDa) are shown on the left. The MW 
calculated at the apex of the peak of eIF2Bα at 1 µM (66.7 kDa, dimer); eIF2Bα at 10 µM 
(83.0 kDa, greater than a dimer); and eIF2Bβ at 1 µM (39.5 kDa, monomer) are shown 
color-coded on the right (see also Table 3.1 below). 
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Table 3.1:2Native molecular weights of eIF2Bα and eIF2Bβ determined by SEC-
MALLS 
Protein 
Starting 
concentration1 
Theoretical MW2 
(monomer) 
MW at apex3 
eIF2Bα-H 1 µM 34.9 kDa 
66.7 kDa (dimer) 
eIF2Bα-H 10 µM 34.9 kDa 
83.0 kDa (> dimer) 
eIF2Bα-H 100 µM 34.9 kDa 
195 kDa (~hexamer) 
H-eIF2Bβ 1 µM 40.7 kDa 
39.5 kDa (monomer) 
H-eIF2Bβ 10 µM 40.7 kDa 
39.7 kDa (monomer) 
1 Concentration at which the samples were loaded onto the SEC column. Sample dilution 
at the end of the run was estimated to be between 2- and 20-fold. 
2 Calculated based on the protein sequence. 
3 The SEC peak of eIF2Bα at 10 µM and 100 µM concentrations was polydisperse, with 
the MW determined by MALLS gradually decreasing along the tail of the peak, likely due 
to the lower protein concentrations in the tail affecting the average oligomer size (see also 
Figure 3.7). 
 
 
 
 
  
 116 
 
and A221D) to generate an eIF2BαI210E/V217E/A221D triple mutant (eIF2Bα-TM). Using 
SEC, we found that eIF2Bα-TM migrated with an MWapp of ~33 kDa, as expected for a 
monomer (Figure 3.5A). To assess the contribution of the “arm” to eIF2Bα dimerization, 
we generated an eIF2Bα deletion mutant missing residues 256-266 (eIF2Bα-Δarm). SEC 
shows that at 1.25 µM, eIF2Bα-Δarm migrates with an MWapp of ~50 kDa (Figure 3.5B), 
a value intermediate between that of a monomer (~33 kDa) and a dimer (~67 kDa), 
indicating that at this concentration eIF2Bα-Δarm is in equilibrium between monomers 
and dimers. As eIF2Bα-Δarm concentration is increased to 12.5 µM and 125 µM, its 
MWapp gradually increases to ~67 kDa (Figure 3.5B). These results show that both the 
main dimer interface and the “arm” play important roles in eIF2Bα dimerization. 
3.2.4. eIF2Bβ is a monomer 
Having determined that eIF2Bα is a dimer, we explored the possibility that the 
homologous eIF2Bβ and eIF2Bδ subunits could also dimerize through their 
corresponding surfaces. We generated homology models for the structures of eIF2Bβ and 
eIF2Bδ (Figure 3.8), using the eIF2Bα structure as a template and the sequence 
alignment shown in Figure 3.9. The ~200-residue eIF2Bδ N-terminal tail is not 
homologous to eIF2Bα and β and was not modeled. As noted previously (Hiyama et al. 
2009; Dev et al. 2009), the homology among eIF2Bα, β and δ was greater for the 
Rossmann fold C-terminal domain (CTD) than for the helical N-terminal domain (NTD) 
(Figure 3.9). Analysis of the putative dimerization surfaces in the CTDs of the eIF2Bβ 
and δ homology models shows that they are among the best-conserved surfaces in the 
proteins (Figure 3.8B). They exhibit significant hydrophobicity (Figure 3.8C), similar to  
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Figure 3.8: Models for the structure of eIF2Bβ and δ 
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Figure 3.8: Models for the structure of eIF2Bβ and δ 
(A) A model for the proposed dimeric structure of eIF2Bβ (yellow) and δ (red), based on 
the structure of eIF2Bα2 and the sequence alignment shown in Figure 3.9. The first eight 
residues of eIF2Bβ and the first 200 residues of eIF2Bδ were not modeled. Segments that 
have no counterpart in eIF2Bα or are not visible in the eIF2Bα crystal structure were 
modeled de novo and are colored black, since their real conformation is unknown. (B) The 
putative eIF2Bβ and δ dimerization surfaces are highly conserved among eIF2Bβ and 
eIF2Bδ homologs. The eIF2Bβδ dimer model is shown in surface representation. Amino 
acids are colored by sequence conservation from white (<30% conservation) to yellow 
(65% conservation), to green (100% conservation). eIF2Bδ is omitted in the middle left 
panel and eIF2Bβ is omitted in the middle right panel, in order to show the dimerization 
surfaces. The dimerization interface is marked with a light blue line. The conserved surface 
unique to eIF2Bδ is circled in the right panel. (C) The putative eIF2Bβ and δ dimerization 
surfaces are highly hydrophobic. The display is as in (B), except that the surface is colored 
by hydrophobicity/charge. Backbones are colored dark grey; hydrophobic side chains are 
yellow; positively charged side chains are blue; negatively charged side chains are red; and 
the remaining side chains are light grey.  
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the corresponding surface of eIF2Bα (Figures 3.2 and 3.3), as expected for a protein-
protein interaction surface (see also the sequence alignment in Figure 3.9). The putative 
dimerization surface of eIF2Bδ is particularly hydrophobic (Figure 3.8C). Both eIF2Bβ 
and δ have the “arm” region (Figure 3.8A), which in eIF2Bα and the more distant 
homologs forms part of the dimer interface. The conservation and charge/hydrophobicity 
patterns of the rest of eIF2Bβ and δ are also similar to those of eIF2Bα (Figures 3.2 and 
3.3), including the highly conserved putative eIF2α-P binding surfaces (Dev et al. 2009), 
where a number of Gcn- mutations in yeast eIF2Bα, β, and δ have been found (Hiyama et 
al. 2009; Dev et al. 2009) (Figure 3.8BC, left panels and Figures 3.2, 3.3; see also 
Figure 3.13). A notable exception is the surface in eIF2Bδ visible in the right panels of 
Figure 3.8BC, which shows greater degree of conservation than its counterparts in 
eIF2Bα (Figures 3.2 and 3.3, right panels) and eIF2Bβ (Figure 3.8BC, right panels). 
Using SEC, we found that eIF2Bβ (~39 kDa) migrates with an MWapp of ~41 
kDa, as expected for a monomer (Figure 3.5C). This result was later confirmed using 
SEC-MALLS, which yielded a MW of ~40 kDa, as expected for a monomer, at both 1 
µM and at 10 µM concentrations (Table 3.1). Unfortunately, we were unable to express 
eIF2Bδ in soluble form in E. coli, and thus could not determine whether or not it is 
monomeric, or study its interaction with eIF2Bβ.  
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Figure 3.9: Sequence alignment of human eIF2Bα, β, and δ 
Identical positions are in white font with red background; conserved positions are in red 
font. The secondary structure and residue numbering above the alignment are for eIF2Bα. 
Amino acids located at the dimer interface are marked with a black “*” below the 
alignment. The position of V183 in eIF2Bα is marked with a red “*”. V183 is buried just 
under the dimerization surface and surrounded by residues that are part of the dimer 
interface (see also Figure 3.13A below). The V183F mutation causes CACH/VWM 
(Fogli & Boespflug-Tanguy 2006; Pronk et al. 2006) and was recently shown to affect 
eIF2Bα dimerization (Wortham et al. 2014). The sequence alignment was obtained with 
HHpred from the HHsuite (Söding 2005; Söding et al. 2005; Remmert et al. 2012). The 
figure was generated with ESPript (Gouet & Courcelle 2002), using the BLOSUM62 
homology scoring matrix. 
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3.2.5. Molecular docking indicates an eIF2Bβδ heterodimer along the 
same interface as eIF2Bα2 
Unlike eIF2Bα, free eIF2Bβ is a monomer (Figure 3.5C), despite a high degree 
of conservation in its putative dimerization surface. The interaction between eIF2Bβ and 
δ is important for the stability of eIF2Bδ in vivo in S. cerevisiae, since eIF2Bβ depletion 
causes co-depletion of eIF2Bδ (Dev et al. 2010). Therefore, we considered the possibility 
that eIF2Bβ and δ form a heterodimer using the same extensive dimerization surfaces as 
eIF2Bα2. Due to our inability to produce soluble eIF2Bδ, we could not test this 
hypothesis directly.  
Since eIF2Bα, β and δ are homologous, we built models of β and δ subunits based 
on the crystal structure of eIF2Bα (3ECS.pdb). Residues were modeled only at positions 
present in the eIF2Bα structure. We used molecular docking with the ClusPro server 
(Kozakov et al. 2010) to evaluate the potential for homo- or heterodimerization of all 
combinations of eIF2Bα, β, and δ. For the eIF2Bα2 homodimer, the highest scoring 
model differs only by 3.5 Å interface root mean square deviation (RMSD) from the dimer 
interface seen in the crystal structure (Figure 3.10A), thus reproducing the 
experimentally confirmed eIF2Bα2 homodimer. The calculated interaction energy values 
show a funnel-shaped distribution in the vicinity of this best model (Figure 3.10B), 
indicative of a stable structure. The interface in the highest scoring model of the eIF2Bβδ 
heterodimer was the same as seen in the eIF2Bα2 homodimer, with a funnel-like local 
energy landscape (Figure 3.10C). This supports the hypothesis that eIF2Bβ and δ interact  
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Figure 3.10: Molecular docking indicates an eIF2Bβδ heterodimer utilizing the same 
interface as the eIF2Bα2 homodimer 
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Figure 3.10: Molecular docking indicates an eIF2Bβδ heterodimer utilizing the same 
interface as the eIF2Bα2 homodimer 
(A) The highest scoring model of the eIF2Bα2 dimer superimposed on the eIF2Bα2 dimer 
observed in the crystal structure of eIF2Bα (3ECS.pdb) (Hiyama et al. 2009). The left 
subunits from each dimer (model and crystal structure) are aligned (shown in grey). The 
second subunit in the modeled dimer is shown in blue; the second subunit in the dimer 
found in the crystal structure is shown in yellow. The interface RMSD between the two 
structures is 3.5 Å. None of the high scoring models showed similarity to any other crystal 
contacts observed in the eIF2Bα structure (3ECS.pdb) (Hiyama et al. 2009). (B) Local 
energy landscape of the eIF2Bα2 models generated by docking, plotted with a model having 
the observed eIF2Bα2 crystal interface placed at the origin. The plot shows that such models 
are surrounded by a well-defined energy funnel. (C) Local energy landscape of the 
eIF2Bβδ models generated by docking, plotted with a model having the eIF2Bα2 crystal 
interface placed at the origin. The plot shows that, along the energy funnel, the models 
converge to ones with the interface seen in the eIF2Bα2 structure. (D) Local energy 
landscape of the eIF2Bβ2 models generated by docking, again plotted with a model having 
the eIF2Bα2 crystal interface placed at the origin. Unlike for the dimers shown in (B) and 
(C), no funnel shaped energy distribution is observed in the vicinity of such models, 
indicating that no stable eIF2Bβ2 homodimer is formed. 
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with each other along an interface corresponding to the homodimerization interface in 
eIF2Bα2 (Figure 3.1B), forming a stable heterodimer similar to the eIF2Bα2 homodimer. 
In contrast, docking generated relatively few models with the putative interface for 
eIF2Bδ2, eIF2Bαβ, and eIF2Bαδ, placing the highest scoring models at least 25 Å 
interface RMSD away in each case, confirming that these combinations do not form 
dimers. The remaining combination, eIF2Bβ2, was found to be an interesting case: 
although the best scoring model included the putative dimer interface, the energy values 
did not exhibit any funnel-like behavior (Figure 3.10D). This indicates that interactions 
between two eIF2Bβ proteins do not result in the formation of a stable homodimer, in 
good agreement with the experimental data.  
All eIF2Bα/β/δ homologs with known structures are dimers utilizing the same 
dimer interface as we show here for eIF2Bα2 (Figures 3.1, 3.4, 3.5). Therefore, this 
dimerization interface has been conserved through evolution of the eIF2B homologs and 
distantly related metabolic enzymes. Since the corresponding surfaces in eIF2Bβ and δ 
are also well-conserved (Figure 3.8B), it is logical to expect that they are not exceptions 
to the rule and are also involved in dimerization (either homo- or heterodimerization). 
The molecular docking results presented here are in full agreement with our experimental 
data and indicate that, while eIF2Bα is a homodimer, eIF2Bβ and δ form a heterodimer. 
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3.3. Discussion 
3.3.1. Implications for the architecture of eIF2B 
Since it was first discovered, eIF2B has been presumed to be a heteropentamer 
with equimolar amounts of its α, β, γ, δ, and ε subunits. Accordingly, the regulatory 
eIF2Bα/β/δ subcomplex has always been presumed to be a 1:1:1 heterotrimer. However, 
the architecture of eIF2B and its regulatory subcomplex has remained a mystery, despite 
decades of research. 
The results presented here show that eIF2Bα is a homodimer and eIF2Bβ is a 
monomer. Our data also indicate that that eIF2Bβ and δ form a heterodimer along the 
same interface as the eIF2Bα2 dimer. What is then the architecture of eIF2B, and the 
regulatory eIF2Bα/β/δ subcomplex in particular? There are two alternative models that 
are consistent with eIF2Bα being a homodimer and eIF2Bβ a monomer, as well as with 
the utilization of the conserved hydrophobic C-terminal surfaces of eIF2Bβ and δ for 
dimerization. One possible model is that the regulatory subcomplex is an eIF2Bα2βδ 
tetramer, made up of an eIF2Bα2 dimer and an eIF2Bβδ dimer, which would imply that 
eIF2B as a whole is a hexamer: α2βδγε. This model fits well with the majority of 
previously published SEC and AUC data about the size of eIF2B, which has been 
reported to have a MWapp of 250-350 kDa (Cesar de Haro & Ochoa 1979; Ranu & 
London 1979; Siekierka et al. 1981). However, it contradicts a recent mass-spectrometry 
study, which showed that all eIF2B subunits are present in equimolar amounts (Kito et al. 
2007). Alternatively, the eIF2B regulatory subcomplex could be an α2β2δ2 hexamer built 
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up of one α2 homodimer and two βδ heterodimers, which would imply that eIF2B is a 
decamer. Such a model is at odds with most SEC and AUC data (Cesar de Haro & Ochoa 
1979; Ranu & London 1979; Siekierka et al. 1981), but is consistent with the recent 
mass-spectrometry report about the stoichiometry of eIF2B subunits (Kito et al. 2007). 
The results presented here alone cannot distinguish between these two models. However, 
Proud and co-authors recently reported that eIF2B is a decamer (Wortham et al. 2014). 
Therefore, in view of their results and the earlier mass-spectrometry report (Kito et al. 
2007), we favor the latter model: a hexameric eIF2B regulatory subcomplex, composed 
of an eIF2Bα2 homodimer and two eIF2Bβδ heterodimers. These authors also found that 
eIF2Bα is a dimer, in agreement with the results presented here. While they did not study 
the interactions of eIF2Bβ and eIF2Bδ, their observation that eIF2Bα stabilizes the 
interaction between two eIF2Bβγδε tetramers (Wortham et al. 2014) is consistent with the 
existence of two eIF2Bβδ heterodimers, rather than an eIF2Bβ2 and an eIF2Bδ2 
homodimer in eIF2B. 
3.3.2. Alternative models for the eIF2Bα/β/δ architecture 
The only attempt to date for a structural model for the regulatory eIF2Bα/β/δ 
subcomplex was by Kakuta and co-authors, based on crystal packing contacts in the 
structure of the archaeal eIF2Bα/β/δ homolog aIF2B from Pyrococcus horikoshii (which 
is a dimer in solution) (Kakuta et al. 2004). As discussed above, the structure shows 
dimerization along the same interface as all other homologs (Hiyama et al. 2009; 
Nakamura et al. 2012; Bumann et al. 2004; Tamura et al. 2008). Therefore, when looking 
for possible implications for the structure of the presumed trimeric eIF2Bαβδ complex, 
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the authors had to ignore the known dimerization interface (>1500 Ǻ2 buried surface, 
light blue line in Figure 3.11AB). Instead they focused on hexameric-like crystal packing 
contacts among three dimers (red line in Figure 3.11B) to propose that eIF2Bαβδ forms a 
symmetrical trimer, leaving the conserved hydrophobic dimerization surfaces 
unoccupied. Any trimeric model of the eIF2Bαβδ regulatory subcomplex in general is 
incompatible with the results presented here, since an even number of subunits is needed 
to occupy all dimerization surfaces. An eIF2Bαβδ trimer would leave at least one of the 
extensive conserved and hydrophobic dimerization surfaces in eIF2Bα, β and δ 
unoccupied, while the model by Kakuta and co-authors specifically would leave all three 
dimerization surfaces unoccupied. In view of the data presented here and in the recent 
report by Proud and co-authors (Wortham et al. 2014), the Kakuta model could be 
considered in the context of a hexameric eIF2Bα2β2δ2 regulatory subcomplex: as a 
possible interface between three dimers, instead of three monomers, especially since it 
was in fact based on crystal packing contacts among three dimers (Figure 3.11B) 
(Kakuta et al. 2004). However, although the coordinates for the proposed trimeric 
arrangement were not deposited, it is clear from Figure 3.11B that the buried surface is 
small and insignificant. It is thus highly unlikely that such a small interface could 
produce a stable complex. In support of this conclusion, we found using an NMR 
chemical shift perturbation assay that eIF2Bα does not bind to eIF2Bβ-NTD, since 
adding unlabeled eIF2Bα did not affect the NMR spectra of 15N-labeled eIF2Bβ-NTD 
(Figure 3.12). Therefore, the proposed trimeric arrangement is not supported by 
experimental data. 
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Figure 3.11: Multimeric assemblies in the crystals of aIF2B from Pyrococcus 
horikoshii 
(A) An aIF2B dimer, with over 1,500 Ǻ2 buried surface area (1VB5.pdb) (Kakuta et al. 
2004), in the same orientation as the top-left dimer in (B). The dimer interface is marked 
with a blue line. (B) A hexameric-like aIF2B assembly (not deposited by the authors) 
(Kakuta et al. 2004), with visibly small buried surface area (marked with red lines) used to 
propose a model for the presumed trimeric eIF2Bαβδ complex by using one subunit from 
each of the three dimers. The dimer interfaces are marked with blue lines. “A” and “B” 
represent the two subunits of each dimer. Adapted from Kakuta et al., (2004), BBRC 319, 
pp. 725-732, with permission.  
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Figure 3.12: eIF2Bβ-NTD does not interact with eIF2Bα 
Overlay of 15N-HSQC (heteronuclear single-quantum coherence) NMR spectra of 100 µM 
15N-labeled eIF2Bβ-NTD in the absence (black) and presence (red) of 150 µM unlabeled 
eIF2Bα. The spectra were collected in phosphate buffer containing 150 mM NaCl. No 
changes are observed in the 15N-HSQC spectra of eIF2Bβ-NTD upon addition of unlabeled 
eIF2Bα, indicating that the two proteins do not interact. 
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3.3.3. Implications for eIF2B function and interactions with its 
substrate eIF2 
Most Gcn- mutations in eIF2Bα, β and δ map to the same conserved surface in the 
CTD (Hiyama et al. 2009; Dev et al. 2009) (Figure 3.13AB, left panels), and have been 
proposed to be the binding sites for phosphorylated eIF2α (eIF2α-P) (Dev et al. 2009). 
How these putative eIF2α-P binding surfaces on the eIF2Bα, β, and δ subunits come 
together to simultaneously interact with eIF2α has remained an open question.  
Remarkably, in the eIF2Bα2 dimer, the C-terminal surfaces from each subunit are 
adjacent to each other across the dimer interface (Figure 3.13A, left panel). Likewise, the 
two C-terminal surfaces of eIF2Bβ and δ end up adjacent to each other in the model of 
the proposed eIF2Bβδ dimer (Figure 3.13B, left panel). The important implication of this 
observation is that bringing these surfaces closer together in eIF2Bα2 and in eIF2Bβδ 
makes it much easier for eIF2α-P to contact them simultaneously, as indicated by the 
mutational studies. Binding between an eIF2Bα2 dimer and two eIF2Bβδ dimers can form 
two binding sites by bringing the putative eIF2α contact surfaces close together (Figure 
3.13C). It should be noted that since the mutual orientation of eIF2Bα2 and eIF2Bβδ is 
not known, their arrangement in Figure 3.13C is purely hypothetical and not based on 
experimental evidence. We did not observe a stable interaction between eIF2Bα and 
eIF2Bβ using SEC and affinity pull-down experiments (data not shown). Therefore, in 
the model, eIF2Bα contacts mainly eIF2Bδ. eIF2Bβ likely also binds to eIF2Bα, but with 
an affinity too low to observe by these assays in the absence of eIF2Bδ. Although in the  
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Figure 3.13: Model for the interaction of eIF2Bα2β2δ2 with eIF2α-P 
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Figure 3.13: Model for the interaction of eIF2Bα2β2δ2 with eIF2α-P  
(A) Positions of Gcn- mutations (red) on the surface of the eIF2Bα2 dimer. The orientations 
are the same as in Figures 3.1 and 3.2. The dimerization interface is marked with a light 
blue line. In the central panel, only one eIF2Bα subunit is shown, in order to show the 
dimerization surface. Only mutations of surface exposed residues that do not involve a 
glycine or a proline are shown, since these are least likely to affect the protein structure or 
stability. The approximate position of V183 (invisible since it is buried under the surface) 
is labeled in the central panel with a dashed arrow. (B) Positions of Gcn- and CACH/VWM 
mutations on the surface of the eIF2Bβδ dimer, in the same orientation as the eIF2Bα2 
dimer in (A). The eIF2Bβδ dimer is in the same orientation as in Figure 3.8. The 
dimerization interface is marked with a light blue line. The two central panels show the 
dimerization surfaces of eIF2Bβ (left) and eIF2Bδ (right). Sites of Gcn- mutations are red 
(eIF2Bβ) and orange (eIF2Bδ); and CACH/VWM mutations are navy (eIF2Bβ) and blue 
(eIF2Bδ). The clusters of CACH/VWM mutations at the eIF2Bβ and eIF2Bδ dimerization 
surfaces are visible in the two central panels. The cluster of CACH/VWM mutations in 
eIF2Bδ-NTD can be seen in the right panel (circled). Residues discussed in the text are 
labeled. The position of V316 (buried under the surface) is labeled in the left central panel 
with a dashed arrow. (C) Model for the interaction of eIF2Bα2β2δ2 with eIF2α-P. One 
eIF2Bα subunit is light blue; the other is dark blue; eIF2Bβ is yellow; and eIF2Bδ is red. 
eIF2α-P (light grey) binds in a pocket (circled on the left) formed between one eIF2Bα 
subunit and one eIF2Bβδ dimer. The proteins are represented by solids, drawn 
approximately to scale with their respective sizes. Unphosphorylated eIF2α should bind to 
an overlapping surface on eIF2Bα2β2δ2 (Dev et al. 2010).  
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model shown in Figure 3.13C the two eIF2Bβδ dimers do not contact each other, they 
could do so, depending on the actual architecture of the eIF2B regulatory subcomplex. 
Gcn- mutations map to several additional surfaces in the regulatory eIF2Bα2βδ 
subcomplex. However, it is likely that not all of these regions contact eIF2 directly: some 
of the mutations could have indirect effects. We did not include in our analysis the vast 
number of Gcd- mutations, since a Gcd- phenotype could arise not only from an impaired 
mode of binding to unphosphorylated eIF2, but also from lower eIF2B activity or 
stability. Accordingly, most Gcd- mutations in eIF2Bβ and eIF2Bα affect buried residues 
(not shown in Figure 3.13) and are thus likely to affect the structure or stability of the 
protein, consistent with a loss-of-function mutation lowering the amount or activity of 
eIF2B.  
3.3.4. CACH/VWM mutations map to the proposed eIF2Bβ/δ dimer 
interface  
The results presented here help explain the molecular basis of CACH/VWM 
mutations found in the human eIF2Bα/β/δ regulatory subcomplex. All known 
CACH/VWM mutations reported to date are recessive: either homozygous or 
heterozygous with another mutation or complete deletion of the gene. Therefore, it is 
clear that they lower eIF2B activity. Since complete disruption or inactivation of the 
eIF2B complex would be lethal, the mutant eIF2B complexes must retain at least a 
certain level of activity. For those mutations that affect a residue buried in the 
hydrophobic core of a folded domain, one can speculate that their effect on eIF2B is 
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mediated by destabilization of protein structure. It is thus more interesting to consider 
mutations in surface-exposed residues. Only three CACH/VWM mutations have been 
reported in eIF2Bα (Fogli & Boespflug-Tanguy 2006; Pronk et al. 2006), two of them 
affecting a buried residue, and the third affecting a proline. One of these CACH/VWM 
mutations, V183F (Fogli & Boespflug-Tanguy 2006; Pronk et al. 2006), was recently 
reported to disrupt eIF2Bα dimerization in vitro (Wortham et al. 2014). This mutation 
affects a residue buried under the eIF2Bα dimerization surface (its approximate location 
is marked with a dashed arrow in the central panel of Figures 3.2, 3.3, and 3.13A). 
As shown in Figure 3.13B (center panels), a number of CACH/VWM mutations 
in eIF2Bβ and δ map to the predicted dimerization surfaces of these two subunits. 
Therefore, they most likely weaken the interaction between eIF2Bβ and δ. Two of these 
mutations, eIF2Bδ-R357W and eIF2Bδ-R483W, both causing a severe form of the 
disease, were reported to destabilize the association of eIF2Bδ with the rest of eIF2B(Liu 
et al. 2011). Another mutation, eIF2Bβ-V316D (not visible in Figure 3.13B), affects a 
residue buried just under the predicted eIF2Bδ-binding surface of eIF2Bβ and was 
reported to weaken interactions with the rest of eIF2B (Li et al. 2004). The corresponding 
mutation in yeast was found to destabilize association with other subunits, especially 
eIF2Bδ, and to have a slow-growth phenotype that was partially rescued by eIF2Bδ 
overexpression (Richardson et al. 2004). Therefore, not only does our model for eIF2Bβδ 
dimerization help explain the phenotypes of many CACH/VWM mutations, but these 
phenotypes in turn support the model. 
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A small group of CACH/VWM mutations map to residues in eIF2Bδ-NTD, which 
appear to cluster on one surface of the domain, away from the proposed eIF2α interface 
(circled in Figure 3.13B, right panel). These mutations could interfere either with 
binding to other eIF2B subunits, or with the role of eIF2Bδ in promoting eIF2 ternary 
complex formation. Consistent with this hypothesis, the surface of eIF2Bδ where these 
mutations map shows a high degree of sequence conservation and hydrophobicity 
(circled in Figure 3.8BC, right panels), unlike the corresponding surfaces of eIF2Bβ 
(Figure 3.8BC, right panels) and eIF2Bα (Figures 3.2 and 3.3, right panels). The 
sequence conservation in this surface and the clustering of CACH/VWM mutations there 
have not been previously identified. Thus, our results indicate that surface-exposed 
CACH/VWM mutations in the regulatory eIF2Bα/β/δ subcomplex affect eIF2B complex 
assembly or stability, with the majority of them mapping to the predicted eIF2Bβδ 
interaction interface. 
In summary, we show here that eIF2Bα is a dimer at physiological concentrations 
while eIF2Bβ is a monomer. We also present evidence that eIF2Bβ and δ likely use the 
same evolutionarily conserved dimer interface as eIF2Bα2 to form a heterodimer similar 
to the eIF2Bα2 homodimer. These findings indicate that the eIF2B regulatory subcomplex 
is most likely an α2β2δ2 hexamer composed of an eIF2Bα2 homodimer and two eIF2Bβδ 
heterodimers. While this conclusion contradicts a number of previous reports about the 
size of eIF2B (see for example (Cesar de Haro & Ochoa 1979; Ranu & London 1979; 
Siekierka et al. 1981)), it is consistent with most of the remaining experimental data 
about eIF2B and its homologs (Kito et al. 2007; Hiyama et al. 2009; Wortham et al. 
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2014; Kakuta et al. 2004; Nakamura et al. 2012; Bumann et al. 2004; Tamura et al. 
2008). The resulting model for the architecture of the eIF2Bα/β/δ regulatory subcomplex 
shows how all the surfaces in the regulatory complex predicted to play a direct role in 
eIF2α binding could indeed contact eIF2α simultaneously and also helps explain the 
molecular basis for a number of CACH/VWM mutations in eIF2Bβ and δ. These 
mutations map at or near the proposed eIF2Bβ/δ dimer interface and are thus likely to 
affect eIF2B complex formation and/or stability. A key question that remains unanswered 
is how the regulatory eIF2Bα2β2δ2 subcomplex discriminates between the substrate eIF2 
and the inhibitor eIF2(α-P). More work is needed to elucidate the architecture of eIF2B 
and its interactions with phosphorylated and unphosphorylated eIF2, as well as 
understand the detailed molecular mechanisms of eIF2B action and regulation. 
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Chapter 4: Novel mechanisms of eIF2B action and regulation by 
eIF2α phosphorylation 
 
4.1. Introduction 
Eukaryotic translation initiation factor 2 (eIF2) is a heterotrimeric G-protein, 
which in its active GTP-bound state is responsible for recruiting the initiator methionyl-
tRNA (Met-tRNAi) to the 40S ribosomal subunit as part of the eIF2-GTP-Met-tRNAi 
ternary complex (TC). Upon start codon recognition and hydrolysis of the eIF2-bound 
GTP, eIF2-GDP dissociates from the ribosome in complex with eIF5, its GTPase-
activating protein (GAP). In order to participate in another round of translation, eIF2 
must be re-activated by recycling its bound GDP for GTP and must bind another Met-
tRNAi. Both nucleotide exchange and Met-tRNAi recruitment are performed by the 
guanine nucleotide exchange factor (GEF) eIF2B, resulting in a new TC capable of 
initiating another round of translation (reviewed in (Marintchev & Wagner 2004; Jackson 
et al. 2010; Hinnebusch 2014)).  
The GEF eIF2B consists of five subunits, α-ε, recently shown by us and others to 
assemble into a ~600 kDa decamer (Bogorad et al. 2014; Gordiyenko et al. 2014; 
Wortham et al. 2014; Kuhle et al. 2015; Kashiwagi et al. 2016), making it one of the 
largest and most complex GEFs characterized to date. eIF2B is the target of multiple 
pathways regulating protein synthesis and the cellular stress response. The catalytic 
activity of eIF2B is regulated by phosphorylation of eIF2B and its substrate eIF2, as well 
as by binding of small molecules, such as nucleotides and sugars, to eIF2B. eIF2 consists 
of α, β, and γ subunits, with eIF2γ being the actual G-protein, and eIF2α and β serving 
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accessory functions. eIF2α is phosphorylated at S51 by four kinases in what is 
collectively known as the integrated stress response (ISR): Protein Kinase R (PKR), in 
response to viral infection; PKR-like Endoplasmic Reticulum Kinase (PERK), in 
response to ER stress, oxidative stress, and other stimuli; General Control 
Nonderepressible 2 Kinase (GCN2), in response to amino-acid deficiency; and Heme-
Regulated Inhibitor Kinase (HRI), in response to heme deficiency. Of all the layers of 
regulation of eIF2B activity, regulation by phosphorylation of it substrate eIF2 has 
attracted the most attention since it has wide-ranging effects on the cell and is at the core 
of ISR.  
eIF2α phosphorylation converts eIF2 into a competitive inhibitor of eIF2B, 
resulting in slowing down protein synthesis, while at the same time inducing the 
production of a set of transcription factors, including Activating Transcription Factor 4 
(ATF4) in mammals, and GCN4 in Saccharomyces cerevisiae (S. cerevisae). The result is 
the activation of both pro-survival pathways aimed at restoring homeostasis and pro-
apoptotic pathways. The fate of the cell ultimately depends on the magnitude and 
duration of the stress response, as well as other factors. Since the stressors themselves can 
cause cell death, either an insufficient or overly aggressive stress response can lead to 
apoptosis (reviewed in (Marintchev & Wagner 2004; Hinnebusch 2005; Dever et al. 
2007; Hinnebusch et al. 2007; Ron & Harding 2007)). While apoptosis can be the desired 
outcome in some cases, such as viral infection, in many cases it occurs as the result of 
uncontrolled ISR and is a causative factor in the pathology of a number of diseases. It 
was recently reported that PERK activation mediates neuronal cell death in prion disease, 
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Alzheimer’s, and other neurodegenerative disorders. Accordingly, PERK inhibitors, as 
well as an eIF2B activator called ISR inhibitor (ISRIB), were shown to be 
neuroprotective in animal models of these diseases. PERK inhibitors, however are 
associated with serious side effects (Moreno et al. 2012; Moreno et al. 2013; Sidrauski et 
al. 2013; Halliday et al. 2015; Sekine et al. 2015; Sidrauski, Tsai, et al. 2015). No drugs 
that prevent eIF2B inhibition by phosphorylated eIF2α are currently available and 
rational design of such drugs would require clear understanding of the molecular 
mechanisms of eIF2B action and inhibition by eIF2α phosphorylation. However, the 
mechanisms of TC regeneration by eIF2B and its regulation still remain poorly 
understood. Mutations in all five eIF2B subunits have been reported to cause a genetic 
neurodegenerative disorder known as childhood ataxia with CNS hypomyelination 
(CACH) or leukoencephalopathy with vanishing white matter (VWM) (reviewed in 
(Fogli & Boespflug-Tanguy 2006; Ron & Harding 2007; Bugiani et al. 2010)). The 
molecular mechanisms of CACH/VWM are not well understood, but the mutations 
appear to affect eIF2B complex assembly, stability, and/or activity (Richardson et al. 
2004; Bogorad et al. 2014; Wortham et al. 2014; Kuhle et al. 2015; Kashiwagi et al. 
2016). 
The eIF2Bε subunit contains the catalytic domain, and together with the eIF2Bγ 
subunit forms the catalytic subcomplex (eIF2Bγε). eIF2Bα, β and δ subunits form the 
regulatory subcomplex (eIF2Bα2(βδ)2). Four of the five eIF2B subunits are essential in 
yeast, except eIF2Bα, which is required for inhibition by eIF2α phosphorylation: its 
deletion has a general control non-derepressible (Gcn-) phenotype. The eIF2Bβ, γ, and ε 
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subunits are essential for nucleotide exchange, whereas eIF2Bδ is essential for Met-
tRNAi binding to eIF2-GTP. Therefore, at least four of the five eIF2B subunits contribute 
to catalysis. In S. cerevisiae, Gcn- mutations have been found in the eIF2Bα, β, and δ 
subunits. Mutations that lower eIF2B activity and mimic the effects of eIF2α 
phosphorylation (General control derepressed, Gcd-) have been reported in all five eIF2B 
subunits, including eIF2Bα. Thus, even eIF2Bα appears to play a role in catalysis, albeit 
not essential, which is also supported by the fact that combining eIF2Bα deletion with 
certain Gcn- mutations causes a Gcd- phenotype. The vast amount of genetic and 
biochemical data points to the conclusion that eIF2 interacts simultaneously with the 
catalytic and regulatory subcomplexes of eIF2B, and that eIF2α phosphorylation causes 
the interaction with the regulatory subcomplex to become inhibitory (Hinnebusch 2005; 
Hinnebusch et al. 2007; Dev et al. 2010).  
The past two years have marked a radical change in our understanding of the 
structure of eIF2B and the nature of the eIF2B:eIF2 interaction. First, we and others 
reported that eIF2B is in fact a decamer with a hexameric regulatory subcomplex 
(Bogorad et al. 2014; Gordiyenko et al. 2014; Wortham et al. 2014; Kuhle et al. 2015). 
Next, the crystal structure of the nearly complete Schizosaccharomyces pombe (S. 
pombe) eIF2B decamer was reported (Kashiwagi et al. 2016) (see Figure 4.1). The only 
eIF2B segments missing from the structure are the eIF2Bε-CTD (the catalytic domain) 
and the long eIF2Bδ N-terminal tail (NTT). The regulatory subcomplex, eIF2Bα2(βδ)2, is  
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Figure 4.1: Structure of eIF2B from S. pombe 
eIF2B is shown in surface representation, derived from the crystal structure (2.99 Å) 
from S. pombe (5B04.pdb) ((Kashiwagi et al. 2016). eIF2Bα, β, and δ form a 
hexameric core, flanked by two eIF2Bγε heterodimers. Cross-links between eIF2α-
NTD and the eIF2Bα/β/δ regulatory pocket are colored orange. Cross-links between 
eIF2γ and eIF2Bγ and eIF2Bε are colored yellow. As eIF2B is symmetric, cross-links 
to the other regulatory pocket and catalytic subcomplex also exist, but are not shown.  
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composed of an eIF2Bα homodimer and two eIF2Bβδ heterodimers, packed against each 
other with a pseudo-three-fold symmetry. The three dimers are organized in such a way 
that the C-terminal domains (CTDs) of the subunits form the core of the hexamer, while 
the N-terminal domains (NTDs) form two pockets. Two eIF2Bγε heterodimers are bound 
on opposite sides of the regulatory subcomplex core, with the ε subunit forming a large 
contact surface with the β subunit and the γ subunit contacting the δ-subunit (Kashiwagi 
et al. 2016). Cross-linking data showed that eIF2α binds in the pocket formed by the 
NTDs of the eIF2Bα, β, and δ subunits, whereas eIF2γ binds to a platform formed by 
eIF2Bγ and ε (Kashiwagi et al. 2016).  
Based solely on their cross-linking data, Kashiwagi and coauthors proposed a 
model in which eIF2α-NTD binds in the eIF2Bαβδ regulatory subcomplex pocket, 
forming key contacts with all three eIF2B regulatory subunits, though primarily laying in 
the groove between the β and δ subunits. As simultaneous binding of eIF2α in the pocket 
and of eIF2γ to the eIF2Bγε catalytic subcomplex appeared to be impossible given their 
orientation of eIF2α-NTD in the eIF2Bαβδ pocket, the authors proposed that binding of 
eIF2α-NTD into the pocket precludes the productive eIF2Bγε/eIF2γ interaction necessary 
for nucleotide exchange. They thus suggested that phosphorylation of eIF2α would favor 
the former and disfavor the latter, leading to the observed inhibition of nucleotide 
exchange (Kashiwagi et al. 2016). However, this idea is in apparent contradiction with 
the vast amounts of data indicating that eIF2α-NTD interactions with the eIF2Bαβδ 
pocket do in fact play a role in catalysis, and not just in eIF2B inhibition by 
phosphorylated eIF2 (eIF2(α-P)). 
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It is commonly assumed that the primary mechanism responsible for the increased 
affinity of eIF2B for eIF2(α-P) over unphosphorylated eIF2 is the direct effect of 
phosphorylation on the affinity of the eIF2α phosphorylation loop (P-loop) for the 
corresponding surface on eIF2B, possibly involving an induced conformational change in 
the P-loop as well. It has been shown in yeast that the loss of eIF2Bα results in loss of 
eIF2B inhibition by eIF2(α-P). Therefore, the “direct effect” is widely believed to be 
mediated by eIF2Bα. Work by Hinnebusch and co-authors (Krishnamoorthy & Pavitt 
2001), however, suggested the mechanism may be more complex. There it was shown 
that while phosphorylated eIF2α (eIF2α-P) could be pulled down using eIF2B and 
unphosphorylated eIF2α could not, a ~100 amino acid C-terminal deletion in eIF2α 
resulted in an equally effective pull-down regardless of eIF2α’s phosphorylation state. 
Later, when the structure of eIF2α was solved (Ito et al. 2004), it became clear that the C-
terminal deletion of eIF2α that abrogates the eIF2B’s preference for eIF2α-P corresponds 
to an effective deletion of most of eIF2α-CTD. This suggests an autoregulatory role for 
eIF2α-CTD in eIF2α binding to eIF2B. We hypothesized that in addition to a potential 
“direct effect,” there is an “indirect effect” whereby phosphorylation of S51 disrupts an 
intramolecular interaction between eIF2α-NTD and CTD. This disruption exposes the 
eIF2B-binding surface on eIF2α-NTD that is otherwise obstructed by eIF2α-CTD. The 
contribution of this new “indirect effect” to the increase in affinity of eIF2B for eIF2α-P 
can be at least as important as the “direct effect” caused by addition of the negatively 
charged phosphate group, if not more so.  
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In this work we demonstrate for the first time that the two domains of eIF2α 
interact with each other and that their interaction is destabilized by phosphorylation of 
S51. This intramolecular binding interface in eIF2α overlaps with the eIF2α binding 
surfaces for eIF2Bβ, and possibly also eIF2Bδ, in support of the hypothesis for an 
indirect effect of eIF2α phosphorylation on eIF2B:eIF2 binding. While eIF2α 
phosphorylation is bound to have some direct effect on eIF2B binding, we show that such 
a direct effect is not mediated by eIF2Bα or eIF2Bβ. We also show that eIF2 can bind 
simultaneously in the eIF2Bαβδ pocket (via eIF2α-NTD) and to eIF2Bγε (via eIF2γ), in 
an “extended” conformation in which the eIF2α-NTD/CTD intramolecular interaction is 
disrupted. We propose a model wherein the eIF2B:eIF2 complex is in equilibrium 
between a “closed” eIF2B:apo-eIF2 state where eIF2 only contacts eIF2Bγε, and an 
“extended” nucleotide-bound state where eIF2 contacts both eIF2Bγε and the eIF2Bαβδ 
pocket simultaneously. When eIF2α is not phosphorylated, eIF2B promotes the apo-state, 
thus destabilizing GDP binding, whereas when bound to eIF2(α-P), eIF2B has no 
preference for the apo- or GDP-bound state and thus has no effect on nucleotide 
exchange. We conclude by placing our model for regulation of nucleotide exchange on 
eIF2 by eIF2B in the context of a comprehensive thermodynamic description of the entire 
eIF2B catalytic cycle. Our results identify promising new drug targets for the treatment of 
Alzheimer’s and other neurodegenerative disorders by manipulating eIF2B activity and 
regulation. 
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4.2. Results 
4.2.1. eIF2α-NTD and -CTD interact with each other 
The structure of human eIF2α (1Q8K.pdb) (Ito et al. 2004) reveals the presence of 
two folded domains, an NTD (aa 1-183) and a CTD (aa 188-280), connected to each 
other by a flexible linker, followed by a C-terminal tail (CTT). eIF2α-NTD consists of 
two subdomains: (1) an OB-fold subdomain formed by residues 18-85, and (2) an α-
helical subdomain formed by residues 91-183. The OB-fold subdomain has an extended 
B3/B4 loop (numbering of secondary structure elements in eIF2α is from (Ito et al. 2004), 
called the phosphorylation loop (P-loop) since it contains the regulatory phosphorylation 
site. This stretch of residues (His46 to Arg66) is highly conserved among eukaryotes and 
is highly positively charged. Most of eIF2α-CTT is intrinsically disordered, except for an 
α-helical region (residues 281-288). 
In order to test whether eIF2α-NTD and -CTD interact with each other, we 
combined NMR chemical shift perturbation (CSP) assay (Qin et al. 2001; Zuiderweg 
2002; Marintchev et al. 2007) with deletion analysis, comparing peak movements 
between spectra of full length eIF2α and spectra of eIF2α-NTD and -CTD alone. This 
approach is effective for observing dynamic interactions (Nag et al. 2016). We collected 
transverse relaxation optimized spectroscopy heteronuclear single-quantum coherence 
(TROSY-HSQC) NMR spectra of 2H/15N-labeled full length eIF2α and its individual 
domains (eIF2α-CTD was 2H/15N/13C-labeled). Comparison of the spectra of the 
individual domains with that of full length eIF2α showed a large number of moving 
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peaks in both domains, confirming the presence of an intramolecular interaction (Figure 
4.2A-C). We next mapped the affected residues on the structure of eIF2α, revealing large 
contiguous surfaces on both eIF2α-NTD and eIF2α-CTD that included the P-loop as well 
as the CTT (Figure 4.2D).  
4.2.2. Phosphorylation destabilizes the eIF2α intramolecular 
interaction 
We next sought to test whether phosphorylation affects the intramolecular 
interaction. Once again we used a CSP assay, this time comparing spectra of 2H/15N-
labeled WT eIF2α and a phosphomimetic mutant, eIF2α-S51D (Figure 4.3AB). A 
number of residues in the CTD were affected by the phosphomimetic mutation (Figure 
4.3C). Mapping these residues on the structure of eIF2α revealed that the same surface on 
eIF2α-CTD is affected by the S51D mutation and deletion of the NTD (Figure 4.3D). 
Residues throughout the NTD were affected by the S51D mutation, with the largest 
chemical shift perturbations occurring in the OB-fold and extending into the first half of 
the α1 helix (Figure 4.3D).  
Having thus established that phosphorylation affects the intramolecular 
interaction, we next looked to understand whether phosphorylation stabilized, 
destabilized, or modified the contact interface between eIF2α-NTD and -CTD. Since 
CSPs in eIF2α-NTD can be a direct result of the S51D mutation, we used eIF2α-CTD to 
analyze the effects of phosphorylation on the intramolecular interaction. Peaks in the 
eIF2α-CTD spectrum served as a reference for the “free” state, while peaks in the full  
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Figure 4.2: Intramolecular interaction in eIF2α 
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Figure 4.2: Intramolecular interaction in eIF2α 
(A) TROSY-HSQC spectra of 2H/15N-labeled eIF2α (black), eIF2α-NTD (blue), and 
2H/15N/13C-labeled eIF2α-CTD (red). (B) Boxed area in (A) with arrows indicating 
movement of peaks away from their full length WT positions. (C) Plot of chemical shift 
perturbations between eIF2α and its individual domains. Grey bars represent indeterminate 
residues for which no analysis could be performed. Key structural features are shown above 
the plot for reference, with the extreme end (aa 302-314) of the C-terminal tail (CTT) 
shown as a wavy line. (D) Residues affected by the intramolecular interaction mapped onto 
the structure of eIF2α, colored from yellow (>1 standard deviation (σ)) to red (>3σ). 
Indeterminate residues are colored grey. Residues <1σ are colored black. A contiguous 
surface is apparent, also involving the CTT. Residues 302-314 were absent in the NMR 
structure and are thus not displayed here and were not obviously affected. 
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Figure 4.3: Effects of the phosphomimetic S51D mutation in eIF2α 
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Figure 4.3: Effects of the phosphomimetic S51D mutation in eIF2α 
(A) TROSY-HSQC spectra of 2H/15N-labeled eIF2α (black) and a phosphomimetic 
mutant, eIF2α-S51D (purple). (B) The boxed area in (A), with arrows indicating movement 
of peaks away from their full length WT positions. (C) Plot of chemical shift perturbations 
between eIF2α and eIF2α-S51D. Grey bars represent indeterminate residues for which no 
analysis could be performed. (D) Residues affected by the phosphomimetic mutation 
mapped onto the structure of eIF2α, colored from yellow (>1σ) to red (>3σ). Indeterminate 
residues are colored grey. Residues <1σ are colored black. Comparison to Figure 4.2D 
reveals that the effect of the phosphomimetic mutation overlaps substantially with the 
intramolecular surface. (E) The same boxed area as in (B), but with the addition of a third 
overlain spectrum of 2H/15N/13C-labeled eIF2α-CTD (red). Peaks corresponding to 
residues affected by the phosphomimetic mutation displayed a consistent pattern of 
movement, where they are located halfway between the peak positions in the eIF2α 
spectrum (“bound” state) and the eIF2α-CTD spectrum (“free” state). Arrows indicate 
movement of peaks away from their full length WT positions. (F) Residues affected by the 
phosphomimetic mutation mapped onto the structure of eIF2α-NTD. Coloring scheme is 
the same as in (D). 
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length WT eIF2α spectrum served as a reference for the “bound” state. When comparing 
residues in the CTD of eIF2α-S51D, we observed a pattern of peak movement along a 
line from “bound” to “free.” Analysis of moving peaks in eIF2α-CTD showed that the 
peaks in the eIF2α-S51D mutant were approximately halfway between the “free” and 
“bound” states, indicating that the S51D mutation destabilizes the intramolecular 
interaction by inducing eIF2α to spend more time open (Figure 4.3E, 4.4). Some of these 
peaks lay slightly off the connecting line, indicating that the S51D mutation might 
modulate the nature of the interaction, in addition to simply destabilizing it. Since no 
correlation could be found between any one surface on eIF2α-CTD and the degree of 
deviation from the line connecting the “free” and “bound” states, there is no specific 
surface in eIF2α-CTD that appears differentially affected by the S51D mutation.  
In order to isolate the effect of phosphorylation on eIF2α-NTD from the 
secondary effect of modulation of the intramolecular interaction, we compared TROSY-
HSQC spectra of 2H/15N-labeled WT eIF2α-NTD and phosphomimetic eIF2α-NTD-
S51D (Figure 4.4B). Consistent with our results from comparison of full length WT and 
phosphomimetic eIF2α, we noticed substantial perturbations throughout the OB-fold and 
extending into the α1 helix (Figure 4.3F). It is clear that the S51D mutation affects a 
large part of the surface on eIF2α-NTD responsible for the intramolecular interaction 
(Figure 4.4E, compare Figures 4.2D and 4.3D). Therefore, it appears that 
phosphorylation not only affects the residues in the immediate vicinity of S51, but also 
changes the P-loop conformation, and likely also the P-loop’s interactions with the rest of  
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Figure 4.4: The phosphomimetic mutation S51D destabilizes the eIF2α 
intramolecular interaction 
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Figure 4.4: The phosphomimetic mutation S51D destabilizes the eIF2α 
intramolecular interaction 
(A) TROSY-HSQC spectra of 2H/15N-labeled full length eIF2α (black), full length 
phosphomimetic eIF2α (purple), and 2H/15N/13C-labeled eIF2α-CTD (red). Arrows 
indicate movement of peaks away from their full length WT positions. The boxed area 
corresponds to the blown up frame shown in Figure 4.3E. (B) TROSY-HSQC spectra of 
2H/15N-labeled eIF2α-NTD (black) and phosphomimetic eIF2α-NTD-S51D (purple). (C) 
Shown in individual insets are eIF2α-CTD residues experiencing chemical shift 
perturbations of 1σ or greater, derived from the spectra comparison shown in (A). The 
pattern of movement indicates a destabilizing effect of the phosphomimetic mutation on 
the intramolecular interaction in eIF2α. (D) For the residues highlighted in (C), the 
fractional displacement along the line and the magnitude of deviation off of the line were 
calculated. A value of 100% corresponds to final location on top of the eIF2α-CTD peak 
position, while a value of 0% indicates no movement and thus a final location on top of the 
wild-type eIF2α peak position. Resulting mean fractional displacement of ~50% indicates 
peak positions are halfway between eIF2α (“bound” state) and eIF2α-CTD (“free” state). 
No pattern emerged based on angular deviation. (E) Plot of chemical shift perturbations 
due to deletion of the opposite domain (black) as well as due to the phosphomimetic 
mutation (purple). Grey bars represent indeterminate residues for which no analysis could 
be performed. A substantial overlap exists between residues affected by intramolecular 
interaction and by the S51D mutation, as can also be visually seen by comparing Figure 
4.2D and 4.3D. 
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eIF2α-NTD, potentially magnifying its effect on the eIF2α-NTD/CTD intramolecular 
interaction. 
4.2.3. eIF2Bα and eIF2Bβ bind to adjacent surfaces on eIF2α-NTD 
As previously described, the eIF2B regulatory subcomplex presents a pocket 
formed by the NTDs of its constituent subunits, eIF2Bα, β, and δ. Cross-linking data 
indicate that eIF2α-NTD binds in this pocket (Kashiwagi et al. 2016), though its 
orientation and contact interfaces in the eIF2Bαβδ pocket remain unknown. In order to 
unambiguously determine the orientation, we sought to map the eIF2Bα and eIF2Bβ 
binding surfaces on the structure of eIF2α. We were unable to study binding to eIF2Bδ by 
NMR due to insufficient solubility. HSQC spectra were initially obtained for 15N-labeled 
eIF2α-S51D, free and mixed with excess eIF2Bα. Addition of eIF2Bα caused nearly 
complete loss of signal due to relaxation, consistent with formation of a large molecular 
weight complex (data not shown). This result confirmed that eIF2α-NTD-S51D binds to 
eIF2Bα, but made any mapping impossible. 
When the experiment was repeated using 2H/15N-labeled eIF2α-NTD and 
collecting TROSY-HSQC spectra, we were able to observe the spectrum of eIF2α-NTD 
in the presence of eIF2Bα (Figure 4.5AB). However, rather than changes in chemical 
shift positions, we observed a selective loss in signal intensity for certain peaks compared 
to the domain as a whole, ranging from a partial to complete loss of signal (Figure 4.5C). 
The observed selective loss in signal is due to cross-relaxation between the free and 
bound state of eIF2α. The phenomenon is observed in cases like this one, with a weak  
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Figure 4.5: eIF2α-NTD surfaces affected by binding to eIF2Bα 
(A) TROSY-HSQC spectra of 2H/15N-labeled eIF2α-NTD, free (black) and in the presence 
of excess unlabeled eIF2Bα (red). (B) The boxed area in (A). Some of the peaks 
experiencing selective signal loss are labeled. (C) Plot of signal loss for residues in eIF2α-
NTD. Grey bars represent indeterminate residues for which no analysis could be 
performed. (D) Residues experiencing selective signal loss mapped onto the structure of 
eIF2α, colored from yellow (>1σ) to red (>3σ). Indeterminate residues are colored grey. 
Residues <1σ are colored black. 
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interaction, where the labeled protein is in fast equilibrium between a free state and a 
complex that is too large to observe by NMR, even with deuteration and TROSY-HSQC. 
The spectrum corresponds to the free state of the protein, but the signal is reduced 
because the protein spends part of the time in a large slowly-tumbling complex 
characterized by fast relaxation (effectively, loss of signal). Peaks that correspond to 
residues experiencing different environments in the free and bound states and have 
different chemical shifts, demonstrate stronger cross-relaxation effects (i.e. signal 
intensity loss) (Anthis & Clore 2015). We mapped those peaks with the largest drops in 
relative signal intensity on the structure of eIF2α, revealing the intermolecular eIF2Bα-
binding surface on eIF2α-NTD (Figure 4.5D). Of note was that there was little to no 
overlap between this intermolecular surface and the previously identified intramolecular 
contact surface with eIF2α-CTD, except for the P-loop, which lies on the periphery.  
The experiment was repeated for 2H/15N-labeled WT eIF2α-NTD-S51D as well as 
for both 2H/15N-labeled full length WT and phosphomimetic eIF2α (Figure 4.6). Both the 
degree of binding and the surface were similar among all four constructs, indicating that 
neither the S51D mutation, nor the presence of eIF2α-CTD affected the observed 
eIF2α/eIF2Bα interaction (Figure 4.6), consistent with the lack of significant overlap 
between the eIF2α/eIF2Bα interface and eIF2α-NTD/CTD interface. It is important to 
note that the similar nature of the interactions between WT and phosphomimetic eIF2α 
with eIF2Bα indicates that the eIF2α-NTD/eIF2Bα interaction does not mediate any 
direct effects of eIF2α phosphorylation. 
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Figure 4.6: Effects of the phosphomimetic S51D mutation and eIF2α-CTD on 
eIF2Bα binding 
Residues in eIF2α-NTD (A), eIF2α (B), eIF2α-NTD-S51D (C), and eIF2α-S51D (D) 
experiencing selective signal loss in TROSY-HSQC spectra of 2H/15N-labeled protein 
samples upon binding to eIF2Bα, mapped onto the structure of eIF2α-NTD, colored from 
yellow (>1σ) to red (>3σ). Indeterminate residues are colored grey. Residues <1σ are 
colored black. eIF2α-NTD is shown in the same orientation as in Figure 4.5D. For full 
length eIF2α and eIF2α-S51D, only the NTD is shown, as no residues in the CTD crossed 
the 1σ threshold. Surfaces appear similar for all four constructs, indicating no obvious 
change in binding to eIF2Bα due to the presence of eIF2α-CTD or due to the 
phosphomimetic mutation. 
 
 158 
 
We next turned to mapping the eIF2Bβ contact surface on eIF2α-NTD. Once 
again TROSY-HSQC spectra were collected for 2H/15N-labeled eIF2α-NTD, eIF2α-
NTD-S51D, WT eIF2α, and eIF2α-S51D, all free and mixed with excess eIF2Bβ. The 
same phenomenon of selective signal loss was observed as with eIF2Bα, however in this 
case we also observed chemical shift perturbation (CSP) effects in addition to and/or 
instead of signal loss in a number of peaks. CSPs tended to be more prevalent at lower 
eIF2Bβ to eIF2α-NTD-S51D ratios, whereas signal loss was more prominent at higher 
eIF2Bβ concentrations (data not shown), consistent with eIF2α-NTD-S51D spending 
more time in a large complex with faster relaxation. The eIF2Bβ contact surface on 
eIF2α-NTD is adjacent to the eIF2Bα contact surface (compare Figures 4.5D and 4.7D) 
and overlapping with the intramolecular eIF2α-NTD/CTD interface (compare Figures 
4.5D and 4.2D). Once again binding appeared similar for both eIF2α-NTD and eIF2α-
NTD-S51D (Figure 4.8AB). This suggests that, as was the case for eIF2Bα binding, 
phosphorylation seems to have no direct effect on the eIF2α-NTD/eIF2Bβ interaction. 
Unlike for eIF2Bα, however, we were unable to observe significant binding of eIF2Bβ to 
either full length WT or phosphomimetic eIF2α (Figure 4.8CD). This indicates that 
eIF2α-CTD must be interfering with eIF2α-NTD binding to eIF2Bβ, as would be 
expected from the overlap between the intramolecular eIF2α-NTD/CTD contact surface 
and the eIF2α-NTD/eIF2Bβ contact surface. 
In order to test for possible direct binding of eIF2α-CTD to eIF2Bα or eIF2Bβ, we 
collected TROSY-HSQC of 2H/15N/13C-labeled eIF2α-CTD both free and in the presence 
of excess eIF2Bα, as well as HSQC of 15N-labeled eIF2α-CTD both free and in the  
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presence of excess eIF2Bβ. No binding was observed between eIF2α-CTD and either 
eIF2Bα or eIF2Bβ (data not shown). 
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Figure 4.7: eIF2α-NTD surfaces affected by binding to eIF2Bβ 
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Figure 4.7: eIF2α-NTD surfaces affected by binding to eIF2Bβ 
(A) TROSY-HSQC spectra of 2H/15N-labeled eIF2α-NTD-S51D, free (black) and in the 
presence of excess unlabeled eIF2Bβ (red). (B) The boxed area in (A). Some of the peaks 
experiencing selective signal loss and/or chemical shift perturbations are labeled. (C) Plot 
of signal loss for residues in eIF2α-NTD-S51D. Grey bars represent indeterminate residues 
for which no analysis could be performed. (D) Residues experiencing selective signal loss 
mapped onto the structure of eIF2α, colored from yellow (>1σ) to red (>2σ). Residues 
experiencing chemical shift perturbations of >0.01ppm, but without significant selective 
signal loss (<1σ), are colored in gold. Indeterminate residues are colored grey. Residues 
<1σ are colored black. Comparison to the intramolecular surface in Figure 4.2D reveals 
overlap between the eIF2Bβ binding surface and the intramolecular interface. 
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Figure 4.8: Effects of the phosphomimetic mutation S51D and eIF2α-CTD on 
eIF2Bβ binding 
(A) TROSY-HSQC spectra of 2H/15N-labeled eIF2α-NTD in the absence (black) and 
presence (red) of excess eIF2Bβ. (B) Boxed area in (A) with boxed area from Figure 4.7B 
for comparison. Intermolecular surface was similar to that of eIF2α-NTD-S51D shown in 
Figure 4.7D. TROSY-HSQC spectra of 2H/15N-labeled eIF2α (C) and eIF2α-S51D (D) in 
the absence (black) and presence (red) of excess eIF2Bβ. No significant binding was 
observed. 
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4.2.4. eIF2Bα and eIF2Bβ show no apparent preference for 
phosphomimetic over wild-type eIF2α-NTD 
It has been noted that loss of the eIF2Bα subunit leads to the inability of eIF2(α-
P) to inhibit eIF2B activity. It is therefore a commonly held (and logical) belief that the 
tight, non-productive binding of eIF2(α-P)-GDP to eIF2B is mediated, at least in part, by 
a “direct effect” characterized by a greater affinity of eIF2Bα for the phosphorylated P-
loop. Our NMR data suggest, however, that eIF2Bα binding to eIF2α-NTD and eIF2α-
NTD-S51D is at the least qualitatively similar, and certainly not sufficiently different to 
explain the substantial increase in affinity expected for competitive inhibition.  
In order to more directly test whether eIF2Bα does, in fact, bind phosphomimetic 
eIF2α-NTD more tightly than WT eIF2α-NTD, we sought to obtain KD’s of these 
interactions using fluorescence anisotropy. eIF2α-NTD and eIF2α-NTD-S51D were 
labeled with fluorescein-5-maleimide using existing surface-exposed cysteines and 
unlabeled eIF2Bα was titrated in up to the maximum achievable concentration. 
Confirming our NMR data, we found that eIF2Bα showed no preference for 
phosphomimetic over WT eIF2α-NTD (Figure 4.9A). 
We next sought to determine whether the “direct effect” of phosphorylation may 
be mediated by eIF2Bβ rather than by eIF2Bα. Titrations were performed in the same 
manner as for eIF2Bα. We observed no substantive preference by eIF2Bβ for 
phosphomimetic over WT eIF2α-NTD either (Figure 4.9B). From this data it can be 
concluded that, if it does exist, any “direct effect” of the phosphate group or  
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Figure 4.9: eIF2Bα and eIF2Bβ bind eIF2α-NTD and eIF2α-NTD-S51D with similar 
affinities 
Plot of the changes in fluorescence anisotropy of fluorescein-labeled eIF2α-NTD (black) 
and eIF2α-NTD-S51D (purple) in the presence of increasing concentrations of unlabeled 
eIF2Bα (A) and eIF2Bβ (B). Calculated KD’s are shown in the inset. No substantive 
difference in affinity was observed for eIF2Bα or eIF2Bβ as a function of the 
phosphorylation state of eIF2α-NTD. 
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rearrangement of the P-loop on the binding of eIF2α-P to the eIF2B regulatory 
subcomplex would have to be mediated either by eIF2Bδ or by an aggregate interaction 
with two or more of the eIF2B regulatory subunits. 
4.2.5. Orientation of eIF2α in the eIF2Bαβδ pocket 
The eIF2α contact surfaces for eIF2Bα and eIF2Bβ identified here by NMR are 
consistent with most of the cross-linking data in (Kashiwagi et al. 2016), but not 
compatible with their model for the eIF2α/eIF2B interaction, in which they suggest that 
eIF2α-NTD enters the eIF2Bαβδ pocket from the side through the groove between 
eIF2Bβ and eIF2Bδ. Docking eIF2α-NTD into the eIF2Bαβδ pocket using our NMR data 
indicated that it is more centrally positioned in the pocket and instead approaches it 
through the groove between eIF2Bα and eIF2Bδ (Figure 4.10A). The resulting complex 
is compatible with most of the cross-linking data, except one of the eIF2α residues cross-
linked to eIF2Bβ (residue 16). A possible explanation for this discrepancy is that the 
cross-link could be to the long loop in eIF2Bβ-NTD, where Gcn- mutations have been 
found (Pavitt et al. 1997). A portion of this loop is seen contacting eIF2Bα, whereas the 
rest of it remains disordered in the eIF2B crystal structure (Kashiwagi et al. 2016). 
Finally, in the new orientation, the eIF2α P-loop faces the two eIF2Bβ residues that 
cross-link only to unphosphorylated eIF2α (shown in orange in Figure 4.10A). 
Therefore, our results indicate that the loss of cross-linking at these positions upon eIF2α 
phosphorylation is due to the “relocation” of the P-loop upon S51 phosphorylation, 
whereas the overall eIF2α orientation remains similar. 
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Figure 4.10: Structural model for the eIF2B/eIF2 interaction. 
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Figure 4.10: Structural model for the eIF2B/eIF2 interaction. 
(A) Model of the eIF2B:eIF2α interaction, where eIF2α-NTD is docked into the eIF2B 
regulatory subcomplex pocket (Kashiwagi et al. 2016). eIF2B subunits are shown in 
surface representation; eIF2α is shown as ribbon. eIF2Bα2(βδ)2 residues shown to cross-
link to both phosphorylated and unphosphorylated eIF2α are red; residues in eIF2Bβ that 
cross-link only to unphosphorylated eIF2α are orange; eIF2Bγε residues shown to cross-
link to eIF2g are blue (Kashiwagi et al. 2016); the conserved NF motif in eIF2Bε is cyan; 
and the sites of CACH/VWM mutations in eIF2Bγε are grey. The same coloring scheme 
for eIF2B is used in all remaining panels. Residues in eIF2α are colored according to the 
following scheme: (i) residues in the P-loop are purple, unless colored as detailed below; 
(ii) residues affected by eIF2Bα binding (see Figure 4.5) are navy; (iii) residues affected 
by eIF2Bβ binding (see Figure 4.7) are cyan; and (iv) residues affected by both are blue. 
The same coloring scheme for eIF2α is used in panel (C). (B) Model of the eIF2B:TC 
complex, oriented and aligned using cross-linking data (Kashiwagi et al. 2016), as well as 
a proposed docking of the eIF2Bε-CTD catalytic domain (purple, semi-transparent). eIF2B 
coloring is as in panel (A). TC is shown as ribbon. The nucleotide is displayed in green. 
(C) Model of the eIF2B complex with nucleotide-bound eIF2 in “extended” conformation, 
obtained by merging the model of the eIF2B:eIF2α complex shown in (A) and the model 
of the eIF2B:TC complex shown in (B). eIF2B and eIF2α coloring is as in panel (A). (D) 
Model of the eIF2B:apo-eIF2 complex, in which eIF2β/γ remain docked as in the 
eIF2B:TC complex shown in (B), but eIF2α is “closed” as per the intramolecular 
interaction displayed in Figure 4.2. eIF2B coloring is as in panel (A). 
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4.2.6. Architecture of the eIF2B:eIF2 complex 
The most important implication of the eIF2α orientation determined here is that 
eIF2α-CTD is directed toward the more proximal eIF2Bγε dimer in eIF2B (instead of 
toward the more distant one, as suggested in (Kashiwagi et al. 2016), and ends up in 
proximity to the eIF2Bγε surface cross-linked to eIF2γ. This observation indicates that 
eIF2 can simultaneously contact the regulatory eIF2Bα2(βδ)2 subcomplex (through 
eIF2α) and the catalytic eIF2Bγε subcomplex (through eIF2γ), in a two-site interaction, 
consistent with a wealth of existing data.  
We proceeded to model the position of eIF2 on eIF2B. The structure of eIF2 is 
rather dynamic (see e.g. (Yatime et al. 2007)), which could compromise the quality of 
docking. We reasoned that TC is the best candidate for docking to eIF2B as: i) it is the 
true product of the eIF2B-catalyzed process and is bound rather tightly to eIF2B 
((Salimans et al. 1984), reviewed in (Marintchev & Wagner 2004)); ii) it is more rigid 
than free eIF2 (Yatime et al. 2007); and iii) by being larger and more complex, it 
provides a greater number of steric constraints. TC was docked to the eIF2B surface 
shown in Figure 4.11A, between the eIF2α- and eIF2γ-binding sites. First, TC was 
positioned with eIF2γ facing the eIF2Bγε surfaces, where it was shown to cross-link 
(Kashiwagi et al. 2016) and oriented such that eIF2α faced in the direction of the 
eIF2Bαβδ pocket, where eIF2α-NTD binds. The eIF2B/TC contacts were then optimized 
to yield the complex shown in Figure 4.11B. The resulting complex displays a 
remarkable degree of surface complementarity, especially considering that there must be 
at least some differences between the structures of TC when bound to the ribosome and 
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when bound to eIF2B, as well as between S. pombe and S. cerevisiae. The eIF2B:TC 
complex also shows good charge complementarity, as shown in Figure 4.12A, with Met-
tRNAi contacting positively charged surfaces. Finally, to further validate our complex, 
we compared it to recently reported cross-links between eIF2 and eIF2B (Gordiyenko et 
al. 2014). As can be seen in Figure 4.12B, the positions of the cross-links are fully 
consistent with the docking model. Therefore, it is safe to conclude that we have 
identified the correct eIF2B/TC interface and that TC binds to eIF2B in roughly the 
orientation shown in Figure 4.11B. 
We then wondered whether we could identify the position of eIF2Bε-CTD (the 
catalytic domain) within the eIF2B:TC complex. eIF2Bε-CTD is connected to the rest of 
eIF2Bε by a flexible linker and is not visible in the S. pombe eIF2B crystal structure. 
However, it is known to contact eIF2γ (Alone & Dever 2006), and if eIF2γ is docked 
onto the eIF2Bγε surface it is likely that eIF2Bε-CTD too occupies a specific position in 
the eIF2B:eIF2 complex. We noticed that while the vast majority of the surface-exposed 
mutations in eIF2B subunits, causing the CACH/VWM neurodegenerative disorder, are 
now known to affect residues buried at intersubunit interfaces or at the interface with 
eIF2γ, one surface on eIF2Bε with a high density of CACH/VWM mutations remains 
unaccounted for. Remarkably, this surface is adjacent to the eIF2γ-binding surface and 
faces the GTPase domain (G-domain) of eIF2γ. Therefore, we docked eIF2Bε-CTD onto 
the eIF2Bε surface, with its N-terminal portion (where critically important residues have 
been identified (Mohammad-Qureshi et al. 2007)) facing the G-domain of eIF2γ, yielding 
the model for the eIF2B:TC complex shown in Figure 4.10B and Figure 4.13A. eIF2Bε-
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CTD is shown semi-transparent in both Figure 4.10 and Figure 4.13, to emphasize that 
its orientation is purely speculative.  
A comparison of Figure 4.10A and Figure 4.10B illustrates that eIF2α-NTD can 
easily bind in the eIF2Bαβδ pocket (as in Figure 4.10A), while the rest of eIF2 is bound 
to eIF2B in the orientation shown in Figure 4.10B, forming a simultaneous two-site 
interaction. Therefore, we postulate that this is the case for the inhibitory interaction 
between eIF2B and eIF2(α-P)-GDP, as well as with unphosphorylated eIF2-GDP and 
eIF2-GTP, in line with the available evidence in the field. To obtain a model for the 
structure of the eIF2B complex with nucleotide-bound eIF2, we merged the model for 
eIF2α binding in the eIF2Bαβδ pocket (Figure 4.10A) with the model of the eIF2B:TC 
complex (Figure 4.10B), by aligning eIF2α-CTD from the eIF2B:eIF2α model to eIF2α-
CTD from the eIF2B:TC model, as shown in Figure 4.13B. This yielded the model 
shown in Figure 4.10C. Here, eIF2α is in an “extended” conformation, where the 
intramolecular contacts between the NTD and the CTD are disrupted, both in order to 
reach the pocket and to fit in it. In contrast, nucleotide-free apo-eIF2 likely binds to 
eIF2B in a “closed” state, where eIF2α-NTD and -CTD contact each other, as we show in 
Figure 4.2, and eIF2α-NTD does not bind in the eIF2Bαβδ pocket (a one-site interaction 
mediated only by eIF2γ). Since phosphorylation destabilizes the intramolecular 
interaction (Figure 4.3), it is easy to see how it would also promote eIF2α-NTD binding 
in the pocket by favoring the “extended” eIF2α conformation. Of course, phosphorylation  
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Figure 4.11: Docking the TC on eIF2B 
(A) Cross-eyed stereo view of the surface on eIF2B proposed to bind the eIF2 heterotrimer. 
eIF2Bα2(βδ)2 residues shown to cross-link to both phosphorylated and unphosphorylated 
eIF2α are red; residues in eIF2Bβ that cross-link only to unphosphorylated eIF2α are 
orange; eIF2Bγε residues shown to cross-link to eIF2γ are blue (Kashiwagi et al. 2016); 
the conserved NF motif in eIF2Bε is cyan; and the sites of CACH/VWM mutations in 
eIF2Bγε are grey. The same coloring scheme for eIF2B is used in panel (B) and in Figures 
4.12B and 4.13. (B) Cross-eyed stereo view of TC from the S. cerevisiae 48S pre-initiation 
complex (3JAQ.pdb) from a cryo-EM structure (6 Å)  (Llácer et al. 2015) docked on eIF2B. 
eIF2B coloring is as in panel (A). TC is shown as ribbon.  
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Figure 4.12: Validating the eIF2B:TC model 
(A) Cross-eyed stereo view of the eIF2B:TC complex, with eIF2B colored based on 
electrostatic potential (blue indicates positive charges, while red indicates negative 
charges). The color scheme of TC is the same as in Figure 4.11B. (B) Cross-eyed stereo 
view of the eIF2B:TC complex, with eIF2B and eIF2 residues reported to cross-link to 
each other (Gordiyenko et al. 2014) shown in magenta and connected with magenta lines). 
The tRNA and nucleotide are not shown so as not to visually obscure cross-links. eIF2B 
and eIF2 coloring is as in Figure 4.11B. 
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Figure 4.13: Building a model of the eIF2B:eIF2(α-P)-GDP complex 
(A) Cross-eyed stereo view of the eIF2B:TC with the structure of human eIF2Bε-CTD 
(3JUI.pdb) (Wei et al. 2010) docked such that it interacts with a CACH/VWM mutation-
rich surface on eIF2Bε as well as oriented such that residues important for catalytic activity 
are facing the G-domain of eIF2γ. eIF2B and eIF2 coloring is as in Figure 4.11B. (B) 
Cross-eyed stereo view of the eIF2B:eIF2α model shown in Figure 4.10A merged with the 
model of the eIF2B:TC complex shown in Figure 4.10B. eIF2α from the eIF2B:eIF2α 
model is shown and colored yellow, with individual residues in eIF2α colored according 
to the following scheme: (i) residues in the P-loop are purple, unless colored as detailed 
below; (ii) residues affected by eIF2Bα binding (see Figure 4.5) are navy; (iii) residues 
affected by eIF2Bβ binding (see Figure 4.7) are cyan; and (iv) residues affected by both 
are blue. Only the CTD of eIF2α from the eIF2B:TC model is shown and colored grey.  
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could also directly affect the affinity of eIF2α-NTD for the pocket as currently thought, 
since the two effects are not mutually exclusive. 
To build a model for the complex of eIF2B with apo-eIF2, we used eIF2 with the 
eIF2α subunit in a “closed” conformation, obtained using the NMR data reported here. 
Modeling eIF2α in the “closed” conformation onto the structure shown in Figure 4.10C 
would cause eIF2α-NTD to clash with eIF2B. To eliminate the steric clash, we rotated 
eIF2α slightly in a way that causes eIF2α-NTD to rotate away from eIF2B, thus yielding 
the model shown in Figure 4.10D. A comparison of our eIF2B:eIF2 docking models with 
the cross-linking results in (Kashiwagi et al. 2016) indicates that eIF2B residues that 
cross-link equally well in the eIF2B:apo-eIF2 and eIF2B:eIF2(α-P)-GDP complexes 
appear to face predominantly eIF2γ domain 3, whereas those that cross-link better in the 
eIF2B:apo-eIF2 complex face eIF2γ domain 1 (the G-domain). Therefore, in the 
eIF2B:apo-eIF2 complex, the eIF2γ G-domain likely moves away from domain 2 and 
toward the sites of cross-links in eIF2Bε. The domain 2 conformation is also likely to 
change, explaining the different orientation of eIF2α-CTD. It should be noted that in the 
model shown in Figure 4.10D, we kept the eIF2γ conformation unchanged because we 
do not have enough restraints to model the apo-eIF2γ state reliably.  
4.3. Discussion 
4.3.1. Implications of the eIF2α intramolecular interaction 
In this work we show that eIF2α-NTD and -CTD interact with each other (Figure 
4.2) and that eIF2α phosphorylation destabilizes this intramolecular interaction (Figures 
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4.3, 4.4). The intramolecular interface in eIF2α overlaps significantly with the 
eIF2α/eIF2Bβ interface (Figure 4.7), and possibly also with the eIF2α/eIF2Bδ interface, 
and must be disrupted for eIF2α to bind in the eIF2Bαβδ regulatory subcomplex pocket 
(Figure 4.10). Therefore, eIF2α phosphorylation increases the affinity of eIF2 for eIF2B 
at least in part by destabilizing the intramolecular interaction within eIF2α and increasing 
the percent of time eIF2α spends in an “extended” conformation able to bind in the 
eIF2Bαβδ pocket. Unfortunately, while we were able to determine that phosphorylation 
decreases the fraction in the “closed” state by 50%, we were unable to determine 
experimentally what fraction of unphosphorylated eIF2α is actually in the “closed” vs. 
“extended” state at any given time. This would have allowed us to quantify the effect of 
phosphorylation on the binding constant of eIF2α for the eIF2Bαβδ pocket. For instance, 
if 5% of eIF2α is in the “extended” state, phosphorylation increasing this fraction to 50% 
(Figures 4.3, 4.4) would lead to ten-fold increase of the effective concentration of free 
eIF2α-NTD, and thus ten-fold increase in the rate of binding. While eIF2α 
phosphorylation must have some direct effect on the binding to eIF2Bα2(βδ)2, as is 
currently believed, such effect does not appear to be mediated by eIF2Bα or eIF2Bβ 
(Figure 4.9). The eIF2α NMR solution structure (Ito et al. 2004) was solved using a 
solubility-enhanced mutant protein and at high salt, 350 mM Na2SO4 (Ito & Wagner 
2004). Even under those conditions, the S51D phosphomimetic mutation had some effect 
on chemical shifts in the CTD (Ito et al. 2004), although far fewer residues were affected, 
and to a lesser degree than what we observed with the WT eIF2α at physiological salt, 
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150 mM NaCl (Figure 4.3). Therefore, even at high salt and with a solubility-enhanced 
mutant eIF2α, the intramolecular interaction was not fully disrupted. 
4.3.2. Implications of the identified eIF2α surfaces responsible for 
binding to eIF2Bα and eIF2Bβ 
Our data indicate that eIF2α-NTD enters the eIF2Bαβδ pocket in between the 
eIF2Bα and δ subunits. This eIF2α orientation allows for simultaneous binding of both 
eIF2α-NTD in the eIF2Bαβδ pocket and eIF2γ to eIF2Bγε (two-site interaction) (Figure 
4.10C). As eIF2α exists in an equilibrium between “extended” and “closed,” in the 
“closed” state, eIF2 would not be able to reach both binding sites on eIF2B 
simultaneously (one-site interaction mediated only by eIF2γ binding to eIF2Bγε) (Figure 
4.10D). Such a scheme has a further important implication: that binding of eIF2α into the 
eIF2Bαβδ pocket does not preclude a productive interaction. Rather, it suggests that the 
preferred eIF2B:eIF2 complex conformation is “extended” for eIF2-GDP or eIF2-GTP, 
and “closed” for apo-eIF2. 
4.3.3. Structural Mechanism of eIF2(α-P) regulation of eIF2B activity 
As we discussed above, the interactions of eIF2α-NTD with the eIF2Bαβδ pocket 
appear to play roles in both catalysis and inhibition by eIF2α phosphorylation. Therefore, 
we propose that when eIF2 is in complex with eIF2B, it is in equilibrium between a 
“closed” apo- state, where eIF2α-NTD and -CTD contact each other (Figure 4.10D) and 
an “extended” nucleotide-bound state, where eIF2α-NTD is bound in the eIF2Bαβδ 
pocket. Judging from the nearly identical cross-linking patterns observed with 
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phosphorylated and unphosphorylated eIF2α (Kashiwagi et al. 2016), the complexes of 
unphosphorylated eIF2-GDP and eIF2-GTP with eIF2B are likely similar to the model 
for the inhibitory eIF2B:eIF2(α-P)-GDP complex in Figure 4.10C, but the respective 
equilibria are shifted toward the “closed” apo- state. Binding to eIF2B lowers the affinity 
of eIF2 for GDP at least 100-fold (Panniers et al. 1988) and accordingly eIF2B has at 
least 100-fold higher affinity for apo-eIF2 than for eIF2-GDP (Goss et al. 1984; Panniers 
et al. 1988; Jennings et al. 2013). Thus, eIF2B shifts the equilibrium toward the “closed” 
apo-eIF2 complex at least 100-fold. These structural and thermodynamic considerations 
are reflected in Figures 4.14, 4.15, and 4.16 below. 
The affinities of eIF2(α-P)-GDP and apo-eIF2(α-P) for eIF2B are approximately 
the same (Goss et al. 1984); therefore, eIF2B does not affect the equilibrium between the 
apo- and GDP-bound forms of eIF2(α-P). Accordingly, eIF2B neither promotes nor 
inhibits GDP release from eIF2(α-P) (Jennings et al. 2013). Apo-eIF2(α-P) has been 
reported to have ~10-fold lower affinity for eIF2B than unphosphorylated apo-eIF2 (Goss 
et al. 1984), while eIF2α-P has a few-fold higher affinity for eIF2B than 
unphosphorylated eIF2α (Kashiwagi et al. 2016). Therefore, the shift from 100-fold 
preference of eIF2B for apo-eIF2 over eIF2-GDP to no preference between apo-eIF2(α-
P) and eIF2(α-P)-GDP appears to result from a ~10-fold destabilization of the apo- state 
and a ~10-fold stabilization of the GDP-bound state. In the context of the role of the 
intramolecular eIF2α-NTD/CTD interaction reported here, eIF2α phosphorylation 
increases the affinity of eIF2B for the “extended” eIF2-GDP state, where eIF2α-NTD is 
bound in the eIF2Bαβδ pocket, at least in part by destabilizing the intramolecular  
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Figure 4.14: Thermodynamic description of eIF2B-mediated nucleotide exchange 
  
 
Figure 4.14: Thermodynamic description of eIF2B-mediated nucleotide exchange 
(A) In the presence of GDP and GTP, eIF2 will partition itself at equilibrium predominantly into the eIF2-GDP bound state. In 
addition to an unfavorable thermodynamic partitioning, nucleotide exchange is kinetically restricted on the time-scale of 
translation. (B) The thermodynamic equilibrium is more favorable for TC formation (eIF2-GDP and TC are equally stable) and 
limited by the Met-tRNAi concentration. However, due to the slow GDP dissociation rate preventing the system form 
reaching thermodynamic equilibrium, only a small eIF2-GTP population is capable of forming a TC with Met-tRNAi, resulting 
in low levels of TC. (C) eIF2 binding by eIF2B changes its affinity for GDP and GTP. While bound to eIF2B, eIF2 is now 
equally partitioned between eIF2-GDP and eIF2-GTP bound states. (D) Met-tRNAi recruitment by eIF2B results in conversion 
of eIF2B-bound eIF2-GTP to TC. (E) The high affinity of TC for eIF2B results in most of it being bound to eIF2B. (F) eIF5 is 
needed to “retrieve” newly formed TC from eIF2B. (G) eIF2B’s catalytic activity is derived from its stabilization of the transition 
apo-eIF2 state, thus reducing the activation energy and relieving the kinetic barrier to nucleotide exchange. (H) When eIF2 is 
phosphorylated, eIF2B is no longer able to stabilize the transition state and thus loses its catalytic activity. 
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Figure 4.15: Thermodynamic description of the eIF2B catalytic cycle 
Thermodynamic description of the pathway of eIF2B-catalyzed recycling of eIF2-GDP to TC and ribosome binding. Solid arrows 
indicate progression along the path, with steps labeled as follows: (Step A) displacement of eIF5 from eIF2-GDP by eIF2B, 
(Step B) eIF2B-promoted dissociation of GDP from eIF2, (Step C) binding of GTP to eIF2B-bound apo-eIF2, (Step D) binding 
of Met-tRNAi to form the TC on eIF2B, and finally (Step E) displacement of eIF2B from the TC by eIF5. Dashed arrows 
represent steps off the main pathway. Red crosses mark steps that can be safely ignored due either to off-rates being too slow on 
the time-scale of translation or to the equilibrium being shifted too far away from the product. Dissociation constants (KDs) are 
provided for each step and represent either experimentally determined values reported in the literature (black), or calculated 
(blue) or estimated (red) values based on thermodynamic coupling considerations (see Table 4.1). 
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Figure 4.16: Effect of phosphorylation on the thermodynamics of the eIF2B catalytic cycle 
A thermodynamic description of how phosphorylation blocks catalysis by inhibiting eIF2B-mediated nucleotide exchange. Color 
and overall scheme is identical to that presented in Figure 4.15. KDs affected by phosphorylation are underlined. Since the 
affinity of eIF2B for apo-eIF2(α-P) (reaction intermediate) is the same as for eIF2(α-P)-GDP (substrate), the enzymatic driving 
force is removed and eIF2B has no effect on GDP dissociation. 
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interaction within eIF2α. Phosphorylation also lowers the affinity of eIF2B for the 
“closed” apo-eIF2 state, at least in part by destabilizing the intramolecular interaction 
within eIF2α. It should be noted that if instead, phosphorylation stabilizes the “extended” 
state 100-fold with no effect on the “closed” state, the final effect on eIF2B activity 
would be the same. The tight binding of eIF2B to eIF2(α-P)-GDP, in the absence of 
conversion to eIF2(α-P)-GTP and eIF2(α-P)-TC, results in eIF2B remaining trapped in an 
eIF2B:eIF2(α-P)-GDP complex, thus explaining the observed competitive inhibition. 
These structural and thermodynamic considerations are reflected in Figure 4.16. 
It is interesting to compare the mechanism described here with models proposed 
previously. Based on extensive genetic and biochemical data, it has been generally 
accepted that eIF2 simultaneously contacts both the eIF2B catalytic and regulatory 
subcomplexes, in both catalysis and inhibition by eIF2α phosphorylation, but in the 
inhibited complex the interactions are different (see e.g. (Dev et al. 2010)). Thus it came 
as a surprise that the recent results of Kashiwagi and coauthors seemed to suggest that 
eIF2 binding to the two sites on eIF2B is mutually exclusive and the eIF2B:eIF2 complex 
exists in one of two alternative one-site interaction states: bound either to the eIF2Bαβδ 
pocket or to the eIF2Bγε catalytic subcomplex (Kashiwagi et al. 2016). Such an 
interpretation is also at odds with their observation that phosphorylated eIF2α shows 
essentially the same pattern of cross-linking to eIF2B α2(βδ)2 as unphosphorylated eIF2α 
and has only a few-fold higher affinity, and that the relative intensities of cross-links 
between eIF2γ and eIF2Bγε change between eIF2 and eIF2(α-P)-GDP (Kashiwagi et al. 
2016). For the latter, mutually exclusive binding would have caused uniform weakening 
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or complete loss of cross-linking over the entire eIF2γ/eIF2Bγε interface. As described 
above, our results placed in the context of the report by Kashiwagi and coauthors confirm 
that eIF2 can contact both eIF2B subcomplexes at the same time, as previously believed. 
The main differences from previous two-site interaction models are that: i) the 
eIF2B:eIF2 complex is in equilibrium between an “extended” two-site interaction state 
and a “closed” one-site interaction state, with this equilibrium playing a central role in 
catalysis by eIF2B; and ii) the effect of eIF2α phosphorylation is not so much remodeling 
the two interactions, as shifting the equilibrium toward the “extended” two-site 
interaction state. 
4.3.4. Thermodynamic description of the eIF2B catalytic cycle 
At this point, we sought to combine the structural insights into the mechanism of 
eIF2B action and regulation described above with binding and rate constants derived 
from decades of research and recent advances to build a complete thermodynamic 
description of the entire process and correlate it to respective structures (Figures 4.15, 
4.16). All experimental, calculated, and estimated KDs used to generate Figures 4.15 and 
4.16 are listed in Table 4.1. The relationships and approaches used for calculation and 
estimation of KDs that have not been determined experimentally are described in Chapter 
2. 
The dissociation rate of GDP from free eIF2 is less than 0.002 s-1 in S. cerevisiae 
(Jennings & Pavitt 2010) and even slower in mammals (Panniers et al. 1988; Sokabe et 
al. 2012), and is thus insignificant in the context of the rates of translation. eIF2-GDP is 
released from the 48S IC in complex with eIF5 upon start codon recognition. Since eIF5 
  
Table 4.1:3Reference KDs of Interactions Relevant to the eIF2 catalytic cycle 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Value not derived from experimental data, but manually selected and used to fit data. 
2  ~1/10 that of eIF5 for eIF2-GDP, based on a competition assay (Jennings et al. 2013). 
3  See Relationship (R2) in Chapter 2. 
4  See Estimation of 𝐾𝐷[𝑡𝑅𝑁𝐴]●[2𝐵: 2-𝐺𝑇𝑃] and 𝐾𝐷[2𝐵]●[2-𝑇𝐶] in Chapter 2. 
5  The KD of eIF2B:eIF2 for GTP was found by (Panniers et al., 1988) to be 10x that of eIF2B:eIF2 for GDP, which they estimated to be 2,000 nM (see 
footnote 1) 
6  See Relationship (R5) in Chapter 2. 
7  See Relationship (R6) in Chapter 2. 
Binding partner A Binding partner B KD (nM) Source KD for Fig. 7 (nM) References 
eIF2 
GTP 
1,700 
1,600 
experimental 
experimental 
1,000 
(Kapp and Lorsch, 2004) 
(Panniers et al., 1988) 
GDP 
20 
5 
experimental 
experimental 
10 
(Kapp and Lorsch, 2004) 
(Panniers et al., 1988) 
eIF2B 
apo-eIF2 0.05 experimental 0.01 (Goss et al., 1984) 
apo-eIF2(α-P) 0.5 experimental 0.1 (Goss et al., 1984) 
eIF2-GDP 
10 
40 (KM) 
2 
0.2 
theoretical1 
experimental 
calculated2 
experimental 
1 
(Panniers et al., 1988) 
(Rowlands et al., 1988) 
Jennings, 2013 
(Goss et al., 1984) 
eIF2(α-P)-GDP 
0.3 
0.3 
experimental 
experimental 
0.1 
(Rowlands et al., 1988) 
(Goss et al., 1984) 
eIF2-GTP 0.1 calculated3 0.1  
TC 1 estimated4 1  
eIF2B:eIF2 
GDP 2,000 theoretical1 1,000 (Panniers et al., 1988) 
GTP 20,000 theoretical5 10,000 (Panniers et al., 1988) 
eIF5 
eIF2-GDP 20 experimental 10 (Algire et al., 2005) 
TC 20 experimental 10 (Algire et al., 2005) 
apo-eIF2 20 calculated6 N/A  
eIF2-Met-tRNAi GTP 200 experimental 100 (Kapp and Lorsch, 2004) 
Met-tRNAi 
eIF2-GTP 10 experimental 10 (Kapp and Lorsch, 2004) 
eIF2B:eIF2-GTP 100 estimated4 100  
eIF5:apo-eIF2 GDP 10 calculated6 10 
(Jennings and Pavitt, 2010) 
(Sokabe et al., 2012) 
eIF5:apo-eIF2-Met-tRNAi  GTP 100 calculated7 100  
1
8
4 
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has no effect on GDP binding in mammals (Sokabe et al. 2012) and stabilizes it ~2-fold 
in yeast (Jennings & Pavitt 2010), no significant GDP dissociation occurs from 
eIF5:eIF2-GDP, either. If eIF2 were able to equilibrate between GDP-bound and GTP-
bound complexes, the ratio would be 10:1 in favor of the inactive eIF2-GDP, as the eIF2 
affinity for GDP is ~100-fold higher than for GTP and the concentration of GDP ~10-
fold lower than that of GTP. Therefore, if eIF2B were to act as a simple nucleotide 
exchange factor that accelerates the equilibration of eIF2-GDP with eIF2-GTP, it would 
result in only a 10% conversion of eIF2-GDP to eIF2-GTP. Instead, as pointed out 
previously (Salimans et al. 1984; Gross et al. 1991; Marintchev & Wagner 2004), eIF2B 
does not release eIF2-GTP, but also catalyzes the next step: Met-tRNAi binding to form 
the TC, the true product of catalysis. In fact, as described in detail below, eIF2 and its 
complexes with GDP, GTP, and Met-tRNAi are channeled from the ribosomal translation 
initiation complexes (ICs) to eIF5, to eIF2B, to eIF5 again, and finally back to the 
ribosomal ICs. 
The following complexes are known to have off-rates slower than 1 min-1 or have 
been observed using analytical centrifugation, size exclusion chromatography or pull-
down experiments and are therefore stable for at least minutes, if not longer: eIF2-GDP, 
TC, eIF2B:eIF2, and eIF2B:TC (see e.g. (Goss et al. 1984; Salimans et al. 1984; Panniers 
et al. 1988; Gross et al. 1991; Kapp & Lorsch 2004)). The complex of eIF2B with eIF2-
GTP is also very stable, which is the reason why eIF2B-catalyzed GDP to GTP exchange 
is not effective in the absence of Met-tRNAi (see e.g. (Gross et al. 1991)). The eIF5:eIF2-
GDP and eIF5:TC complexes also appear stable enough to withstand pull-down 
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(Jennings et al. 2013). The affinity of eIF2B for eIF2-GDP is at least 10-fold higher than 
that of eIF5 (Jennings et al. 2013), indicating that the dissociation rate of eIF2B from 
eIF2-GDP is also slow. Since the processes of translation initiation and nucleotide 
exchange occur on the time scale of seconds, the spontaneous dissociation of these 
complexes is too slow to be physiologically relevant. 
Of the above slow off-rates, two present a challenge for the eIF2B-catalyzed 
nucleotide exchange: eIF5 dissociation from eIF2-GDP (Figure 4.15, Step A) and eIF2B 
dissociation from TC (Figure 4.15, Step E). The issue of the tight binding of eIF5 to 
eIF2-GDP has been identified previously (Singh et al. 2006; Jennings et al. 2013). The 
KD of eIF5 for eIF2-GDP is ~20 nM (Kapp & Lorsch 2004) and therefore there is no 
significant dissociation to free eIF2-GDP at cellular concentrations. Instead, Pavitt and 
co-authors postulated that eIF5 acts as a GDP dissociation inhibitor (GDI) (Jennings & 
Pavitt 2010), and that eIF2B has to displace eIF5 from eIF2-GDP by forming an unstable 
eIF5:eIF2:eIF2B complex leading to a faster eIF5 dissociation rate, thus serving an 
additional GDI-dissociating factor (GDF) function (Jennings et al. 2013). This idea is 
supported by the observation that no eIF5:eIF2:eIF2B complex has been observed 
(Jennings et al. 2013). eIF2B most likely engages eIF5-bound eIF2-GDP through the 
interaction of eIF2Bγε with eIF2γ reported by (Kashiwagi et al. 2016) (Figure 4.10). The 
stability of the eIF2B:TC complex (Salimans et al. 1984) also indicates that the rate of 
eIF2B displacement from TC by eIF5 (Figure 4.15, Step E) must be faster than the 
spontaneous rate of TC release from eIF2B, which means that eIF5 must act as a “GEF 
displacing factor” (“GEF-DF”).  
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The relative instability of the eIF5:eIF2:eIF2B complex also offers a mechanism 
for acceleration of eIF2B displacement from TC by eIF5. That is, simultaneous binding 
of eIF5 and eIF2B to eIF2 destabilizes both the eIF2B/eIF2 and the eIF5/eIF2 
interactions equally. While eIF5 may have lower or comparable affinity for TC compared 
to that of eIF2B, the cellular concentration of eIF5 is higher than that of eIF2B, and so is 
the concentration of free eIF5. eIF5 could bind to the eIF2β-NTT in eIF2B:TC complexes 
when eIF2β-NTT is transiently released from eIF2Bε-CTD, yielding a meta-stable 
eIF5:TC:eIF2B complex, similar to the eIF5 displacement from eIF2-GDP in Figure 
4.15, Step A. It is also possible that eIF5 and eIF2B can bind to different portions of 
eIF2β-NTT simultaneously, destabilizing each other’s binding. The “classical” GDI 
effect (stabilization of GDP binding to eIF2) is only two-fold in yeast (Jennings & Pavitt 
2010) and not observed in mammals (Sokabe et al. 2012), yet in yeast, impairment of the 
GDI function of eIF5 or the GDF function of eIF2B causes distinct phenotypes (Jennings 
& Pavitt 2010; Jennings et al. 2013). Since eIF2B has to displace eIF5 from eIF2-GDP in 
order to catalyze nucleotide exchange, the eIF5 GDI function is likely due to impeding 
eIF2B binding to eIF2-GDP, rather than slowing down the already slow GDP 
dissociation rate from free eIF2-GDP. Therefore, the concept of GDI and GDF functions 
of eIF5 and eIF2B, and potentially the “GEF-DF” function of eIF5, should be viewed in a 
broader sense: the two proteins displacing each other as eIF2-GDP is recycled to TC and 
recruited to the ribosome for a new round of translation initiation.  
eIF2 and eIF5 appear to have comparable concentrations in the cell, likely as high 
as ~10 µM and up to 10-fold higher than that of eIF2B (Duncan et al. 1983; von der Haar 
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& McCarthy 2002; Ghaemmaghami et al. 2003; Gholami et al. 2013). The eIF2B affinity 
for eIF2-GDP appears to be at least 10-fold higher than the affinity of eIF5 for eIF2-GDP 
(Jennings et al. 2013), which puts its KD at ~2 nM or lower. A KD for eIF2B binding to 
eIF2-GDP as low as 0.2 nM has been reported (Goss et al. 1984), as well as a KD of 10 
nM (Panniers et al. 1988), a value selected manually to use to fit data, rather than one 
directly measured. It has also been shown that the dissociation rates of eIF2-GDP and TC 
from eIF2B are similar (Gross et al. 1991). Therefore, in Figure 4.15 we have set the KDs 
of eIF2B binding to both eIF2-GDP and TC at 1 nM. Since the KDs of eIF5 and eIF2B 
for eIF2-GDP and TC are 20 nM or lower, there isn’t much free eIF2-GDP or TC in the 
cell, unless there is more eIF2 than eIF5 and eIF2B combined.  
In building the model shown in Figures 4.15 and 4.16 we used the following set 
of considerations:  
- The available KDs have been reported by various groups, using proteins from various 
species, and under various buffer conditions. It is not surprising then that some differed 
by up to an order of magnitude. Furthermore, since eIF2B activity is highly regulated, it 
is expected to vary significantly in vivo, as well. Therefore, we rounded all KDs to 
multiples of 10.  
- All KDs must be mutually consistent, based on thermodynamic coupling (Fersht 1999). 
The concept of thermodynamic coupling stems from the Conservation of Energy 
Principle and states that thermodynamically coupled interactions exert reciprocal effects 
on each other. For instance, if binding of molecule A to molecule B increases the affinity 
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of the AB complex for molecule C 10-fold, then binding of C to B must likewise increase 
the affinity of the BC complex for A 10-fold.  
- Where experimentally determined KDs were not available, we used thermodynamic 
coupling to calculate the missing KDs (colored blue in Figures 4.15, 4.16) or at least 
estimate and determine bounds for their possible values (colored red in Figure 4.15, 
4.16). A list of all KDs used in Figure 4.15 and 4.16 can be found in Table 4.1. Relevant 
ratios among KDs based on thermodynamic coupling are described in Chapter 2. 
While a detailed analysis of the eIF2B catalyzed process of TC regeneration is 
beyond the scope of this paper, the thermodynamic scheme shown in Figures 4.15 and 
4.16 has some obvious important implications.  
(1) Apo-eIF2 and eIF2-GTP are reaction intermediates, tightly bound to eIF2B and 
not released. As previously pointed out (Salimans et al. 1984; Marintchev & 
Wagner 2004) and also stemming from the relevant KDs, eIF2B binding to apo-
eIF2 and eIF2-GTP is very tight (KDs in the pM range). Thus, in order to 
destabilize GDP binding to eIF2 and shift the equilibrium toward eIF2-GTP, 
eIF2B binds apo-eIF2 and eIF2-GTP with higher affinity than eIF2-GDP. 
Therefore, apo-eIF2 and eIF2-GTP are reaction intermediates that are never 
released. Instead, eIF2B produces a significant pool of eIF2B:eIF2-GTP available 
to bind Met-tRNAi.  
(2) eIF2B-bound eIF2 exists in a 1:1 ratio between eIF2-GDP and eIF2-GTP 
complexes. eIF2B destabilizes GDP binding to eIF2 ~100-fold compared to free 
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eIF2: from 10 nM to ~1 µM (the basis for its catalytic effect on nucleotide 
exchange). It also destabilizes GTP binding to eIF2 ~10-fold from 1 µM to 10 
µM. Therefore, as previously reported (Panniers et al. 1988), eIF2B-bound eIF2 
equilibrates to 1:1 the ratio of eIF2-GDP and eIF2-GTP complexes, because the 
eIF2B:eIF2 affinity for GDP is ~10-fold higher and the concentration of GDP 
~10-fold lower (Steps B and C in Figure 4.15). Thanks to the increased GDP 
dissociation rate from eIF2B:eIF2, equilibration should only take seconds. And 
since these KDs are lower than the cellular concentrations of GDP and GTP, there 
should be little eIF2B:apo-eIF2.  
(3) The eIF2B complexes with eIF2-GDP, eIF2-GTP, and TC could be at a 1:1:1 
equilibrium. With the KD of Met-tRNAi for eIF2B:eIF2 at ~100 nM (Figure 4.15, 
Table 4.1), the equilibrium between eIF2B:eIF2-GTP and eIF2B:TC should not 
be shifted much toward eIF2B:TC. If the eIF2B complexes with eIF2-GDP, eIF2-
GTP, and TC are near a 1:1:1 equilibrium, the practical implication is that the 
equilibrium will be dependent on, and potentially regulated by, the GTP/GDP 
ratio in the cell, as well as by the concentration of charged Met-tRNAi.  
The eIF2B-catalyzed regeneration of TC and its delivery to the 43S initiation 
complex is thus dependent on the concentration of the eIF2B:TC complex and the rate of 
transfer of TC from eIF2B to eIF5, which are determined by the GTP/GDP ratio in the 
cell, the Met-tRNAi concentration in the cell, the relative affinities of eIF2B for eIF2-
GDP, eIF2-GTP and TC, as well as the relative affinities of eIF5 and eIF2B for eIF2-
GDP and TC. These parameters are in turn dependent on, and can be regulated by, 
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phosphorylation of eIF2, eIF2B, and eIF5 by a number of kinases, the energy state of the 
cell, as well as by direct ligand binding to eIF2B.  
The thermodynamic model shown in Figure 4.15 and 4.16  also illustrates the 
limitations of the assay for in vitro eIF2B activity using exchange of eIF2-bound labeled 
GDP (typically [3H]GDP) with unlabeled GDP, as we had suggested earlier (Marintchev 
& Wagner 2004). The assay measures the slower of two rates: the off-rate of eIF2-GDP 
from eIF2B (rate of substrate release) or the off-rate of GDP from eIF2B:eIF2 (the first 
step in the actual catalysis). Under normal conditions, eIF2-GDP release from eIF2B is 
slower and thus is rate-limiting (Figure 4.15). If eIF2B fails to stimulate GDP release 
from eIF2, as is the case with eIF2(α-P)-GDP, GDP release becomes rate-limiting and the 
results of the assay are informative. Thus, this assay measuring the rate of exchange of 
labeled and unlabeled GDP is able to reproduce the inhibition of eIF2B activity by eIF2α 
phosphorylation, because formation of the stable eIF2B:eIF2(α-P)-GDP complex is the 
end-point of the inhibition and the slow off-rate of eIF2(α-P)-GDP from eIF2B is what 
leads to competitive inhibition of eIF2B (Figure 4.16). This is the likely reason (together 
with its relative simplicity) why the assay has been used almost exclusively to measure 
eIF2B activity for the last two decades. However, it fails to reproduce the in vivo effects 
of a vast number of CACH/VWM mutations in eIF2B, phosphorylation of eIF2Bε by 
some kinases, or the requirement for the eIF2Bβ and eIF2Bγ subunits for eIF2B activity 
in vivo (reviewed in (Marintchev and Wagner 2004)). The [3H]GDP/GDP exchange assay 
is completely insensitive to changes in the GDI activity of eIF5 or the GDF activity of 
eIF2B (Figure 4.15, Step A), as pointed out recently (Jennings et al. 2013), or to changes 
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in the relative affinities of eIF5 and eIF2B for TC (Figure 4.15, Step E), i.e. the “GEF-
DF” role of eIF5. Therefore, in cases where the GDP dissociation rate does not become 
limiting, reliable information about eIF2B activity can only be obtained using in vivo 
phenotypes or using a complete in vitro reconstituted system for recycling of eIF2-GDP 
to TC that includes not only eIF2B and Met-tRNAi, but also eIF5, as well as 
physiological concentrations of GTP and GDP. It is interesting that the [3H]GDP/GDP 
exchange assay measures significant GDP dissociation rate with free eIF2Bε (Pavitt et al. 
1998), and even in eIF2Bε-CTD (the catalytic domain) (Gomez et al. 2002). Therefore, 
eIF2Bε alone stimulates the GDP dissociation rate from eIF2. eIF2Bε, however, is not 
sufficient to perform the eIF2B function in vivo, likely because it may not shift the 
equilibrium from GDP to GTP in the eIF2Bε:eIF2 complex and/or because it does not 
bind eIF2-GTP tightly enough to prevent its dissociation. If the eIF2-GTP dissociation 
rate from eIF2Bε is fast enough, then eIF2Bε could act as a “simple” GEF, releasing 
eIF2-GTP as the product of catalysis and one would be able to use GTP, instead of GDP 
to observe GDP exchange in vitro (impossible for WT eIF2B, which does not release 
eIF2-GTP). Of course, this has little in vivo benefit, since the most eIF2Bε can do is help 
eIF2-GDP and eIF2-GTP reach equilibrium, which is 10:1 in favor of eIF2-GDP; thus the 
maximum possible activity of such “simple” GEF is 10% (see above). 
eIF2B is allosterically regulated by small molecules, such as nucleotides, 
dinucleotides and phosphosugars, and all eIF2B subunits are homologs of metabolic 
enzymes. While the eIF2B subunits have most likely lost the enzymatic activity of their 
distant ancestors, the interdomain active site pockets are highly conserved and are the 
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most likely binding sites for these allosteric regulators (reviewed in (Marintchev & 
Wagner 2004)). In the model for the eIF2B:eIF2 complex (Figure 4.10), the positions of 
the ligand-binding sites in all eIF2B subunits are such that it is possible, and even likely, 
that ligand binding would affect the eIF2B/eIF2 interactions (Figure 4. 16). The ligand-
binding sites in eIF2Bγ and ε lie underneath the eIF2γ-binding surface (compare Figure 
4.17A and 4.17B). Based on the structures of the hexameric enzyme ribose 1,5-
bisphosphate isomerase from Thermococcus kodakarensis (tkRBPI) bound to substrate, 
product and in ligand-free form (Nakamura et al. 2012), it was proposed by Kuhle and 
coauthors that the eIF2Bαβδ pocket undergoes conformational changes upon eIF2α 
binding (Kuhle et al. 2015). The tkRBPI active sites alternate between a closed and an 
open state, with the latter characterized by the NTDs of its subunits moving away from 
the CTDs and closer to each other. If the eIF2Bα2(βδ)2 regulatory subcomplex undergoes 
similar conformational changes, the open state would result in a “narrowing” of the 
eIF2α-binding pocket. The authors proposed that ligand binding to the interdomain 
pockets of eIF2Bα, β, and/or δ could modulate the conformation of the eIF2α-binding 
pocket and thus its affinity for eIF2α (Kuhle et al. 2015). In the eIF2B crystal structure 
(Kashiwagi et al. 2016), eIF2Bα and δ are in an open (“narrowed”) conformation, 
whereas eIF2Bβ is in a closed (“widened”) conformation (Figure 4.17A). If eIF2Bα were 
in an open conformation, it would be fully compatible with the contact surfaces we report 
here and with the cross-linking data of (Kashiwagi et al. 2016). A closed conformation 
for eIF2Bβ does not appear favorable as it would pull the eIF2α contact surface on 
eIF2Bβ away from those on eIF2Bα and δ. An open conformation for eIF2Bδ also  
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Figure 4.17: Potential mechanisms of eIF2B regulation by small molecules 
(A) Cross-eyed stereo view of eIF2B in ribbon representation with potential ligand-binding 
locations shown as black spheres. Only one copy of each subunit is displayed for 
simplicity. eIF2B coloring is as in Figure 4.11. (B) The same view as in (A), but with 
eIF2(α-P)-GDP overlaid. eIF2B coloring is as in panel (A). eIF2 coloring is as in Figure 
4.13B. (C) The same view as in (B), but with eIF2B in surface representation. 
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appears unfavorable as it would make the pocket too narrow for eIF2α to fit. Therefore, 
conformational changes in any of the eIF2Bα, β, or δ subunits could have an effect on 
eIF2α binding and thus eIF2B activity. 
In summary, we have proposed a novel model for the structural and 
thermodynamic basis of the eIF2B/eIF2 and eIF2B/eIF2(α-P) interactions, the 
mechanism of catalysis, and the inhibition of eIF2B activity by eIF2α phosphorylation. 
Our model differs in two critical ways from current ones in the field. First, catalysis 
involves an equilibrium between an “extended” nucleotide-bound conformation of eIF2 
in which eIF2 binds the regulatory eIF2Bαβδ pocket (via eIF2α-NTD) and the catalytic 
eIF2Bγε complex (via eIF2γ) simultaneously, and a “closed” apo- conformation in which 
eIF2 only binds the catalytic eIF2Bγε complex (via eIF2γ). Second, eIF2α 
phosphorylation exerts its inhibitory effects by shifting the equilibrium of the eIF2B:eIF2 
complex toward the “extended” GDP-bound state, at least in part by destabilizing an 
intramolecular interaction between eIF2α-NTD and -CTD. Finally, we place our findings 
about the structure of the eIF2B:eIF2 complex and the mechanisms of eIF2B action and 
regulation within a broader framework and present a complete thermodynamic 
description of the entire eIF2B catalytic cycle. This work offers a wide array of testable 
predictions that will guide future research. Understanding the structural and 
thermodynamic mechanisms of eIF2B catalysis and regulation offers new targets and 
avenues for rational drug design aimed at manipulating eIF2B activity, in particular for 
developing promising treatment strategies for neurodegenerative disorders. 
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Chapter 5: Future Directions 
 
This chapter presents ongoing efforts meant for future publications. Only the most 
recent or the most successful efforts are described here. In some cases, optimization 
remains to be performed. In others, experiments need to be repeated for confirmation. 
Others simply required more time. 
5.1. Assembling the eIF2B Regulatory Subcomplex 
As we had been able to readily express soluble eIF2Bα and eIF2Bβ, we had hoped 
we might be able to express soluble eIF2Bδ as well. This would allow us to both (a) 
directly investigate the eIF2Bβ:eIF2Bδ interaction in the same manner as we did for 
eIF2Bα homodimerization, and (b) potentially assemble the eIF2B regulatory 
subcomplex in vitro. Several exciting experiments become possible, assuming we can 
form a functional eIF2B regulatory subcomplex. While binding of eIF2α constructs to 
eIF2Bα and eIF2Bβ individually was too weak to determine KDs by fluorescence 
anisotropy assays, the expected affinity of eIF2α-NTD for the eIF2αβδ regulatory pocket 
should be high enough to do so and we observed modest eIF2α-NTD binding at 
eIF2Bαβδ concentration as low as 1 μM (data not shown). This would allow us to more 
cleanly and thoroughly compare the contribution of the “direct” and “indirect” effects 
discussed in Chapter 4. In addition, we would be able to develop a straightforward 
fluorescence screen for small molecules and compounds that could modulate the 
interaction of eIF2α in the eIF2Bαβδ regulatory pocket, in a manner that parallels the 
methods used to discover PERK inhibitors, and phosphatase inhibitors. 
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As described earlier, while some optimization had to be performed, neither 
expression nor purification proved particularly challenging for eIF2Bα and eIF2Bβ. This 
was not the case, however, for eIF2Bδ. A variety of E. coli strains were tried at various 
temperatures and for varied lengths of expression. Unfortunately, none generated soluble 
monomeric GH-eIF2Bδ. Attempts at co-expression of GH-eIF2Bδ with H-eIF2Bβ also 
failed to generate soluble monomeric GH-eIF2Bδ. Co-expression with varying amounts 
of chaperones (GroEL, GroES, and Trigger factor) failed as well. Expression of just the 
C-terminal domain failed, as did expression of an N-terminal deletion mutant. 
We were approached by a company (BiologicsCorp) seeking to demonstrate a 
proprietary process for protein expression. Given our difficulties expressing eIF2Bδ, we 
placed an order for soluble eIF2Bδ. Despite their own substantial difficulties, they 
eventually generated a codon-optimized N-terminal deletion construct, eIF2Bδ169-523, 
with a non-cleavable N-terminal His6-tag and a maximum solubility of ~20 μM. They 
also provided an expression protocol, which provided instructions for extraction of 
eIF2Bδ from insoluble inclusion bodies (i.e. a refolding protocol). A modified version of 
their protocol was used, which is described in Chapter 2. Careful and consistent 
purification and refolding, while maintaining appropriate pH at all times, generated large 
amounts of soluble GH-eIF2Bδ with a solubility ~20 μM, similar to that of H-eIF2Bδ-
blg. Problems with aggregation remain to be investigated. 
As we were now able to produce eIF2Bδ, we wondered whether we might be able 
to assemble the entire eIF2B regulatory hexamer from its constituent components. 
eIF2Bα-CM-H, eIF2Bβ, and GH-eIF2Bδ were individually prepared. In order to avoid 
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precipitation, a mixture of all three was prepared at a low concentration. Both eIF2Bα-
CM-H (15 μM) and eIF2Bβ (15 μM) were added in a roughly 2-fold excess over GH-
eIF2Bδ (8 μM) and the mixture was incubated at room temperature for one hour. 
Following filtration through a 0.22 μm filter, the mixture was loaded onto the SEC650 
column. The three individual components were separately loaded onto the SEC650 
column as controls, making sure to load the same total amount and concentration as was 
present in the mix (Figure 5.1C). Comparison of traces of absorbance at 280 nm as well 
as fractions by SDS-PAGE identified a distinct change in the elution pattern of both 
eIF2Bα-CM-H and eIF2Bβ from their reference positions (compare Figure 5.1A and 
5.1B). This indicated an interaction with GH-eIF2Bδ. Free GH-eIF2Bδ loaded at 8 μM 
did not elute from the column and presumably stuck to the resin (Figure 5.1A). 
Interestingly, the concentration at which the complex is formed prior to loading on SEC 
appears to make a difference in the behavior and elution pattern of the mixture. The 
apparent molecular weight of the eIF2Bαβδ complex varied as a function of 
concentration and protocol for preparation. It remains to be determined whether 
complexes of different size have different biological activities. Further work will need to 
be performed to answer these questions, and to identify an optimal protocol for eIF2B 
regulatory subcomplex formation.  
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Figure 5.1: Assembly of the eIF2B regulatory subcomplex 
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Figure 5.1: Assembly of the eIF2B Regulatory Subcomplex 
(A) eIF2Bα-CM-H (15 μM), eIF2Bβ (15 μM), and GH-eIF2Bδ (8 μM) were run separately 
on an SEC650 column, equilibrated in Complex Formation Buffer (20 mM Na-phosphate 
(pH 7.2), 150 mM NaCl, 10% glycerol, 1 mM AEBSF and 7 mM BME). Samples were 
loaded onto the column in an 830 μL volume. 0.5 mL fractions were collected from each 
run into the same tubes. Traces of absorption at 280 nm are shown, with eIF2Bα-CM-H 
marked in purple, eIF2Bβ marked in grey, and GH-eIF2Bδ marked in blue. Fractions were 
visualized by SDS-PAGE. eIF2Bδ did not elute from the column and thus did not appear 
in fractions. (B) eIF2Bα-CM-H, eIF2Bβ, and GH-eIF2Bδ were directly mixed to a volume 
of 830 μL, with final concentrations of each component matching that in (A). A trace of 
the absorption at 280 nm is shown. Fractions were visualized by SDS-PAGE. (C) Samples 
of the starting material loaded in the SEC runs described in (A) and (B) were visualized by 
SDS-PAGE as a control. The loading volume of eIF2Bα-CM-H and eIF2Bβ was half that 
of GH-eIF2Bδ. 
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5.2.  Identifying potential roles of the eIF2α-CTT 
5.2.1. Role of the eIF2α-CTT in modulating the intramolecular 
interaction 
eIF2α contains a long, flexible C-terminal tail (CTT, residues 281-314), found 
only in eukaryotic versions of the protein. The first half of the tail spends at least a 
fraction of the time ordered (e.g. the α8 helix (residues 281-288)), while the final 12 
residues are completely disordered (Ito et al. 2004). As we showed in Chapter 4, a 
number of residues within the CTT are affected by deletion of eIF2α-NTD, and thus play 
a role in the intramolecular interaction. In order to test more directly the role of the CTT 
in modulating the intramolecular interaction and mapping where on eIF2α it binds, we 
performed a series of HSQC and TROSY-HSQC experiments on various eIF2α 
constructs.  
In order to identify the surface on eIF2α-CTD to which the CTT binds, we 
collected HSQC spectra of 15N-labeled eIF2α-CTD and of the 15N-labeled truncation 
mutant eIF2α-CTD280. Comparison of these spectra revealed numerous chemical shift 
perturbations. We next mapped the affected residues on the structure of eIF2α, revealing 
a contiguous surface adjacent to the previously demonstrated intramolecular surface 
(Figure 5.2A). In order to identify a potential binding surface on eIF2α-NTD, as well as 
a possible effect on the intramolecular interaction, we needed to compare full length 
eIF2α to the eIF2α280 truncation. However, both constructs possess a non-cleavable C-
terminal His6-tag, which might potentially complicate interpretation of the effect of the  
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Figure 5.2: Role of the eIF2α-CTT in modulating the intramolecular eIF2α 
interaction 
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Figure 5.2: Role of the eIF2α-CTT in modulating the intramolecular eIF2α 
interaction 
(A) HSQC spectra of 15N-labeled eIF2α-CTD (310 μM) and 15N-labeled eIF2α-CTD280 
(180 μM) were collected at 298K on a Bruker 500 MHz magnet, equipped with a cryo-
probe. The effect of CTT deletion on the surface of eIF2α-CTD is shown on a surface 
model of eIF2α-CTD (1Q8K.pdb) (Ito et al. 2004). eIF2α-CTT is shown as a ribbon and 
colored blue. Residues with chemical shift perturbations between the two spectra of more 
than one, two, and three standard deviations from the mean are colored in yellow, orange, 
and red, respectively. Residues with less than one standard deviation are colored in black. 
Indeterminate residues are colored in grey. The extreme end of the C-terminal tail (aa 303-
314) is not present in the structure and is not shown. (B) TROSY-HSQC spectra of 2H/15N-
labeled eIF2α-H (270 μM) and 2H/15N-labeled eIF2α280-H (50 μM) were collected at 298K 
on a Bruker 500 MHz magnet, equipped with a cryo-probe. The effect of CTT deletion on 
the surface of eIF2 in the context of the full-length protein is shown on a surface model of 
eIF2α (1Q8K.pdb), oriented such that the C-terminal domain is aligned with that in (A). 
Residues are colored as in (A). The extreme end of the C-terminal tail (aa 303-314) is not 
present in the structure and is not shown. (C) Residues affected by CTT deletion both in 
the context of CTD alone as well as in the context of the full length protein are colored 
teal. Residues affected by CTT deletion in the context of full-length protein (i.e. (B)) only 
are colored purple (left). Purple and teal residues represent those with perturbations from 
the mean of greater than one standard deviation in their respective spectra comparisons. 
Residues that are indeterminate in either comparison are colored grey. Residues with 
perturbations less than one standard deviation from the mean are colored black. The 
intramolecular interaction surface identified in Chapter 4 is shown on the surface of eIF2α 
(1Q8K.pdb) (right). Residues on the intramolecular surface are colored as in (A) and (B). 
(D) Residues for which deletion of the CTT results in a shift to the “more closed” state are 
colored green on a surface model of eIF2α (1Q8K.pdb). Remaining residues affected by 
CTT are marked in salmon. The CTT is colored blue. Representative peaks corresponding 
to residues that shift to a “more closed” state are highlighted. Peaks are taken from a spectra 
overlay of the two spectra described in (B) as well as from a TROSY-HSQC spectrum of 
2H/15N-labeled eIF2α-CTD. eIF2α-H residues are colored black, eIF2α280-H residues are 
colored green, and eIF2α-CTD residues are colored blue. 
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CTT, particularly of its extreme terminus. For this reason, new constructs were created 
with the tag shifted to the N-terminal domain.  
Unfortunately, expression of both GH-eIF2α and GH-eIF2α280 did not generate 
sufficient soluble protein for NMR, despite extended attempts at optimization. Instead we 
collected a spectrum of 2H/15N-labeled eIF2α280-H and compared it to a spectrum of 
2H/15N-labeled eIF2α-H. CTT deletion in the context of the full-length protein affected a 
larger surface of the CTD (Figure 5.2B) than in the context of the CTD alone (Figure 
5.2A) The additional affected surface overlapped with the intramolecular contact surface 
with the NTD (Figure 5.2C). A similar effect emerged as that described in Chapter 4 
(Figure 4.3E and 4.4). Here, peaks corresponding to residues in eIF2α280-H appeared 
more “bound” or “closed” than their full length eIF2α counterparts (Figure 5.2D). Thus, 
the CTT appeared to destabilize the intramolecular interaction. Further investigation will 
need to be performed to confirm this result, as well as pursue its potential significance. 
For example, analysis of additional truncations, such as eIF2α302-H, will help to narrow 
down which sequences in the CTT are responsible for this destabilization. 
5.2.2. Role of the eIF2α-CTT in tRNA binding 
Given the role of the CTT in modulating the intramolecular interaction, as well as 
the fact that it consists disproportionately of negatively charged residues, we wondered 
whether it might play a role in modulating tRNA binding as well. Such a possibility 
seems likely, as there exists substantial overlap between the surface on eIF2α-CTD to 
which the CTT binds and that responsible for binding tRNA (compare Figure 5.3A and 
Figure 5.2A). This possibility is further supported by data demonstrating that deletion of 
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the CTT enables cross-linking between eIF2α and Met-tRNAi, where before there was 
none (Tatyana Pestova, personal communication). As the negatively charged tail could 
theoretically be competing with the negatively charged tRNA for binding to a positively 
charged surface on eIF2α-CTD, we attempted to identify and compare interactions 
between eIF2α-CTD and tRNA and between eIF2α-CTD280 and tRNA. Since recognition 
of the acceptor end of Met-tRNAi, including the methionine, is performed by eIF2γ 
(Kapp & Lorsch 2004), we were able to use bulk yeast uncharged tRNA. tRNA was 
reconstituted into NMR buffer to create a 10 mM stock, from which an amount was 
added to a sample of 15N-labeled GH-eIF2α-CTD for a final concentration of 1 mM 
tRNA. HSQC spectra were collected of the 15N-labeled GH-eIF2α-CTD in the presence 
and absence of tRNA. HSQC spectra were also collected of 15N-labeled eIF2α-CTD280 in 
the presence and absence of tRNA. Unfortunately, we were unable to observe binding of 
either eIF2α-CTD or eIF2α-CTD280 to tRNA (Figure 5.3B). These experiments will need 
to be repeated to confirm this result, with appropriate controls to make sure tRNA 
remains functional and non-degraded. 
Lack of binding of eIF2α-CTD may be expected given subsequent data (Tatyana 
Pestova, personal communication). Although the deletion mutant eIF2α-ΔCTT apparently 
binds Met-tRNAi, it is possible that this interaction requires both the N-terminal and C-
terminal domains of eIF2α. From the binding surface of eIF2α for tRNA (Figure 5.3A), 
it is apparent that the interactions with the N-terminal domain constitute the majority of 
the binding surface. It is a distinct possibility, therefore, that to definitively determine the 
role of eIF2α-CTT in modulating tRNA binding to eIF2, we need to test the CTT deletion 
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Figure 5.3: Role of the eIF2α-CTT in modulating tRNA binding to eIF2α 
 207 
 
Figure 5.3: Role of the eIF2α-CTT in modulating tRNA binding to eIF2α 
(A) A surface model of mammalian eIF2α from a cryo-EM (5.8 Å) structure of the ternary 
complex (5K0Y.pdb) (Simonetti et al. 2016). Residues within 5 Å of the bound Met-tRNAi 
are colored in red. Met-tRNAi is shown as a black ribbon. Residues 271 through 280, as 
well as the entire C-terminal tail (280-314) are missing in this structure. Residue 270 is 
colored blue to mark the start of the missing stretch of residues. A surface model of the C-
terminal domain of human eIF2α (1Q8K.pdb) is provided as a reference (boxed), oriented 
in the same manner as the C-terminal domain of the right-most view of eIF2α. In the 
reference, residues 270-279 (missing in (A)) are marked in blue and the CTT is marked in 
orange. The extreme end of the C-terminal tail (aa 302-314) is not present in the structure 
and is not shown. (B) HSQC spectra of 15N-labeled GH-eIF2α-CTD (500 μM) and 15N-
labeled GH-eIF2α-CTD280 (155 μM) were collected in the presence (red) and absence 
(black) of 1 mM tRNA. All spectra were collected at 298K on a Bruker 500 MHz magnet, 
equipped with a cryo-probe. 
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construct eIF2α280-H, which otherwise possesses all the tRNA binding surfaces. 
5.3. Investigating binding of the African Swine Virus NLS1 protein 
to eIF2α 
Protein phosphatase 1 (PP1) is unable to bind eIF2α directly, thus requiring an 
adapter protein (GADD34 or CReP) to dephosphorylate eIF2(α-P). Both GADD34 and 
CReP possess an acidic N-terminal domain responsible for localization/targeting to the 
endoplasmic reticulum, as well as a conserved C-terminal domain. GADD34, however, 
possesses in its central domain an additional series of PEST motifs, named for the 
disproportionate abundance of prolines, acidic residues, serines, and threonines. While 
PEST motifs canonically modulate protein turnover, it was demonstrated that these PEST 
motifs bind eIF2α (Choy et al. 2015; Brush & Shenolikar 2008). Nevertheless, CReP and 
known viral protein homologs of GADD34/CReP, who function to recruit PP1 to eIF2α, 
in order to suppress induction of ISR, are perfectly capable of binding eIF2α and 
promoting PP1-mediated dephosphorylation without these PEST domains. All these 
proteins share a well-conserved, yet intrinsically-disordered C-terminal segment adjacent 
to the PP1-binding motif, RVxF.  
The function of this segment, as well as the mechanism by which it binds eIF2α, 
remain unclear. It was recently reported that a stretch of residues in the C-terminal 
domain of GADD34, highly conserved among viral protein homologs, was able to bind 
eIF2α and do so tightly enough to be visible in pull-down assays. Using the GADD34 
homolog from African swine fever virus, known as DP71L or NLS1, the authors were 
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able to identify a minimal eIF2α binding sequence of ~19 residues (Rojas et al. 2015). 
Interestingly, a pair of reports came out identifying patients with a mutation in CReP 
corresponding to the first residue in this minimal binding sequence, for whom the 
outcome was microcephaly, short stature, intellectual disability, and diabetes 
(Abdulkarim et al. 2015; Kernohan et al. 2015). Understanding how GADD34 interacts 
with eIF2α to promote the latter’s dephosphorylation by PP1 would have significant 
implications. First, it might provide an insight into the mechanism of the inhibitors of 
eIF2α dephosphorylation, as neither appear to work as originally predicted by inhibiting 
the GADD34:PP1 interaction (Choy et al. 2015). Second, understanding the surfaces 
responsible for the eIF2α:GADD34 interaction may allow for new therapeutic 
possibilities for anti-viral therapies, as well as more generally an ability to therapeutically 
maintain or increase ISR induction at will. 
Our investigation of the GADD34 binding site on eIF2α was initiated as a 
collaborative effort with the Dever Lab (Section on Protein Biosynthesis, NIH) and the 
Sicheri Lab (Dept. of Biochemistry, University of Toronto). The Dever Lab had 
identified the novel minimal binding motif within GADD34 capable of binding eIF2α 
that possessed substantial sequence similarity with CReP and viral proteins used to 
recruit PP1 to circumvent activation of the integrated stress response by PKR (e.g. 
Herpes Simplex Virus (HSV) γ34.5 protein, African Swine Virus (ASV) DP71L/NLS1 
protein, and the Canarypox Virus (CNPV) 231 protein) (Rojas et al. 2015; He et al. 1997; 
Rivera et al. 2007).  
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The Sicheri Lab was seeking to crystallize NLS1 or its minimal binding motif, 
NLS132-50, in complex with eIF2α. With our NMR assignments and wild-type eIF2α 
constructs, we aimed to provide three pieces of information: (1) the surface on eIF2α to 
which the motif binds, (2) the minimum sequence necessary for binding, and (3) an 
orientation of that minimal sequence on eIF2α. The latter two would aid in the Sicheri 
Lab’s attempts to crystallize an NLS1:eIF2α complex. Theoretically, a structure of the 
NLS1:eIF2α complex could also be solved by NMR, if necessary. The effort remains 
ongoing, as many issues in expression and purification remain to be resolved. Initial 
clones and expression protocols were provided by Dr. Margarito Rojas (Dever Lab). The 
constructs currently being used were derived from these clones and ordered from DNA 
Express. At one point, responsibility for the project transitioned to another member of our 
lab, Cora Lin.  
We faced substantial difficulties in trying to express soluble full-length GST-
NLS1 and the truncation GST-NLS122-71. Both experienced a combination of aggregation 
and substantial truncation/degradation. Cleavage with TEV protease led to complete 
precipitation of both samples. Despite the low purity of full length GST-NLS122-71, we 
nevertheless proceeded with preparing a sample for NMR. As the GST-NLS122-71 fusion 
was unlabeled, any non-functional degradation/truncation products could potentially be 
ignored, and even a small amount of functional NLS1 would presumably result in an 
observable binding, as the affinity had already been demonstrated to be tight enough to 
be observed by pull-down (Rojas et al. 2015). Ultimately an NMR sample was prepared 
containing 55 μM 2H/15N/13C-labeled eIF2α-NTD-H as the labeled species and our mix of 
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full length and truncation/degradation products from the GST-NLS122-71 purification as 
unlabeled species. A TROSY-HSQC spectrum was collected of the mix and compared to 
a reference TROSY-HSQC spectrum of the same concentration of 2H/15N/13C-labeled 
eIF2α-NTD-H. We observed a nearly complete loss of signal, indicative of binding of 
unlabeled and potentially labelled protein as well.  
Upon retrieval of the NMR sample, substantial precipitation was observed. In 
order to determine which one or more of the four species present had precipitated, we 
took samples for SDS-PAGE of the NMR sample, as well as a sample of the supernatant. 
The resulting gel indicated that it was our GST-NLS122-71 fusion that had precipitated out. 
By running SEC, we observed that the labeled eIF2α-NTD-H partitioned between a free 
state and a bound state, in which it formed a complex with the truncation/degradation 
product of GST-NLS122-71. The latter complex itself existed in both an aggregate state 
eluting with the void volume, but also as a complex (consistent with the MW of the 
truncation/degradation product alone). The combination of being incorporated in a large 
complex, as well as a propensity for aggregation, likely explains the observed signal loss. 
We next attempted to express the Prescission cleavage site constructs. Despite 
losing a majority of the protein during purification, an NMR sample was prepared of ~50 
μM 15N-labeled eIF2α-NTD-H and a theoretical ~300 μM of unlabeled GST-NLS132-50. 
HSQC spectra were collected of 15N-labeled eIF2α-NTD-H, both free and in the presence 
of GST-NLS132-50. Comparison of the spectra revealed no binding. Converting to a 
pET21a-GB1 expression vector yielded a successful expression and purification using 
Rosetta2(DE3) cells and expressing at 20C overnight. An NMR sample was prepared, 
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and a spectrum was collected of 2H/15N-labeled eIF2α-NTD-S51D-H in the presence of 
GH-NLS132-50, and compared to a reference. Again no binding was observed. Continued 
optimization was pursued by Cora Lin from this point forward. 
 We next attempted to express full-length NLS1 using our pET21a-GB1 
expression vector. Despite substantial problems with degradation, an NMR sample was 
prepared of 2H/15N-labeled eIF2α-NTD-S51D-H mixed with GH-NLS1 at 500 mM NaCl 
and in 10% glycerol (to further improve stability). TROSY-HSQC spectra were collected 
of this sample and a reference sample of 2H/15N-labeled eIF2α-NTD-S51D-H in the 500 
mM NaCl, 10% glycerol buffer. Interestingly, a pattern was observed, characterized by 
signal loss compared to reference peaks and the additional presence of “satellite peaks” 
roughly 50% the intensity of the main peaks (which was in turn ~2/3 that of the 
reference) (Figure 5.4A). Loss of signal was not due to loss of eIF2α-NTD-S51D, as 
confirmed by SDS-PAGE. Such an effect could be observed in the case that only ~1/3 of 
the labeled eIF2α-NTD-S51D was interacting with GH-NLS1, due to degradation of GH-
NLS1 and/or its aggregation. Such an effect would further indicate that the system was in 
slow exchange (on the timescale of NMR) between two states visible by NMR: 2/3 free 
labeled eIF2α-NTD-S51D (responsible for the reduced intensity “main” peak) and 1/3 
bound labeled eIF2α-NTD-S51D (responsible for the “satellite peaks” of ~50% intensity 
compared to the “main” peaks). This is consistent with the fact that the affinity of the 
eIF2α-NTD-S51D:NLS1 interaction is high enough to be demonstrated by a pull-down 
assay. CSPs and the above effect were subsequently mapped to a structure of eIF2α  
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Figure 5.4: Binding Surface of NLS1 on eIF2α-NTD 
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Figure 5.4: Binding Surface of NLS1 on eIF2α-NTD 
(A) TROSY-HSQC spectra of eIF2α-NTD-S51D-H (30 μM) in the presence (red) and 
absence (black) of GH-NLS1 (10 μM) were collected at 298K on a Bruker 500 MHz 
magnet, equipped with a cryo-probe. A pattern of satellite peaks is present for a 
subpopulation of residues, as marked by boxes. (B) Residues with large displacements in 
the position of the satellite are marked in red on a surface model of human eIF2α 
(1Q8K.pdb) (Ito et al. 2004), while those with smaller displacements are marked in orange. 
Only residues, for which satellite peaks could be unambiguously identified are shown. 
Therefore, the analysis is likely to be missing some of the peaks that are the most affected, 
for which the satellite peaks are too far from the original peak to allow unambiguous 
identification. 
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(1Q8K.pdb) (Ito et al. 2004) and yielded the surface on eIF2α responsible for binding 
NLS1 (Figure 5.4B).  
Our second objective in the collaborative effort was to identify the absolute 
minimal sequence responsible for binding to eIF2α-NTD. This required labeling NLS1 
instead of eIF2α-NTD, and looking to identify which residues were responsible for 
eIF2α-NTD binding. Unfortunately, we were never able to observe binding of NLS132-50, 
despite results from the Dever Lab of being able to do so. We therefore had to use full-
length NLS1, despite its poor solubility, high degree of degradation, and larger size. 
Although it is our general policy (and that of others) to cleave the GB1 tag off of a 
labeled protein so as to reduce the number of extraneous confounding peaks in the NMR 
spectrum, cleavage of GH-NLS1 proved problematic and was abandoned. TROSY-
HSQC spectra were collected of 15N-labeled GH-NLS1 in the presence and absence of 
eIF2α-NTD-S51D-H. Unfortunately, these spectra were effectively those of GB1, with 
little signal coming from NLS1 peaks.  
At this point, several efforts need to be made to complete the “story.” First, 
further optimization of expression of NLS1-fl needs to be performed, ideally resulting in 
a soluble tag-less preparation at a physiological (150 mM) salt concentration. Second, it 
remains unclear why in our system the minimal binding sequence comprising residues 
32-50 did not bind eIF2α, despite its stability, solubility, and high concentration. Third, 
conditions will need to be found in which labeled NLS1 can be seen by NMR to bind to 
eIF2α-NTD. Upon evidence of binding, a series of 3D experiments will need to be 
performed on labeled NLS1 in order to perform backbone assignments and allow for 
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subsequent identification of bound residues. Finally, further experimentation with other 
viral homologs of GADD34, such as CNPV231, might provide alternative avenues to 
identifying the minimal binding sequence of GADD34 and the surface on eIF2α to which 
it binds.  
5.4. Identifying the binding site of the small molecule ISRIB on 
eIF2B 
Due to the recent and growing excitement surrounding ISRIB as a potential 
research and therapeutic tool, we sought to identify its mechanism of action. Mutations in 
mammalian eIF2B that reversed the effect of ISRIB were localized to the N-terminal 
domain of eIF2Bδ, namely at residues R171, V178, and L180 (Sekine et al. 2015). It was 
also shown that ISRIB increased the thermodynamic stability of the eIF2Bδ (Sidrauski, 
Tsai, et al. 2015). Both groups speculated that ISRIB may have a role in the stabilization 
of eIF2B complex assembly. Supporting this line of reasoning is the symmetrical nature 
of the molecule, as well as its potential location, as identified on the S. pombe structure 
by mapping the mutations listed above (Kashiwagi et al. 2016). To date no evidence 
exists confirming a direct interaction between ISRIB and any subunits of eIF2B. We thus 
sought to test whether ISRIB binds to eIF2Bα, eIF2Bβ, or eIF2Bδ by NMR. 
Both unlabeled and 13C-labeled ISRIB were obtained from FB Reagents (Cambridge, 
MA). The latter was synthesized using 13C-labeled bromoacetic acid, resulting in 
replacement of the second carbon of each of the acetamide groups that flank the central 
bi-substituted cyclohexane with 13C (Figure 5.5). Since the molecule is symmetric, only  
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Figure 5.5: 13C-labeled ISRIB 
The molecular structure of the integrated stress response inhibitor (ISRIB) is shown, with 
the sites of 13C labeling highlighted in grey. 
 
 218 
 
a single peak is expected, corresponding to both 13C carbons. As ISRIB has low solubility 
in water, a stock was made instead in a solution of deuterated dimethyl sulfoxide (d6-
DMSO). A sample was prepared for NMR by dilution of the stock of unlabeled ISRIB 
into D2O. A 1D proton spectrum was collected, which clearly revealed the presence of 
ISRIB. A stock of 13C-labeled ISRIB was also prepared in d6-DMSO. An HSQC 
spectrum was collected of this high concentration stock (in d6-DMSO), revealing strong 
signal from the 13C carbon of ISRIB. Interestingly, the other carbons were also visible, 
though weakly, due to natural abundance of 13C carbon. When diluted ~1000-fold into 
D2O (no background d6-DMSO), 
13C-labeled ISRIB remained visible, though naturally 
with substantially weaker signal than the stock.  
Future work will involve mixing of 13C-labeled ISRIB with eIF2Bα, eIF2Bβ, 
eIF2Bδ, and eIF2Bαβδ and looking for loss of signal. Unfortunately, as the only human 
structure solved to date is of eIF2Bα, as well as the fact that any assignments would have 
to be done de novo on large proteins, it would be a challenge to go the additional step of 
identifying the exact surface on these proteins responsible for ISRIB binding. 
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Chapter 6: Concluding Thoughts and Future Experiments 
 
 
Regulation of eIF2B activity by phosphorylation of eIF2α is now widely 
recognized as a central regulatory mechanism used by cells to tune proteostasis and 
survive a variety of stresses. The underlying mechanism and key proteins are highly 
conserved among all eukaryotes. From the discovery in 1966 (Grayzel et al. 1966; 
Waxman & Rabinovitz 1966) that translation is rapidly inhibited upon depletion of heme 
to the publication of the structure of eIF2B in 2016 (Kashiwagi et al. 2016), this system 
has been an active area of research. Over the past five decades, the “big picture” has 
slowly been filled in. The role of the eIF2-GTP:Met-tRNAi ternary complex in translation 
initiation has been determined, as has the requirement for exchange of eIF2-bound GDP 
for GTP in the creation of new ternary complexes. eIF2B has been identified as the factor 
responsible for promoting nucleotide exchange on eIF2, and thus for maintaining 
necessary levels of ternary complex in the cell. Four kinases have been identified in 
eukaryotes as responsible for phosphorylating eIF2α in response to key stresses, which in 
turn results in conversion of eIF2 into a competitive inhibitor of eIF2B activity.  
Collectively known as the integrated stress response, activation of these kinases 
by cellular stress leads to a reduction in the rate of protein translation, allowing the cell to 
more effectively respond to the stress at hand. A host of proteins and pathways have been 
identified to play a role in stress resolution, and the mechanism underlying their 
paradoxical translational upregulation upon activation of the integrated stress response 
has been identified. In the last decade, the integrated stress response has been implicated 
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in progression and severity of an increasingly wide variety of pathologies, from 
neurodegenerative disorders to metabolic disorders to cancer. 
The work described in this dissertation aims to fill in one of the main “holes” in 
our understanding of this system: the mechanism whereby phosphorylation of eIF2α 
leads to inhibition of eIF2B activity. The broad strokes are widely appreciated. 
Phosphorylated eIF2 binds more tightly to eIF2B than does unphosphorylated eIF2, 
leading both to a non-productive interaction as well as the sequestration of the bound 
eIF2B molecule. As levels of eIF2B in the cell are lower than those of eIF2, only a small 
amount of phosphorylated eIF2 is capable of sequestering a substantial fraction of eIF2B, 
thus causing a reduction in ternary complex levels in the cell. However, the relative 
paucity of structures of key proteins as well as long-standing assumptions regarding the 
assembly of eIF2B and its interactions with eIF2 has remained a stumbling block. 
One such assumption was that eIF2B is a pentamer, consisting of one copy of 
each of its five subunits. Such a belief may have been driven initially by analytical 
ultracentrifugation data from the 1980s indicating the overall molecular weight of eIF2B 
was roughly equivalent to the sum of the molecular weight of its five subunits (C de Haro 
& Ochoa 1979; Ranu & London 1979; Siekierka et al. 1981). New data were therefore 
interpreted in light of a trimeric regulatory subcomplex and a dimeric catalytic 
subcomplex, with contradictory evidence rationalized, missed, or dismissed. For 
example, all homologs of the eIF2B regulatory subunits (i.e. α, β, and δ) with known 
structure are homodimers, with an extensive dimerization interface contained in the C-
terminal domain (Figures 3.1, 3.4). The corresponding surfaces in the eIF2Bα, β, and δ 
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subunits are rich in hydrophobic residues, reinforcing their role as a protein-protein 
binding interface (Figures 3.1, 3.8). They are also much larger than those surfaces on the 
N-terminal domains proposed as the assembly interface in a trimeric regulatory 
subcomplex (Figure 3.11B). Furthermore, sequence conservation between eIF2B 
regulatory subunits and their homologs is higher in the C-terminal domain compared to 
the protein as a whole. 
 For the reasons listed above, we set out to demonstrate that the eIF2B regulatory 
subcomplex could not be a trimer and therefore that eIF2B could not be a pentamer. The 
first step was to determine how three C-terminal domain interfaces with high 
hydrophobicity and known homology could be assembled. The crystal structure of human 
eIF2Bα had recently been solved, revealing unsurprisingly a homodimer along the same 
C-terminal domain interface (Hiyama et al. 2009). Our own data confirmed that this 
assembly was physiologically relevant (Figure 3.5A). Interestingly, our data also 
demonstrated that eIF2Bβ was a monomer and not a dimer under physiological 
conditions (Figure 3.5C). This suggested then that eIF2Bβ and eIF2Bδ must form 
heterodimers, and that eIF2B was overall a decamer with a hexameric regulatory 
subcomplex (Figure 3.13). Publication of a crystal structure of eIF2B confirmed our 
hypothesis of a hexameric eIF2B regulatory subcomplex, consisting of an eIF2Bα 
homodimer and two eIF2Bβδ heterodimers (Figure 4.1) (Kashiwagi et al. 2016). 
The next major assumption we sought to overturn involved the presumed 
mechanism whereby phosphorylation of eIF2α leads to a higher affinity interaction with 
eIF2B. It was commonly believed that this higher affinity was due to a “direct effect” on 
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the eIF2B:eIF2 interaction of the highly negatively charged phosphate and/or subsequent 
re-arrangement of the positively charged phosphorylation loop. We hypothesized an 
additional “indirect effect” existed, in which the C-terminal domain of eIF2α plays an 
inhibitory role in the eIF2B:eIF2 interaction, and does so in a manner relieved by 
phosphorylation.  
 We first identified and mapped the intramolecular interaction on the structure of 
human eIF2α. NMR spectra were collected of full-length and N-/C-terminal deletion 
mutants of eIF2α, as well as of their phosphomimetic S51D variants. Chemical shift 
perturbation assays revealed a large, contiguous surface on eIF2α-NTD and eIF2α-CTD 
responsible for an intramolecular interaction (Figure 4.2). Comparison of NMR spectra 
of the full-length WT and phosphomimetic variants revealed a destabilizing effect of 
phosphorylation on the intramolecular interface (Figures 4.3, 4.4). Finally, NMR spectra 
were collected of eIF2α-NTD and its phosphomimetic variant in the presence and 
absence of either eIF2Bα or eIF2Bβ. Surfaces on eIF2α-NTD responsible for binding 
eIF2Bα and eIF2Bβ were identified (Figures 4.5, 4.7). They revealed an overlap between 
the intramolecular interaction surface on eIF2α-NTD normally bound by eIF2α-CTD and 
the surface on eIF2α-NTD responsible for interacting with eIF2Bβ (compare Figure 4.2D 
and 4.7D). This competition was further confirmed by the fact that while binding was 
observed between eIF2α-NTD and eIF2Bβ, no binding could be observed between full-
length eIF2α and eIF2Bβ (Figure 4.8). 
 Fluorescence anisotropy experiments were conducted to determine the relative 
affinity of eIF2Bα and eIF2Bβ for the phosphomimetic eIF2α variants compared to the 
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WT. If the “direct effect” model were true, we would expect to see a higher affinity of 
eIF2Bα and/or eIF2Bβ for the former as compared to the latter. These experiments 
revealed no significant preference of either eIF2Bα or eIF2Bβ for phosphomimetic eIF2α 
over WT (Figure 4.9). The former is particularly important, as it is the α-subunit of 
eIF2B that is commonly believed to be responsible for discrimination of the 
phosphorylation state of eIF2α. These data therefore suggest that the “direct effect” 
cannot be mediated by either eIF2Bα or eIF2Bβ. Rather, if it does exist, it must be 
mediated either by eIF2Bδ or by a combination of two or more of the three subunits of 
the eIF2B regulatory subcomplex.  
We next sought to develop a model of the eIF2B:eIF2 interaction to explain how 
the “indirect effect” might operate. This model was based both on the recently solved 
structure of eIF2B, our NMR mapping data for the surfaces in eIF2α that bind eIF2Bα 
and eIF2Bβ, as well as extensive data indicating that binding of eIF2α to the eIF2B 
regulatory subcomplex is necessary for both normal, catalytic eIF2B activity as well as 
for inhibition by eIF2(α-P). We docked eIF2α-NTD in the eIF2Bαβδ pocket and showed 
that eIF2α and eIF2γ can bind simultaneously to eIF2Bαβδ and eIF2Bγε, respectively. In 
our model, eIF2α exists in an equilibrium between a “closed” and an “open” 
conformation, as determined by the presence or absence of the intramolecular interaction, 
respectively. This means that the eIF2 heterotrimer can adopt a “closed” or “extended” 
conformation, depending on the conformation of its α-subunit.  
The nucleotide binding site within eIF2γ must necessarily interact with the 
catalytic region on eIF2Bε-CTD, and existing data indicates that eIF2α-NTD must bind 
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the eIF2Bαβδ regulatory pocket, at the same time as eIF2γ binds to eIF2Bγε. Cross-
linking data show that the interactions of phosphorylated and unphosphorylated eIF2α 
with the eIF2Bαβδ pocket are essentially the same, indicating that the enzyme-substrate 
(eIF2B:eIF2-GDP) and enzyme-inhibitor (eIF2B:eIF2(α-P)-GDP) complexes are similar. 
Cross-linking data also indicate that the interaction interface between eIF2γ and eIF2Bγε 
is different between the enzyme-substrate and enzyme-inhibitor complexes. Finally, 
eIF2α phosphorylation stabilizes the eIF2B:eIF2(α-P)-GDP complex, which is extended, 
suggesting that the alternative (i.e. the apo-) complex is the closed one. 
We therefore proposed that eIF2 binds eIF2B in one of two states: a “closed” apo- 
state and an “extended” nucleotide-bound state (Figure 4.10). The latter is characterized 
by a two-site interaction in which eIF2γ binds eIF2Bγε and eIF2α-NTD binds in the 
eIF2Bαβδ pocket, and the former by a one-site interaction in which eIF2γ binds eIF2Bγε, 
but eIF2α does not contact eIF2Bαβδ. eIF2B has a roughly 100-fold higher affinity for 
the “closed” apo- state (Goss et al. 1984; Rowlands et al. 1988; Jennings et al. 2013), 
meaning that eIF2B catalytic activity can be explained by its stabilization of the transition 
state (i.e. the apo- state) between eIF2-GDP and eIF2-GTP.  
Our model also incorporates the long known, yet underappreciated fact that eIF2B 
has an additional role in formation of the ternary complex. The affinity of the product of 
nucleotide exchange (eIF2-GTP) for the enzyme is too high for eIF2-GTP to 
spontaneously dissociate in a physiologically relevant time-scale. Recruitment of Met-
tRNAi to bind to eIF2-GTP weakens the affinity of eIF2-GTP for eIF2B by ~10-fold. 
eIF2B’s role therefore extends beyond simply speeding nucleotide exchange. Further, we 
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noted that even the affinity of the ternary complex for eIF2B appears too high to allow 
fast enough dissociation of the ternary complex from eIF2B. Therefore, we propose that 
eIF2B serves as a “scaffold” upon which populations of eIF2-GDP, eIF2-GTP, and 
ternary complex are maintained and then the ternary complex is channeled to eIF5 
(Figure 4.14). 
Phosphorylation of eIF2α drives the equilibrium of eIF2 towards the “extended” 
GDP-bound state and away from the “closed” apo- state. The result is that the affinity of 
eIF2B for the “extended” eIF2(α-P)-GDP is the same or higher than that for the “closed” 
apo-eIF2(α-P) state. As a result, eIF2B is no longer stabilizing the transition state, and 
therefore no longer acting as an enzyme (Figure 4.14). The system is now trapped in the 
“extended” GDP-bound state, resulting in a non-productive interaction and sequestration 
of eIF2B. 
Understanding the mechanisms and interfaces involved in eF2B-mediated 
recycling of eIF2-GDP to active ternary complex is a critical pre-requisite for potential 
therapeutic applications targeting the integrated stress response. While PERK inhibition 
and ISRIB serve as validation of such targeting, both approaches have serious drawbacks. 
PERK inhibition has substantial off-target effects inherent in its mechanism of action, 
while the efficacy of ISRIB in animal models is rather modest. By targeting the 
eIF2B:eIF2 interaction directly, the high efficacy of PERK inhibition can be coupled with 
the high safety profile of ISRIB, while remaining equally applicable no matter the source 
of the stress. Future work will aim to identify small molecules that can modulate the 
interfaces described in this dissertation. Disruption of the intramolecular interface on 
 226 
 
eIF2α might allow for therapeutic activation of the integrated stress response. Disruption 
of the putative GADD34 binding surface on eIF2α-NTD may provide control over the 
“off-switch” of the integrated stress response. A key implication of our two-state model 
of the eIF2B:eIF2 interaction is that disrupting binding of eIF2α-NTD in the eIF2Bαβδ 
regulatory pocket may not be a simple solution to preventing activation of the integrated 
stress response. Such an approach may appear to counter the effects of phosphorylation 
(i.e. by reducing the population of “extended” state), but would also serve to inhibit the 
necessary binding of the substrate (eIF2-GDP) as well.  
By proposing a testable model of the mechanism of eIF2(α-P) inhibition of eIF2B 
activity, as well as providing a thermodynamic context for eIF2B-mediated recycling of 
eIF2-GDP, this dissertation aims to build a foundation upon which therapeutic modulation 
of the integrated stress response can be developed. Not only would such a modality provide 
relief for patients with pathologies related to dysfunction within this system, but it could 
also serve to unlock a powerful and highly effective natural tool for balancing pro- and 
anti-apoptotic forces within cells. 
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